Compounds or their salts, and antibodies obtained therefrom.
A specific compound modifies thiol groups in antibodies, addressing the limitation of existing methods by producing antibody compositions with low aggregation rates, suitable for pharmaceutical and diagnostic uses.
Patent Information
- Application Number
- JP2025068381
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-01-18
- Filing Date
- 2025-04-17
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-01-18
AI Technical Summary
Existing methods do not effectively modify thiol groups chemically introduced into antibodies, limiting the production of desired antibody compositions with desirable properties.
A specific compound is used to efficiently modify thiol groups in antibodies, including those in cysteine residues, resulting in antibody compositions with low aggregation rates and enabling the production of antibody intermediates and conjugates with bioorthogonal functional groups.
The method allows for the efficient production of antibody compositions with low aggregation rates, facilitating the creation of antibody-functional substance conjugates suitable for pharmaceutical and diagnostic applications.
Smart Images

Figure 0007948363000127 
Figure 0007948363000128 
Figure 0007948363000129
Abstract
Description
[Technical Field]
[0001] This invention relates to compounds or salts thereof, and antibodies obtained therefrom. [Background technology]
[0002] In recent years, research and development of antibody-drug conjugates (ADCs) has been actively pursued. ADCs are drugs in which an antibody is conjugated with a drug (e.g., an anticancer drug), and they have direct cytotoxic activity against cancer cells and other cells. A representative ADC is T-DM1 (trade name: Kadcyla®), jointly developed by Immunogene and Roche.
[0003] ADCs are produced by attaching functional groups in the side chains of specific amino acid residues present in antibodies to a drug. An example of such functional groups used in the production of ADCs is the thiol group in the side chain of a cysteine residue present in the antibody. Known techniques for modifying thiol groups in antibodies include techniques using 3-arylpropionitrile compounds (Patent Document 1) and techniques using aryl / heteroarylsulfone / sulfoxide compounds (Patent Document 2). The above prior art for modifying thiol groups in antibodies modifies the thiol group in the side chain of a cysteine residue in the antibody (e.g., cysteine residues naturally present in antibodies, and thiol groups in the side chain of cysteine residues genetically engineered into antibodies).
[0004] However, to the best of our knowledge, the prior art neither teaches nor suggests modifying thiol groups chemically introduced into antibodies (e.g., thiol groups introduced into antibodies via side chains of amino acid residues other than cysteine residues in the antibody). [Prior art documents] [Patent Documents]
[0005] [Patent Document 1] International Publication No. 2015 / 001117 [Patent Document 2] International Publication No. 2014 / 144878 [Overview of the Initiative] [Problems that the invention aims to solve]
[0006] The object of the present invention is to provide a desired antibody or antibody composition by modifying the antibody with a thiol group that has been chemically introduced into the antibody. [Means for solving the problem]
[0007] As a result of diligent research, the inventors have discovered that a specific compound can efficiently modify thiol groups chemically introduced into antibodies. Because such a specific compound exhibits excellent reaction efficiency, it is considered useful not only for modifying thiol groups chemically introduced into antibodies, but also for modifying thiol groups in cysteine residues within antibodies. Furthermore, using such a specific compound, it is possible to produce desired antibodies in which thiol groups are efficiently modified.
[0008] The inventors also found that antibodies modified with the specific compound exhibited excellent desirable properties, such as low antibody aggregation.
[0009] The inventors have further discovered that, according to the present invention, a special antibody composition containing a desired antibody having the above-mentioned characteristics can be obtained, thus completing the present invention.
[0010] In other words, the present invention is as follows: [1] (A) an antibody intermediate or salt thereof having a bioorthogonal functional group which may be protected, represented by formula (A), and (B) a thiol-transformed antibody or salt thereof, represented by formula (B). The sulfur atom (S) adjacent to the antibody (Ab) in formula (A), and the thiol group (SH) adjacent to the antibody (Ab) in formula (B), are either directly bound to the atom in the side chain of the same amino acid residue located at the same position in the constant region of the antibody heavy chain, or are bound via a linker. The molecular weight of the substructure represented by LR is 700 or less. The percentage of the amount of the antibody intermediate or its salt relative to the total amount of the antibody intermediate or its salt and the thiol-modified antibody or its salt [100(%) × (amount of the antibody intermediate or its salt) / (total amount of the antibody intermediate or its salt and the thiol-modified antibody or its salt)] is 80% or more. An antibody composition in which the aggregation rate of the antibody intermediate or a salt thereof and the thiol-introduced antibody or a salt thereof is 5% or less. [2] The antibody composition of [1], wherein the antibody intermediate is represented by formula (I'), (II'), (III'), or (IV'). [3] The antibody composition of [1] or [2], wherein the amino acid residue is an amino acid residue other than a cysteine residue. [4] An antibody composition according to any of [1] to [3], wherein the sulfur atom (S) adjacent to the antibody (Ab) in formula (A) and the thiol group (SH) adjacent to the antibody (Ab) in formula (B) are regioselectively bound to the nitrogen atom in the side chain of a lysine residue located at the same position in the constant region of the antibody (Ab) heavy chain, via a linker that does not contain a peptide. [5] Any antibody composition according to [1] to [4], wherein the antibody is an IgG antibody. [6] The antibody composition of [4] or [5], wherein the lysine residue is located at one or more positions selected from the group consisting of positions 246 / 248, 288 / 290, and 317 of the human IgG heavy chain in EU numbering. [7] An antibody composition according to any of [1] to [6], wherein the antibody intermediate is selected from the group consisting of antibody intermediates represented by formulas (1') to (10'). [8] Any antibody composition of [1] to [7] wherein the bioorthogonal functional group which may be protected is an alkyne residue or an azide. [9] The antibody composition of [8] wherein the alkyne residue is a ring group having an intercarbon triple bond, which may be substituted.
[10] A reagent for derivatization of thiol-transferred antibodies or salts thereof, comprising a compound represented by formula (I), (II), (III), or (IV) or a salt thereof.
[11] The reagent of
[10] , wherein the reagent reacts with a thiol group introduced via a side chain of an amino acid residue other than a cysteine residue in the thiol group-introduced antibody or a salt thereof to derivatize the thiol group-introduced antibody or a salt thereof.
[12] The reagent of
[10] or
[11] , wherein the thiol group in the thiol-transformed antibody is regioselectively bound to the nitrogen atom in the side chain of a lysine residue in the constant region of the antibody heavy chain via a linker that does not contain a peptide.
[13] Any of the reagents from
[10] to
[12] , wherein the thiol group-introduced antibody is an IgG antibody.
[14] The reagent according to
[12] or
[13] , wherein the lysine residue is located at one or more positions selected from the group consisting of positions 246 / 248, 288 / 290, and 317 of the human IgG heavy chain in EU numbering.
[15] The divalent group is alkylene, arylene, -C(=O)-, -NR2-, -C(=O)-NR2-, -NR2-C(=O)-, -O-, and -(O-R3) m - consists of It is either one group selected from the group, or The divalent groups are alkylene, arylene, -C(=O)-, -NR2-, -C(=O)-NR2-, -NR2-C(=O)-, -O-, and -(O-R3) m -A divalent group consisting of two or more groups selected from the group, R2 is a hydrogen atom or an alkyl group. R3 is alkylene or arylene. A reagent from
[10] to
[14] where m is an integer from 1 to 5.
[16] A reagent from
[10] to
[15] , selected from the group consisting of compounds represented by formulas (1) to (10).
[17] Compounds represented by formula (I), (II), (III), or (IV), or salts thereof.
[18] The compound of
[17] or a salt thereof, wherein the compound is selected from the group consisting of compounds represented by formulas (2) to (10).
[19] An antibody intermediate or salt thereof having a bioorthogonal functional group which may be protected, represented by formula (I'), (II'), (III'), or (IV').
[20] An antibody intermediate or salt of
[19] wherein a sulfur atom (S) adjacent to the antibody (Ab) in formula (I'), (II'), (III'), or (IV') is directly bound to an atom in the side chain of an amino acid residue other than a cysteine residue in the constant region of the antibody (Ab) heavy chain, or is bound via a linker.
[21] An antibody intermediate or salt of
[20] wherein a sulfur atom (S) adjacent to the antibody (Ab) in formula (I'), (II'), (III'), or (IV') is regioselectively bound to a nitrogen atom in the side chain of a lysine residue in the constant region of the antibody (Ab) heavy chain via a peptide-free linker.
[22] Any antibody intermediate or salt thereof from
[19] to
[21] , wherein the antibody intermediate is an IgG antibody.
[23] An antibody intermediate or salt of
[21] or
[22] wherein the lysine residue is located at one or more positions selected from the group consisting of positions 246 / 248, 288 / 290, and 317 of the human IgG heavy chain in EU numbering.
[24] The antibody intermediate is selected from the group consisting of antibody intermediates represented by formulas (1') to (12'), and is one of the antibody intermediates or a salt thereof from
[19] to
[23] .
[25] A method for producing an antibody intermediate or salt having a protected bioorthogonal functional group, comprising reacting a compound or salt thereof represented by formula (I), (II), (III), or (IV) with a thiol-modified antibody or a salt thereof to produce an antibody intermediate or salt thereof having a protected bioorthogonal functional group represented by formula (I'), (II'), (III'), or (IV'), which may be protected.
[26] A conjugate of an antibody and a functional substance or a salt thereof, represented by formula (I''), (II''), (III''), or (IV'').
[27] The conjugate of
[26] or a salt thereof, wherein the conjugate is selected from the group consisting of conjugates represented by formulas (1'') to (12'').
[28] The method involves reacting an antibody intermediate or a salt thereof having a bioorthogonal functional group, which may be protected, represented by formula (I'), (II'), (III'), or (IV'), with a functional substance having a bioorthogonal functional group that can react with the bioorthogonal functional group held by the antibody intermediate, to produce an antibody-functional substance conjugate or a salt thereof, represented by formula (I''), (II''), (III''), or (IV''). If the antibody intermediate or its salt has an alkyne residue, the antibody intermediate or its salt is reacted with a functional substance having an azide. A method for producing an antibody and a conjugate of a functional substance or a salt thereof, wherein, if the antibody intermediate or a salt thereof has an azide, the antibody intermediate or a salt thereof is reacted with a functional substance having an alkyne residue.
[29] Compounds represented by formula (I), (II), (III), or (IV) or The method of
[28] further comprises reacting a salt with a thiol-modified antibody or a salt thereof to produce an antibody intermediate or salt thereof having a protected bioorthogonal functional group represented by formula (I'), (II'), (III'), or (IV'). [Effects of the Invention]
[0011] The antibody composition of the present invention can efficiently produce antibody and functional substance conjugates or salts thereof in a state with low aggregation rate. The reagents of the present invention can derivatize thiol-transformed antibodies or salts thereof. The compounds of the present invention or their salts can be used in the derivatization of thiol-transferred antibodies or their salts. The antibody intermediate or a salt thereof of the present invention can be used in the production of antibody and functional substance conjugates or salts thereof. The conjugate or salt of the present invention can be used as a pharmaceutical or reagent (e.g., a diagnostic agent, a research reagent). [Brief explanation of the drawing]
[0012] [Figure 1] Figure 1 shows an overview of an antibody composition obtained by the reaction of a thiol-transferred antibody with a compound represented by "leaving group-LR" or a salt thereof (where L is a divalent group and R is an optionally protected bioorthogonal functional group). The antibody composition obtained by such a reaction includes an antibody intermediate having an optionally protected bioorthogonal functional group represented by formula (A) or a salt thereof, and a thiol-transferred antibody represented by formula (B) or a salt thereof. [Figure 2] Figure 2 shows an overview of the modification of a thiol group-introduced antibody with the compound of the present invention represented by formula (I) or a salt thereof. [Figure 3] Figure 3 shows an overview of the modification of a thiol group-introduced antibody with the compound of the present invention represented by formula (II) or a salt thereof. [Figure 4] Figure 4 shows an overview of the modification of a thiol group-introduced antibody with the compound of the present invention represented by formula (III) or a salt thereof. [Figure 5] Figure 5 shows an overview of the modification of a thiol group-introduced antibody with the compound of the present invention represented by formula (IV) or a salt thereof. [Figure 6] Figure 6 shows (1) the amino acid sequence of the heavy chain of trastuzumab (SEQ ID NO: 1) and (2) the amino acid sequence of the light chain of trastuzumab (SEQ ID NO: 2). [Figure 7]Figure 7 shows the MS spectrum (measured value: m / z 577.03606, theoretical value: 577.03557, tetravalent) of the peptide fragment FNWYVDGVEVHNAKTKPR (SEQ ID NO: 3), which consists of 18 amino acid residues including a lysine residue modification site (thiol derivative (+145.019Da)) induced by trypsin digestion of trastuzumab. [Figure 8] Figure 8 shows the CID spectrum of the product ion with m / z 682.13 (theoretical value: 682.01), corresponding to trivalent y16, which shows the modification of the lysine residue at positions 288 / 290 of the human IgG heavy chain in EU numbering. [Figure 9] Figure 9 shows the results of searching for peptide fragments containing thiol derivatives (+145.019 Da) that have undergone lysine residue modification (carbonamide methylation with iodoacetamide) in the trypsin digest of trastuzumab using BioPharma Finder. The horizontal axis shows the identified lysine residues, and the vertical axis shows the intensity. [Figure 10] Figure 10 shows the MS spectrum (measured value: m / z 577.03571, theoretical value: 577.03557, tetravalent) of the peptide fragment FNWYVDGVEVHNAKTKPR (SEQ ID NO: 3), which consists of 18 amino acid residues including a lysine residue modification site (thiol derivative that has undergone carboxymethylation with iodoacetamide (+145.019Da)) by trypsin digestion of trastuzumab. [Figure 11] Figure 11 shows the CID spectrum of the product ion with m / z 682.41 (theoretical value: 682.01), corresponding to trivalent y16, which shows modification of the lysine residue at positions 288 / 290 of the human IgG heavy chain in EU numbering. [Figure 12]Figure 12 shows the results of searching for peptide fragments containing thiol derivatives (+145.019Da) that have undergone lysine residue modification (carbonamide methylation with iodoacetamide) in the trypsin digest of trastuzumab using BioPharma Finder. The horizontal axis shows the identified lysine residues, and the vertical axis shows the intensity. [Figure 13] Figure 13 shows the MS spectrum (measured value: m / z 769.04506, theoretical value: 769.04482, trivalent) of the peptide fragment FNWYVDGVEVHNAKTKPR (SEQ ID NO: 3), which consists of 18 amino acid residues including a lysine residue modification site (thiol derivative that has undergone carboxymethylation with iodoacetamide (+145.019Da)) by trypsin digestion of trastuzumab. [Figure 14] Figure 14 shows the CID spectrum of the product ion with m / z 1022.71 (theoretical value: 1022.51), corresponding to the divalent y16, which shows the modification of the lysine residue at positions 288 / 290 of the human IgG heavy chain in EU numbering. [Figure 15] Figure 15 shows the results of searching for peptide fragments containing thiol derivatives (+145.019Da) that have undergone lysine residue modification (carbonamide methylation with iodoacetamide) in the trypsin digest of trastuzumab using BioPharma Finder. The horizontal axis shows the identified lysine residues, and the vertical axis shows the intensity. [Modes for carrying out the invention]
[0013] 1. Definitions of general terms (Antibodies and related terminology) In this invention, the term "antibody" is defined as follows. The term "immunoglobulin unit" corresponds to the divalent monomer unit that is the basic building block of such an antibody, and is a unit that includes two heavy chains and two light chains. Therefore, the definition, examples, and preferred examples of immunoglobulin units, including their origin, type (polyclonal or monoclonal, isotype, and full-length antibody or antibody fragment), antigen, lysine residue position, and regioselectivity, are the same as those for antibodies described below.
[0014] The origin of the antibodies is not particularly limited and may be derived from animals such as mammals or birds (e.g., chickens). Preferably, the immunoglobulin units are derived from mammals. Examples of such mammals include primates (e.g., humans, monkeys, chimpanzees), rodents (e.g., mice, rats, guinea pigs, hamsters, rabbits), companion animals (e.g., dogs, cats), livestock (e.g., cattle, pigs, goats), and working animals (e.g., horses, sheep), preferably primates or rodents, and more preferably humans.
[0015] The type of antibody may be a polyclonal antibody or a monoclonal antibody. The antibody may also be a bivalent antibody (e.g., IgG, IgD, IgE) or a quadrivalent or higher antibody (e.g., IgA antibody, IgM antibody). Preferably, the antibody is a monoclonal antibody. Examples of monoclonal antibodies include chimeric antibodies, humanized antibodies, human antibodies, antibodies to which a predetermined glycan has been added (e.g., antibodies modified to have a glycan-binding consensus sequence such as an N-linked glycan-binding consensus sequence), bispecific antibodies, Fc region proteins, and Fc fusion proteins. Examples of isotypes of monoclonal antibodies include IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgM, IgA, IgD, IgE, and IgY. In this invention, the monoclonal antibody may be a full-length antibody or a variable region antibody. While antibody fragments (e.g., antibody fragments containing the CH1 and CH2 domains, and antibody fragments without the constant region) can be used, full-length antibodies are preferred. The antibody is preferably a human IgG monoclonal antibody, and more preferably a human IgG full-length monoclonal antibody.
[0016] Any antigen can be used as the antigen for the antibody. For example, such antigens include proteins (including oligopeptides and polypeptides; proteins modified with biomolecules such as sugars (e.g., glycoproteins)), glycans, nucleic acids, and small molecule compounds. Preferably, the antibody may be an antibody that uses a protein as its antigen. Examples of proteins include cell membrane receptors, cell membrane proteins other than cell membrane receptors (e.g., extracellular matrix proteins), ligands, and soluble receptors.
[0017] More specifically, the antigen protein of the antibody may be a disease target protein. Examples of disease target proteins include the following:
[0018] (1) Oncology PD-L1, GD2, PDGFRα (platelet-derived growth factor receptor), CD22, HER2, phosphatidylserine (PS), EpCAM, fibronectin, PD-1, VEGFR-2, CD33, HGF, gpNMB, CD27, DEC-205, folate receptor, CD37, CD19, Trop2, CEACAM5, S1P, HER3, IGF-1R, DLL4, TNT-1 / B, CPAAs, PSMA, CD20, CD105 (endoglin), ICAM-1, CD30, CD16A, CD38, MUC1, EGFR, KIR2DL1,2,, NKG2A, tenascin-C, IGF (Insulin-like growth factor), CTLA-4, mesothelin, CD138, c-Met, Ang2, VEGF-A, CD79b, ENPD3, folate receptor α, TEM-1, GM2, グリピカン3, macrophage inhibitory factor, CD74, Notch1, Notch2, Notch3, CD37, TLR-2, CD3, CSF-1R, FGFR2b, HLA-DR, GM-CSF, EphA3, B7-H3, CD123, gpA 33. Frizzled7 receptor, DLL4, VEGF, RSPO, LIV-1, SLITRK6, Nectin-4, CD70, CD40, CD19, SEMA4D (CD100), CD25, MET, Tissue Factor, IL-8, EGFR, cMet, KIR3DL2, Bst1(CD157), P-カドヘリン, CEA, GITR, TAM (tumor associated macrophage), CEA, DLL4, Ang2, CD73, FGFR2, CXCR4, LAG-3, GITR, Fucosyl GM1, IGF-1, Angiopoietin 2. CSF-1R, FGFR3, OX40, BCMA, ErbB3, CD137(4-1BB), PTK7, EFNA4, FAP, DR5, CEA, Ly6E, CA6, CEACAM5, LAMP1, tissue Factor, EPHA2, DR5, B7-H3, FGFR4, FGFR2, α2-PI, A33, GDF15, CAIX, CD166, ROR1, GITR, BCMA, TBA, LAG-3, EphA2, TIM-3, CD-200, EGFRvIII, CD16A, CD32B, PIGF, Axl, MICA / B, Thomsen-Friedenreich, CD39, CD37, CD73, CLEC12A, Lgr3, Transfeline Receiver, TGFβ, IL-17, 5T4, RTK, Immune Suppressor Protein, NaPi2b, Lysil B Antigen, A34, Lysil-Oxidase, DLK-1, TROP-2, α9 Integrin, TAG-72 (CA72-4), CD70,
[0019] (2) Autoimmune diseases and inflammatory diseases IL-17, IL-6R, IL-17R, INF-α, IL-5R, IL-13, IL-23, IL-6, ActRIIB, β7-Integrin, IL-4αR, HAS, Eotaxin-1, CD3, CD19, TNF-α, IL-15, CD3ε, Fibronectin, IL-1β, IL-1α, IL-17, TSLP (Thymic Stromal Lymphopoietin), LAMP (Alpha4 Beta 7 Integrin), IL-23, GM-CSFR, TSLP, CD28, CD40, TLR-3, BAFF-R, MAdCAM, IL-31R, IL-33, CD74, CD32B, CD79B, IgE (immunoglobulin E), IL-17A, IL-17F, C5, FcRn, CD28, TLR4, MCAM, B7RP1, CXCR1,2 Ligands, IL-21, Cadherin-11, CX3CL1, CCL20, IL-36R, IL-10R, CD86, TNF-α, IL-7R, Kv1.3, α9 integrin, LIFHT
[0020] (3) Neurological diseases CGRP, CD20, β-amyloid, β-amyloid protofibrin, Calcitonin Gene-Related Peptide Receptor, LINGO (Ig Domain Containing 1), α-synuclein, extracellular tau, CD52, insulin receptor, tau protein, TDP-43, SOD1, TauC3, JC virus
[0021] (4) Infectious disease Clostridium Difficile toxin B, cytomegalovirus, RSV, LPS, S. Aureus Alpha-toxin, M2e protein, Psl, PcrV, S. Aureus toxin, influenza A, alginate, Staphylococcus aureus, PD-L1, influenza B, Acinetobacter, F-protein, Env, CD3, pathogenic Escherichia coli, Klebsiella, Streptococcus pneumoniae
[0022] (5) Hereditary and rare diseases Amyloid AL, SEMA4D (CD100), insulin receptor, ANGPTL3, IL4, IL13, FGF23, adrenocorticotropic hormone, transthyretin, huntingtin
[0023] (6) Eye diseases Factor D, IGF-1R, PGDFR, Ang2, VEGF-A, CD-105 (Endoglin), IGF-1R, β-amyloid
[0024] (7) Bone and orthopedics field Sclerostin, Myostatin, Dickkopf-1, GDF8, RNAKL, HAS, Siglec-15
[0025] (8) Blood disorders vWF, Factor IXa, Factor X, IFNγ, C5, BMP-6, Ferroportin, TFPI
[0026] (9) Other diseases BAFF (B cell activating factor), IL-1β, PCSK9, NGF, CD45, TLR-2, GLP-1, TNFR1, C5, CD40, LPA, prolactin receptor, VEGFR-1, CB1, Endoglin, PTH1R, CXCL1, CXCL8, IL-1β, AT2-R, IAPP
[0027] Specific examples of monoclonal antibodies include certain chimeric antibodies (e.g., rituximab, basiliximab, infliximab, cetuximab, siltuximab, dinutuximab, ol). Tatoxacimab), specific humanized antibodies (e.g., daclizumab, palivizumab, trastuzumab, allentuzumab, omalizumab, efalizumab, bevacizumab, natalizumab (IgG4), tocilizumab, eclizumab (IgG2), mogamulizumab, pertuzumab, obinutuzumab, vedolizumab, pemprolizumab (IgG4), mepolizumab, elotuzumab, daratumumab, ikesekizumab (IgG4), reslizumab (IgG4), atezolizumab), specific Examples of human antibodies include adalimumab (IgG1), panitumumab, golimumab, ustekinumab, canakinumab, ofatumumab, denosumab (IgG2), ipilimumab, belimumab, laxibakumab, ramucirumab, nivolumab, dupilumab (IgG4), secukinumab, evolocumab (IgG2), alirocumab, necitumumab, brodalumab (IgG2), and olaratumab (IgG1). (If the IgG subtype is not mentioned, it is assumed to be IgG1.)
[0028] The positions of amino acid residues in antibodies and the positions of constant regions in the heavy chain (e.g., the CH2 domain) follow EU numbering (see http: / / www.imgt.org / IMGTScientificChart / Numbering / Hu_IGHGnber.html). For example, when targeting human IgG, the lysine residue at position 246 corresponds to the 16th amino acid residue in the human IgG CH2 domain, the lysine residue at position 248 corresponds to the 18th amino acid residue in the human IgG CH2 domain, the lysine residue at position 288 corresponds to the 58th amino acid residue in the human IgG CH2 domain, the lysine residue at position 290 corresponds to the 60th amino acid residue in the human IgG CH2 domain, and the lysine residue at position 317 corresponds to the 87th amino acid residue in the human IgG CH2 domain. The notation 246 / 248 indicates that the target is the lysine residue at position 246 or 248. The notation 288 / 290 indicates that the target is the lysine residue at position 288 or 290.
[0029] (Halogen atom) Examples of halogen atoms include fluorine, chlorine, bromine, and iodine.
[0030] (Monovalent hydrocarbon group, and related terminology) Examples of monovalent hydrocarbon groups include monovalent linear hydrocarbon groups, monovalent alicyclic hydrocarbon groups, and monovalent aromatic hydrocarbon groups.
[0031] A monovalent linear hydrocarbon group refers to a hydrocarbon group composed solely of a linear structure, and whose main chain does not contain a cyclic structure. However, the linear structure may be linear or branched. Examples of monovalent linear hydrocarbon groups include alkyl, alkenyl, and alkynyl groups. Alkyl, alkenyl, and alkynyl groups may be linear or branched.
[0032] As alkyls, alkyls having 1 to 12 carbon atoms are preferred, alkyls having 1 to 6 carbon atoms are more preferred, and alkyls having 1 to 4 carbon atoms are even more preferred. If the alkyl has substituents, the number of carbon atoms of the substituents is not included in the above carbon number. Examples of alkyls having 1 to 12 carbon atoms include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and dodecyl.
[0033] As the alkenyl, alkenyls having 2 to 12 carbon atoms are preferred, alkenyls having 2 to 6 carbon atoms are more preferred, and alkenyls having 2 to 4 carbon atoms are even more preferred. If the alkenyl has substituents, the number of carbon atoms of the substituents is not included in the above carbon atom count. Examples of alkenyls having 2 to 12 carbon atoms include vinyl, propenyl, and n-butenyl.
[0034] As for the alkynyl, alkynyls having 2 to 12 carbon atoms are preferred, alkynyls having 2 to 6 carbon atoms are more preferred, and alkynyls having 2 to 4 carbon atoms are even more preferred. If the alkynyl has substituents, the number of carbon atoms of the substituents is not included in the above carbon atom count. Examples of alkynyls having 2 to 12 carbon atoms include ethynyl, propynyl, and n-butynyl.
[0035] Alkyl groups are preferred as monovalent chain hydrocarbon groups.
[0036] A monovalent alicyclic hydrocarbon group refers to a hydrocarbon group that contains only alicyclic hydrocarbons as its ring structure and does not contain an aromatic ring. The alicyclic hydrocarbon may be monocyclic or polycyclic. However, it does not need to be composed solely of alicyclic hydrocarbons; it may contain a chain-like structure as part of it. Examples of monovalent alicyclic hydrocarbon groups include cycloalkyl, cycloalkenyl, and cycloalkynyl, which may be monocyclic or polycyclic.
[0037] As for cycloalkyls, cycloalkyls having 3 to 12 carbon atoms are preferred, cycloalkyls having 3 to 6 carbon atoms are more preferred, and cycloalkyls having 5 to 6 carbon atoms are even more preferred. If the cycloalkyl has substituents, the number of carbon atoms of the substituents is not included in the above carbon atom count. Examples of cycloalkyls having 3 to 12 carbon atoms include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0038] As the cycloalkenyl, cycloalkenyls having 3 to 12 carbon atoms are preferred, cycloalkenyls having 3 to 6 carbon atoms are more preferred, and cycloalkenyls having 5 to 6 carbon atoms are even more preferred. If the cycloalkenyl has substituents, the number of carbon atoms of the substituents is not included in the above carbon atom count. Examples of cycloalkenyls having 3 to 12 carbon atoms include cyclopropenyl, cyclobutenyl, cyclopentenyl, and cyclohexenyl.
[0039] As the cycloalkynyl, cycloalkynyls having 3 to 12 carbon atoms are preferred, cycloalkynyls having 3 to 6 carbon atoms are more preferred, and cycloalkynyls having 5 to 6 carbon atoms are even more preferred. If the cycloalkynyl has substituents, the number of carbon atoms of the substituents is not included in the above carbon atom count. Examples of cycloalkynyls having 3 to 12 carbon atoms include cyclopropynyl, cyclobutynyl, cyclopentynyl, and cyclohexynyl.
[0040] As the monovalent alicyclic hydrocarbon group, cycloalkyl is preferred.
[0041] A monovalent aromatic hydrocarbon group refers to a hydrocarbon group containing an aromatic ring structure. However, it does not need to consist solely of an aromatic ring; it may also contain a chain structure or an alicyclic hydrocarbon as part of it, and the aromatic ring may be monocyclic or polycyclic. Preferred monovalent aromatic hydrocarbon groups are aryl groups having 6 to 12 carbon atoms, more preferably aryl groups having 6 to 10 carbon atoms, and even more preferably aryl groups having 6 carbon atoms. If the monovalent aromatic hydrocarbon group has substituents, the number of carbon atoms of the substituents is not included in the above carbon atom count. Examples of aryl groups having 6 to 12 carbon atoms include phenyl and naphthyl.
[0042] Phenyl is preferred as the monovalent aromatic hydrocarbon group.
[0043] Among these, alkyl, cycloalkyl, and aryl groups are preferred as monovalent hydrocarbon groups.
[0044] (Monovalent heterocyclic groups and related terminology) A monovalent heterocyclic group is a group obtained by removing one hydrogen atom from the heterocyclic ring of a heterocyclic compound. The valence heterocyclic group is either a monovalent aromatic heterocyclic group or a monovalent non-aromatic heterocyclic group. The heteroatoms constituting the heterocyclic group preferably include one or more selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus, boron, and silicon atoms, and more preferably include one or more selected from the group consisting of oxygen, sulfur, and nitrogen atoms.
[0045] As monovalent aromatic heterocyclic groups, those having 1 to 15 carbon atoms are preferred, those having 1 to 9 carbon atoms are more preferred, and those having 1 to 6 carbon atoms are even more preferred. If the monovalent aromatic heterocyclic group has substituents, the number of carbon atoms of the substituents is not included in the above carbon atom count. Examples of monovalent aromatic heterocyclic groups include pyrrolyl, furanyl, thiophenyl, pyridinyl, pyridadinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, indolyl, prinyl, anthraquinolyl, carbazonal, fluorenyl, quinolinyl, isoquinolinyl, quinazolinyl, and phthalazinyl.
[0046] As monovalent non-aromatic heterocyclic groups, non-aromatic heterocyclic groups having 2 to 15 carbon atoms are preferred, non-aromatic heterocyclic groups having 2 to 9 carbon atoms are more preferred, and non-aromatic heterocyclic groups having 2 to 6 carbon atoms are even more preferred. If the monovalent non-aromatic heterocyclic group has substituents, the number of carbon atoms of the substituents is not included in the above carbon atom count. Examples of monovalent non-aromatic heterocyclic groups include oxylanil, azilidinil, azetidinil, oxetanil, thietanil, pyrrolidinil, dihydrofuranil, tetrahydrofuranil, dioxolanil, tetrahydrothiophenyl, pyrrolinil, imidazolidinil, oxazolidinil, piperidinil, dihydropyranil, tetrahydropyranil, tetrahydrothiopyranil, morpholinil, thiomorpholinil, piperazinil, dihydrooxazinil, tetrahydrooxazinil, dihydropyrimidinil, and tetrahydropyrimidinil.
[0047] Among these, a 5-membered or 6-membered heterocyclic group is preferred as the monovalent heterocyclic group.
[0048] (Divalent base) Divalent groups include divalent linear hydrocarbon groups, divalent cyclic hydrocarbon groups, divalent heterocyclic groups, -C(=O)-, -C(=S)-, -NR2-, -C(=O)-NR2-, -NR2-C(=O)-, -C(=S)-NR2-, -NR2-C(=S)-, -O-, -S-, and -(O-R3). m -, and -(S-R3) m -A group having a main chain structure comprising one group selected from the group consisting of -, or two or more of these groups (for example, 2 to 10, preferably 2 to 8, more preferably 2 to 6, even more preferably 2 to 5, and particularly preferably 2 or 3). R2 represents a hydrogen atom or a substituent described later. R3 represents a divalent linear hydrocarbon group, a divalent cyclic hydrocarbon group, or a divalent heterocyclic group. m is an integer from 1 to 10, preferably an integer from 1 to 8, more preferably an integer from 1 to 6, even more preferably an integer from 1 to 5, and particularly preferably an integer from 1 to 3.
[0049] Divalent linear hydrocarbon groups are linear alkylenes, linear alkenylenes, or linear alkylenes. The linear alkylenes are linear alkylenes having 1 to 6 carbon atoms, with linear alkylenes having 1 to 4 carbon atoms being preferred. Examples of linear alkylenes include methylene, ethylene, n-propylene, n-butylene, n-pentylene, and n-hexylene. Linear alkenylenes are linear alkenylenes having 2 to 6 carbon atoms, with linear alkenylenes having 2 to 4 carbon atoms being preferred. Examples of linear alkenylenes include ethyleneylene, n-propynylene, n-butenylene, n-pentenylene, and n-hexenylene. The linear alkynylene is a linear alkynylene having 2 to 6 carbon atoms, and linear alkynylene having 2 to 4 carbon atoms is preferred. Examples of linear alkynylenes include ethynylene, n- Examples include propynylene, n-butynylene, n-pentynylene, and n-hexynylene. As the divalent linear hydrocarbon group, linear alkylenes are preferred.
[0050] Divalent cyclic hydrocarbon groups are arylenes or divalent non-aromatic cyclic hydrocarbon groups. As for the arylene, arylene having 6 to 14 carbon atoms is preferred, arylene having 6 to 10 carbon atoms is more preferred, and arylene having 6 carbon atoms is particularly preferred. Examples of arylene include phenylene, naphthylene, and anthracenylene. As for the divalent non-aromatic cyclic hydrocarbon group, a monocyclic or polycyclic divalent non-aromatic cyclic hydrocarbon group having 3 to 12 carbon atoms is preferred, a monocyclic or polycyclic divalent non-aromatic cyclic hydrocarbon group having 4 to 10 carbon atoms is more preferred, and a monocyclic divalent non-aromatic cyclic hydrocarbon group having 5 to 8 carbon atoms is particularly preferred. Examples of divalent non-aromatic cyclic hydrocarbon groups include cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, and cyclooctylene. Arylene is preferred as the divalent cyclic hydrocarbon group.
[0051] A divalent heterocyclic group is either a divalent aromatic heterocyclic group or a divalent non-aromatic heterocyclic group. The heteroatoms constituting the heterocycle preferably include one or more selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus, boron, and silicon atoms, and more preferably include one or more selected from the group consisting of oxygen, sulfur, and nitrogen atoms. As for the divalent aromatic heterocyclic group, a divalent aromatic heterocyclic group having 3 to 15 carbon atoms is preferred, a divalent aromatic heterocyclic group having 3 to 9 carbon atoms is more preferred, and a divalent aromatic heterocyclic group having 3 to 6 carbon atoms is particularly preferred. Examples of divalent aromatic heterocyclic groups include pyrrolediyl, franziyl, thiophenediyl, pyridinediyl, pyridazinediyl, pyrimidinediyl, pyrazinediyl, triazinediyl, pyrazolediyl, imidazolediyl, thiazolediyl, isothiazolediyl, oxazolediyl, isoxazolediyl, triazolediyl, tetrazolediyl, indolediyl, purinediyl, anthraquinonediyl, carbazolediyl, fluoradiyl, quinolinediyl, isoquinolinediyl, quinazolinediyl, and phthalazinediyl. As for the divalent non-aromatic heterocyclic group, a non-aromatic heterocyclic group having 3 to 15 carbon atoms is preferred, a non-aromatic heterocyclic group having 3 to 9 carbon atoms is more preferred, and a non-aromatic heterocyclic group having 3 to 6 carbon atoms is particularly preferred. Examples of divalent non-aromatic heterocyclic groups include pyrroledionediyl, pyrrolinedionediyl, oxylandiyl, aziridindiyl, azetidinediyl, oxetanediyl, thietandiyl, pyrrolidinediyl, dihydrofranziyl, tetrahydrofranziyl, dioxolanediyl, tetrahydrothiophenediyl, pyrrolinediyl, imidazolidinediyl, oxazolidinediyl, piperidinediyl, dihydropyrandiyl, tetrahydropyrandiyl, tetrahydrothiopyrandiyl, morpholinediyl, thiomorpholinediyl, piperazinediyl, dihydrooxazinediyl, tetrahydrooxazinediyl, dihydropyrimidinediyl, and tetrahydropyrimidinediyl. A divalent aromatic heterocyclic group is preferred as the divalent heterocyclic group.
[0052] Preferably, the divalent group is alkylene, arylene, -C(=O)-, -NR2-, -C(=O)-NR2-, -NR2-C(=O)-, -O-, and -(O-R3) m -A divalent group having a main chain structure containing one group selected from the group consisting of -, alkylene, arylene, -C(=O)-, -NR2-, -C(=O)-NR2-, -NR2-C(=O)-, -O-, and -(O-R3) m - is a divalent group having a main chain structure containing two or more groups selected from the group consisting of, R2 is a hydrogen atom or alkyl, R3 is alkylene or arylene, m may be an integer of 1 to 5 (i.e., 1, 2, 3, 4, or 5). Alkylene, arylene, and alkyl are the same as those described above.
[0053] The main chain structure in the divalent group may be substituted with one or more (for example, 1 to 10, preferably 1 to 8, more preferably 1 to 6, even more preferably 1 to 5, particularly preferably 1 to 3) substituents described later.
[0054] (Substituent) Examples of the substituent include the following: (i) a halogen atom; (ii) a monovalent hydrocarbon group; (iii) a monovalent heterocyclic group; (iv) aralkyl; (v) R a -O-, R a -C(=O)-, R a -O-C(=O)-, or R a -C(=O)-O- (R a represents a hydrogen atom or a monovalent hydrocarbon group.); or (vi) NR b R c -, NR b R c -C(=O)-, NR b R c -C(=O)-O-, or R b -C(=O)-NR c - (R b and R c are the same or different and each represents a hydrogen atom or a monovalent hydrocarbon group.); (vii) Nitro group, sulfate group, sulfonic acid group, cyano group, and carboxyl group.
[0055] The definitions, examples, and preferred examples of halogen atoms, monovalent hydrocarbon groups, and monovalent heterocyclic groups in the above substituents are the same as those described above.
[0056] An aralkyl refers to an arylalkyl. The definitions, examples, and preferred examples of aryl and alkyl in arylalkyls are as described above. Preferred aralkyls have 3 to 15 carbon atoms. Examples of such aralkyls include benzoyl, phenethyl, naphthylmethyl, and naphthylethyl.
[0057] Preferably, the substituents may be: (i) halogen atom; (ii) alkyl, phenyl, or naphthyl atoms having 1 to 12 carbon atoms; (iii) Aralkyl groups with 3 to 15 carbon atoms; (iv) A complex ring with 5 or 6 members; (v)R a -O-, R a -C(=O)-, R a -OC(=O)-, or R a -C(=O)-O-(R a This represents a hydrogen atom or an alkyl group with 1 to 12 carbon atoms. );(vi)NR b R c -, NR b R c -C(=O)-, NR b R c -C(=O)-O- or R b -C(=O)-NR c -(R b and R c This represents, either identical or distinct, a hydrogen atom or an alkyl group having 1 to 12 carbon atoms. (vii) The same base as those listed in (vii) above.
[0058] More preferably, the substituents may be: (i) halogen atom; (ii) Alkyl atoms having 1 to 12 carbon atoms; (iii)R a -O-, R a -C(=O)-, R a -OC(=O)-, or R a -C(=O)-O-(R a This represents a hydrogen atom or an alkyl group with 1 to 12 carbon atoms. (iv)NR b R c -, NR b R c -C(=O)-, NR b R c -C(=O)-O- or R b -C(=O)-NR c -(R b and R c This represents, either identical or distinct, a hydrogen atom or an alkyl group having 1 to 12 carbon atoms. (v) The same base as those listed in (vii) above.
[0059] More preferably, the substituents may be: (i) halogen atom; (ii) Alkyl atoms having 1 to 6 carbon atoms; (iii)R a -O-, R a -C(=O)-, R a -OC(=O)-, or R a -C(=O)-O-(R a This represents a hydrogen atom or an alkyl group with 1 to 6 carbon atoms. (iv)NR b R c -, NR b R c -C(=O)-, NR b R c -C(=O)-O- or R b -C(=O)-NR c -(R b and R cThis represents, either identical or distinct, a hydrogen atom or an alkyl group having 1 to 6 carbon atoms. (v) The same base as those listed in (vii) above.
[0060] Particularly preferred, the substituents may be: (i) halogen atom; (ii) Alkyl atoms having 1 to 4 carbon atoms; (iii)R a -O-, R a -C(=O)-, R a -OC(=O)-, or R a -C(=O)-O-(R a This represents a hydrogen atom or an alkyl group with 1 to 4 carbon atoms. (iv)NR b R c -, NR b R c -C(=O)-, NR b R c -C(=O)-O- or R b -C(=O)-NR c -(R b and R c This represents, either identically or distinctly, a hydrogen atom or an alkyl group having 1 to 4 carbon atoms. (v) The same base as those listed in (vii) above.
[0061] (Biocorthogonal functional groups) Bioorthogonal functional groups are groups that do not react with biological components (e.g., amino acids, proteins, nucleic acids, lipids, sugars, phosphates), or react slowly with biological components, but selectively react with components other than biological components. Bioorthogonal functional groups are well known in the art (see, for example, Sharpless KB et al., Angew. Chem. Int. Ed. 40, 2004 (2015); Bertozzi CR et al., Science 291, 2357 (2001); Bertozzi CR et al., Nature Chemical Biology 1, 13 (2005)).
[0062] In this invention, a bioorthogonal functional group for proteins is used as the bioorthogonal functional group. This is because the thiol-transferred antibody to be derivatized by the reagent of this invention is a protein. A bioorthogonal functional group for proteins is a group that does not react with the side chains of the 20 natural amino acid residues that make up proteins, or reacts slowly with those side chains, but reacts with the desired functional group. The 20 natural amino acids that make up proteins are alanine (A), asparagine (N), cysteine (C), glutamine (Q), glycine (G), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), proline (P), serine (S), threonine (T), tryptophan (W), tyrosine (Y), valine (V), aspartic acid (D), glutamic acid (E), arginine (R), histidine (H), and lysine (L). Of these 20 naturally occurring amino acids, glycine, which lacks a side chain (i.e., a hydrogen atom), and alanine, isoleucine, leucine, phenylalanine, and valine, whose side chains are hydrocarbon groups (i.e., their side chains do not contain heteroatoms selected from the group consisting of sulfur, nitrogen, and oxygen atoms), are inert to normal reactions. Therefore, bioorthogonal functional groups for proteins are those that do not react with the side chains of these amino acids, which have side chains that are inert to normal reactions, as well as those that react with the side chains of asparagine, glutamine, methionine, proline, serine, threonine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, histidine, and lysine, or react slowly, but do react with the functional group of interest.
[0063] Examples of such bioorthogonal functional groups include azide residues, aldehyde residues, thiol residues, alkene residues (in other words, any residue that has a vinylene (ethenylene) moiety, which is the smallest unit having an intercarbon double bond; the same applies below), alkyne residues (in other words, any residue that has an ethynylene moiety, which is the smallest unit having an intercarbon triple bond; the same applies below), halogen residues, tetrazine residues, nitrone residues, hydroxylamine residues, nitrile residues, hydrazine residues, ketone residues, boronic acid residues, cyanobenzothiazole residues, allyl residues, phosphine residues, maleimide residues, disulfide residues, thioester residues, α-halocarbonyl residues (e.g., carbonyl residues having a fluorine atom, chlorine atom, bromine atom, or iodine atom at the α-position; the same applies below), isonitrile residues, cydonone residues, and selenium residues.
[0064] More specifically, the bioorthogonal functional group may correspond to any one chemical structure selected from the group consisting of the following: [ka] [Here, R 1a , one or more R 1b , and one or more R 1c These are identical or different substituents or electron-withdrawing groups as described above. • is a joint.
[0065] Examples of electron-withdrawing groups include halogen atoms, alkyl groups substituted with halogen atoms (e.g., trifluoromethyl), boronic acid residues, mesyl, tosyl, triflate, nitro, cyano, phenyl, and keto groups (e.g., acyl), with halogen atoms, boronic acid residues, mesyl, tosyl, and triflate being preferred.
[0066] Preferably, the bioorthogonal functional group may be an alkyne residue or an azide. More preferably, the alkyne residue may be a ring group having a triple bond between carbon atoms, which may be substituted with the substituents described above.
[0067] Bioorthogonal functional groups may be protected. Bioorthogonal functional groups that may be protected This refers to either an unprotected or protected bioorthogonal functional group. An unprotected bioorthogonal functional group corresponds to the bioorthogonal functional group described above. A protected bioorthogonal functional group is a group that generates a bioorthogonal functional group by cleaving a protecting group. Cleavage of the protecting group can be performed by specific treatments under conditions (mild conditions) that do not cause protein denaturation or degradation (e.g., cleavage of amide bonds). Such specific treatments include, for example, (a) treatment with one or more substances selected from the group consisting of acidic substances, basic substances, reducing agents, oxidizing agents, and enzymes, (b) treatment with physicochemical stimuli selected from the group consisting of light, or (c) standing up with a cleavage linker containing a self-degrading cleavageable moiety. Such protecting groups and their cleavage conditions are common technical knowledge in the field (e.g., G. Leriche, L. Chisholm, A. Wagner, Bioorganic & Medicinal Chemistry. 20, 571 (2012); Feng P. et al.). al.,Journal of American Chemical Society.132,1500(2010).;Bessodes M. et al.,Journal of Controlled Release, 99,423(2004).;DeSimone,JM,Journal of American Chemical Society.132,17928(2010);Thompson,DH,Journal of Controlled Release, 91, 187 (2003); Schoenmarks, RG, Journal of Controlled Release, 95, 291 (2004)).
[0068] Examples of protected bioorthogonal functional groups include disulfide residues, ester residues, acetal residues, ketal residues, imine residues, and vicinaldiol residues.
[0069] More specifically, the protected bioorthogonal functional group may correspond to any one chemical structure selected from the following group: [ka] [Here, the wavy lines perpendicular to the joint indicate the cutting points.] One or more R 2a These are selected from the group consisting of hydrogen atoms or the substituents described above, either identical or different. • is a joint.
[0070] Preferably, the bioorthogonal functional group, which may be protected, is an unprotected bioorthogonal functional group.
[0071] (Functional substance) Functional substances are not particularly limited as long as they are substances that confer any desired function to antibodies, and examples include drugs, labeling substances, and stabilizers, but are preferably drugs or labeling substances. The functional substance may also be a single functional substance, or a substance formed by linking two or more functional substances.
[0072] The drug may be any drug used for any disease. Examples of such diseases include cancer (e.g., lung cancer, stomach cancer, colorectal cancer, pancreatic cancer, kidney cancer, liver cancer, thyroid cancer, prostate cancer, bladder cancer, ovarian cancer, uterine cancer, bone cancer, skin cancer, brain tumors, melanoma), autoimmune and inflammatory diseases (e.g., allergic diseases, rheumatoid arthritis, systemic lupus erythematosus), neurological diseases (e.g., cerebral infarction, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis), infectious diseases (e.g., bacterial infections, viral infections), hereditary and rare diseases (e.g., hereditary spherocytosis, non-dystrophic myotonia), eye diseases (e.g., age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa), bone and orthopedic diseases (e.g., osteoarthritis), blood disorders (e.g., leukemia, purpura), and other diseases (e.g., metabolic disorders such as diabetes and hyperlipidemia, liver diseases, kidney diseases, lung diseases, cardiovascular diseases, digestive system diseases). The drug may be a preventative or therapeutic agent for a disease, or a drug to alleviate side effects.
[0073] More specifically, the drug may be an anticancer agent. Examples of the anticancer agent include chemotherapeutic agents, toxins, radioisotopes, or substances containing the same. Examples of the chemotherapeutic agents include DNA damaging agents, antimetabolites, enzyme inhibitors, DNA intercalating agents, DNA cleaving agents, topoisomerase inhibitors, DNA binding inhibitors, tubulin binding inhibitors, cytotoxic nucleosides, and platinum compounds. Examples of the toxins include bacterial toxins (e.g., diphtheria toxin) and plant toxins (e.g., ricin). Examples of the radioisotopes include radioisotopes of hydrogen atoms (e.g., 3 H), radioisotopes of carbon atoms (e.g., 14 C), radioisotopes of phosphorus atoms (e.g., 32 P), radioisotopes of sulfur atoms (e.g., 35 S ), radioisotopes of yttrium (e.g., 90 Y), radioisotopes of technetium (e.g., 99m Tc), radioisotopes of indium (e.g., 111 In), radioisotopes of iodine atoms (e.g., 123 I, 125 I, 129 I, 131 I), radioisotopes of samarium (e.g., 153 Sm), rheni um radioisotopes (e.g., 186 Re), radioisotopes of astatine (e.g., 211 At), and radioisotopes of bismuth (e.g., 212 Bi). More specific examples of the drug include auristatins (MMAE, MMAF), maytansines (DM1, DM4), PBD (pyrrolobenzodiazepine), IGN, camptothecin analogs, calicheamicin, duocarmycin, eribulin, anthracycline, dmDNA31, and tubulysin.
[0074] Labeling substances are substances that enable the detection of targets (e.g., tissues, cells, materials). Examples of labeling substances include enzymes (e.g., peroxidase, alkaline phosphatase, luciferase, β-galactosidase), affinity substances (e.g., streptavidin, biotin, digoxigenin, aptamers), fluorescent substances (e.g., fluorescein, fluorescein isothiocyanate, rhodamine, green fluorescent protein, red fluorescent protein), luminescent substances (e.g., luciferin, aequorin, acridinium ester, tris(2,2'-bipyridyl)ruthenium, luminol), radioisotopes (e.g., those mentioned above), or substances containing them.
[0075] Stabilizers are substances that enable the stabilization of antibodies. Examples of stabilizers include diols, glycerin, nonionic surfactants, anionic surfactants, natural surfactants, saccharides, and polyols.
[0076] Functional substances may also be peptides, proteins, nucleic acids, small organic compounds, glycans, lipids, high molecular weight polymers, metals (e.g., gold), and chelators. Examples of peptides include cell membrane permeable peptides, blood-brain barrier permeable peptides, and peptide pharmaceuticals. Examples of proteins include enzymes, cytokines, fragment antibodies, lectins, interferons, serum albumin, and antibodies. Examples of nucleic acids include DNA, RNA, and artificial nucleic acids. Other examples of nucleic acids include RNA interference-inducible nucleic acids (e.g., siRNA), aptamers, and antisenses. Examples of small organic compounds include proteolytic chimeric molecules, dyes, and photodegradable compounds.
[0077] If a functional substance does not possess a bioorthogonal functional group that readily reacts with the bioorthogonal functional group possessed by the antibody intermediate, the functional substance may be derivatized to possess such a bioorthogonal functional group. The bioorthogonal functional group possessed by the functional substance, or the derivatized functional substance, is selected from the bioorthogonal functional groups described above, taking into consideration the bioorthogonal functional group possessed by the antibody intermediate. For example, if the bioorthogonal functional group possessed by the antibody intermediate is an alkyne residue (preferably a ring group having a triple bond between carbon atoms, which may be substituted with the substituents described above), the bioorthogonal functional group possessed by the functional substance, or the derivatized functional substance, may be an azide. Alternatively, if the bioorthogonal functional group possessed by the antibody intermediate is an azide, the bioorthogonal functional group possessed by the functional substance, or the derivatized functional substance, may be an alkyne residue (preferably a ring group having a triple bond between carbon atoms, which may be substituted with the substituents described above). Derivatization is common technical knowledge in the art (e.g., International Publication No. 2004 / 010957, U.S. Patent Application Publication No. 2006 / 0074008, U.S. Patent Application Publication No. 2005 / 0238649). For example, derivatization may be carried out using any crosslinking agent. Alternatively, derivatization may be carried out using a specific linker having the desired functional group. For example, such a linker may be capable of separating the functional substance and the antibody by linker cleavage in a suitable environment (e.g., intracellular or extracellular). Examples of such linkers include peptidyl linkers that are degraded by specific proteases (e.g., intracellular proteases (e.g., proteases present in lysosomes or endosomes), extracellular proteases (e.g., secretory proteases)) (e.g., U.S. Patent No. 6,214,345; Dubowchik et al., Pharm. Therapeutics 83:67-123 (1999)), and linkers that can be cleaved at locally acidic sites present in the body (e.g., U.S. Patent Nos. 5,622,929, 5,122,368; 5,824,805).The linker may be self-immolative (e.g., International Publication No. 02 / 083180, International Publication No. 04 / 043493, International Publication No. 05 / 112919). In this invention, derivatized functional substances are also simply referred to as "functional substances."
[0078] (salt) In the present invention, the term "salt" includes, for example, salts with inorganic acids, salts with organic acids, salts with inorganic bases, salts with organic bases, and salts with amino acids. Examples of salts with inorganic acids include salts with hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, and nitric acid. Examples of salts with organic acids include salts with formic acid, acetic acid, trifluoroacetic acid, lactic acid, tartaric acid, fumaric acid, oxalic acid, maleic acid, citric acid, succinic acid, malic acid, benzenesulfonic acid, and p-toluenesulfonic acid. Examples of salts with inorganic bases include salts with alkali metals (e.g., sodium, potassium), alkaline earth metals (e.g., calcium, magnesium), and other metals such as zinc and aluminum, as well as ammonium. Examples of salts with organic bases include salts with trimethylamine, triethylamine, propylenediamine, ethylenediamine, pyridine, ethanolamine, monoalkylethanolamine, dialkylethanolamine, diethanolamine, and triethanolamine. Examples of salts with amino acids include salts with basic amino acids (e.g., arginine, histidine, lysine, ornithine) and salts with acidic amino acids (e.g., aspartic acid, glutamic acid). Preferably, the salt is a salt with an inorganic acid (e.g., hydrogen chloride) or an organic acid (e.g., trifluoroacetic acid).
[0079] 2. Antibody composition The present invention relates to (A) the following formula (A): [ka] (In the formula, Ab is an antibody containing immunoglobulin units that include two heavy chains and two light chains, and have disulfide bonds between the heavy chains and between the heavy chains and light chains. S is a sulfur atom, L is a divalent group, R is a bioorthogonal functional group which may be protected. n is an integer from 1 to 8. An antibody intermediate or salt thereof having a protected bioorthogonal functional group, represented as ( ), and (B) The following formula (B): [ka] (In the formula, Ab is the same antibody as the antibody in formula (A), SH is a thiol group, n is the same integer as n in formula (A). The antibody comprises a thiol group-introduced antibody or a salt thereof, represented by ). The sulfur atom (S) adjacent to the antibody (Ab) in formula (A), and the thiol group (SH) adjacent to the antibody (Ab) in formula (B), are either directly bound to the atom in the side chain of the same amino acid residue located at the same position in the constant region of the antibody heavy chain, or are bound via a linker. The molecular weight of the substructure represented by LR is 700 or less. The percentage of the amount of the antibody intermediate or its salt relative to the total amount of the antibody intermediate or its salt and the thiol-modified antibody or its salt [100(%) × (amount of the antibody intermediate or its salt) / (total amount of the antibody intermediate or its salt and the thiol-modified antibody or its salt)] is 80% or more. The present invention provides an antibody composition in which the aggregation rate of the antibody intermediate or a salt thereof and the thiol-introduced antibody or a salt thereof is 5% or less.
[0080] The antibody composition of the present invention can be obtained by reacting a thiol-modified antibody with a compound represented by a "leaving group -LR" (Figure 1). Therefore, the common symbols Ab and n in formulas (A) and (B) are the same between formulas (A) and (B). Although such an antibody composition can be obtained according to the present invention, there is no motivation to obtain such an antibody composition in the prior art.
[0081] In formulas (A) and (B), Ab is an antibody containing two heavy chains and two light chains, and containing immunoglobulin units having disulfide bonds between the heavy chains and between the heavy chains and light chains. Examples of such antibodies include IgG antibodies, IgD antibodies and IgE antibodies containing two heavy chains and two light chains, and containing immunoglobulin units having disulfide bonds between the heavy chains and between the heavy chains and light chains; IgA antibodies containing four heavy chains and four light chains, and containing immunoglobulin units having disulfide bonds between the heavy chains and between the heavy chains and light chains; and antibodies containing eight heavy chains and eight light chains, and having disulfide bonds between the heavy chains and between the heavy chains and light chains. Examples include IgM antibodies containing immunoglobulin units with rufid bonds, but IgG antibodies (e.g., IgG1, IgG2, IgG3, IgG4) are preferred. The antibody is preferably a human IgG monoclonal antibody, and more preferably a human full-length IgG monoclonal antibody.
[0082] The divalent group represented by L in formula (A) is the same as that described above.
[0083] The bioorthogonal functional group that may be protected, represented by R in formula (A), is the same as that described above.
[0084] In equations (A) and (B), n is an integer between 1 and 8. Preferably, n is an integer between 1 and 6, and more preferably an integer between 1 and 4 (i.e., 1, 2, 3, or 4).
[0085] The sulfur atom (S) adjacent to the antibody (Ab) in formula (A), and the thiol group (SH) adjacent to the antibody (Ab) in formula (B), are either directly bound to the same amino acid residue in the side chain located at the same position in the constant region of the antibody heavy chain, or bound via a linker. Since the antibody composition of the present invention can be obtained by modifying a thiol-introduced antibody with a compound represented by a "leaving group -LR" (Figure 1), the binding modes of the sulfur atom (S) and the thiol group (SH) to the antibody are the same. That is, if the sulfur atom (S) is directly bound to the atom in the side chain, the thiol group (SH) is also directly bound to the same atom in the same side chain. Furthermore, if the sulfur atom (S) is bound to the atom in the side chain via a linker, the thiol group (SH) is also bound to the same atom in the same side chain via the same linker.
[0086] In one embodiment, the amino acid residue in the antibody used for binding the sulfur atom (S) and thiol group (SH) may be an amino acid residue other than a cysteine residue. As an amino acid residue other than a cysteine residue, amino acid residues having easily modifiable side chains (e.g., amino group, carboxyl group, amide group, hydroxyl group) (e.g., lysine residue, aspartic acid residue, glutamic acid residue, asparagine residue, glutamine residue, threonine residue, serine residue, tyrosine residue) can be used. Preferably, the amino acid residue is a lysine residue having a side chain containing a nitrogen atom (amino group), a tyrosine residue having a side chain containing an oxygen atom (hydroxyl group), a serine residue, and a threonine residue, and more preferably, a lysine residue.
[0087] In another embodiment, the amino acid residue in the antibody used for the binding of the sulfur atom (S) and the thiol group (SH) may be a cysteine residue. This is because the compounds used in the present invention are highly efficient in their reaction and are therefore considered useful not only for modifying thiol groups chemically introduced into antibodies, but also for modifying thiol groups in cysteine residues in antibodies.
[0088] The amino acid residues in the antibody used for the binding of the sulfur atom (S) and thiol group (SH) can be those located at predetermined positions within the constant region of the antibody heavy chain (e.g., CH1, CH2, or CH3, preferably CH2 or CH3).
[0089] In preferred specific embodiments, the amino acid residue in the antibody used for binding the sulfur atom (S) and thiol group (SH) is a lysine residue having a side chain containing a nitrogen atom (amino group). Examples of lysine residues include one or more lysine residues selected from the group consisting of positions 246 / 248, 288 / 290, and 317 in the human IgG heavy chain.
[0090] Methods for producing antibodies containing specific atoms or groups at predetermined positions by regioselectively modifying specific amino acid residues at predetermined positions are described, for example, in International Publications / 2018 / 199337, 2019 / 240288, 2019 / 240287, and 2020 / 090979. Furthermore, according to the methods described in these publications, regioselective modification of specific amino acid residues at predetermined positions can be achieved without using linkers containing peptides. Peptide moieties have potential immunogenicity and are readily hydrolyzed in the blood. Therefore, avoiding the use of linkers containing peptide moieties is desirable in clinical applications.
[0091] Preferably, as the thiol-introduced antibody, an antibody containing a thiol group that is regioselectively bound to an atom in the side chain of a specific amino acid residue located at a predetermined position in the constant region of the heavy chain (preferably a nitrogen atom in the side chain of a lysine residue) via a linker that does not contain a peptide can be used. By modifying such a thiol-introduced antibody with a compound represented by a "leaving group -LR", an antibody composition of the present invention can be obtained in which the sulfur atom (S) adjacent to the antibody (Ab) in formula (A) and the thiol group (SH) adjacent to the antibody (Ab) in formula (B) are regioselectively bound directly to an atom in the side chain of the same amino acid residue located at the same position in the constant region of the antibody heavy chain, or regioselectively bound via a linker. In this specification, "regioselectivity" means that even though a specific amino acid residue is not eclectically distributed in a particular region of the antibody, a predetermined structural unit that can bind to a specific amino acid residue in the antibody is eclectically distributed in a particular region of the antibody. Therefore, expressions related to regioselectivity, such as "regioselectively possessing," "regioselectively binding," and "regioselectively binding," mean that the possession or binding rate of a predetermined structural unit in a target region containing one or more specific amino acid residues is significantly higher than the possession or binding rate of the same structural unit in a non-target region containing multiple amino acid residues of the same type as the specific amino acid residue in the target region. Such regioselective binding or possession can be achieved by using an antibody obtained by the above method, which can regioselectively modify a specific amino acid residue at a predetermined position with a thiol group, as the thiol group-introduced antibody. Such regioselectivity may be 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, particularly preferably 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100%. Site selectivity can be confirmed, for example, by peptide mapping [see, for example, International Publication No. 2019 / 240287 (WO2019 / 240287A1)].
[0092] As a linker that does not contain peptides, the divalent group described above can be used. Preferably, when the amino acid residue in the antibody used for bonding the sulfur atom (S) and the thiol group (SH) is a lysine residue, a carbonyl-containing linker containing a -C(=O)- moiety that can form an amide bond with the amino group in the side chain of the lysine residue can be used as a linker that does not contain peptides.
[0093] Carbonyl-containing linkers include those having a -C(=O)- moiety at the end, and consisting of divalent linear hydrocarbon groups, divalent cyclic hydrocarbon groups, divalent heterocyclic groups, -C(=O)-, -C(=S)-, -NR4-, -C(=O)-NR4-, -NR4-C(=O)-, -C(=S)-NR4-, -NR4-C(=S)-, -O-, -S-, and -(O-R5). m1 -, and -(S-R5) m1 One group selected from the group consisting of -, or a group having a main chain structure containing two or more of these groups (for example, 2 to 10, preferably 2 to 8, more preferably 2 to 6, even more preferably 2 to 5, and particularly preferably 2 or 3), can be used. R4 represents a hydrogen atom or a substituent described later. R5 represents a divalent linear hydrocarbon group, a divalent cyclic hydrocarbon group, or a divalent heterocyclic group. m1 is an integer from 1 to 10, preferably an integer from 1 to 8, more preferably an integer from 1 to 6, even more preferably an integer from 1 to 5, and particularly preferably an integer from 1 to 3.
[0094] Preferably, the carbonyl-containing linker has a -C(=O)- moiety at its terminus and contains alkylene, arylene, -C(=O)-, -NR2-, -C(=O)-NR4-, -NR4-C(=O)-, -O-, and -(O-R5) m1 -A divalent group having a main chain structure containing one group selected from the group consisting of -, It has -C(=O)- at its terminus, and is alkylene, arylene, -C(=O)-, -NR4-, -C(=O)-NR4-, -NR4-C(=O)-, -O-, and -(O-R5) m -A divalent group having a main chain structure containing two or more groups selected from the group consisting of, R2 is a hydrogen atom or an alkyl group. R3 is alkylene or arylene. m may be an integer between 1 and 5 (i.e., 1, 2, 3, 4, or 5). Alkylenes, arylenes, and alkyls are the same as those described above.
[0095] More preferably, the carbonyl-containing linker may be a divalent group having a -C(=O)- moiety at its terminus and a main chain structure containing alkylene or arylene or a combination thereof.
[0096] More preferably, the carbonyl-containing linker may be a divalent group having a main chain structure including a -C(=O)- moiety and an alkylene (e.g., -C(=O)-CH2-CH2-).
[0097] The main chain structure of the carbonyl-containing linker may be substituted with one or more of the above-mentioned substituents (for example, 1 to 10, preferably 1 to 8, more preferably 1 to 6, even more preferably 1 to 5, and particularly preferably 1 to 3).
[0098] In the present invention, the molecular weight of the substructure represented by LR in formula (A) is 700 or less. When the molecular weight of the substructure represented by LR is 700 or less, antibody intermediates or salts thereof having bioorthogonal functional groups that may be protected, and thiol-transformed antibodies or salts thereof, are difficult to separate based on molecular weight differences because the ratio of the molecular weight of the substructure to the molecular weight of the entire antibody is very small. The molecular weight of the substructure represented by LR is preferably 600 or less, more preferably 500 or less, even more preferably 400 or less, and particularly preferably 300 or less, 250 or less, 200 or less, or 150 or less.
[0099] In the present invention, the percentage of the amount of antibody intermediate or its salt relative to the total amount of antibody intermediate or its salt and thiol-modified antibody or its salt [100 (%) × (amount of antibody intermediate or its salt) / (total amount of antibody intermediate or its salt and thiol-modified antibody or its salt)] is 80% or more. The compounds or their salts used in the present invention exhibit excellent reaction efficiency with thiol-modified antibodies or their salts, thus enabling the achievement of such good reactivity expressed in percentages. Such percentages are preferably 82% or more, more preferably 84% or more, even more preferably 86% or more, particularly preferably 88% or more, 90% or more, 92% or more, 94% or more, or 96% or more. Such percentages can be determined based on measurements by reverse-phase HPLC or mass spectrometry under reducing conditions (see Examples).
[0100] In this invention, the aggregation rate of the antibody intermediate or its salt and the thiol-modified antibody or its salt is 5% or less. Modification of the thiol-modified antibody with the compounds used in this invention can be carried out under conditions (mild conditions) that do not cause protein denaturation or degradation (e.g., cleavage of amide bonds), and is therefore less likely to cause antibody aggregation. The aggregation rate is preferably 4%. The antibody aggregation rate is 0.8% or less, more preferably 4.6% or less, even more preferably 4.4% or less, and particularly preferably 4.2% or less, 4.0% or less, 3.8% or less, 3.6% or less, or 3.4% or less. The antibody aggregation rate can be measured by size exclusion chromatography (SEC)-HPLC (see Examples and ACS Omega 2020, 5, 7193-7200).
[0101] Details of the antibody intermediates or salts contained in the antibody composition are described below regarding the antibody intermediates or salts.
[0102] The antibody composition of the present invention may further include (A) an antibody intermediate having an optionally protected bioorthogonal functional group or a salt thereof, and (B) a thiol-transferred antibody or a salt thereof, in addition to an antibody used as a raw material for the production of the thiol-transferred antibody. In this case, the properties of the antibody used as a raw material for the production of the thiol-transferred antibody can be inherited by the "antibody intermediate having an optionally protected bioorthogonal functional group" and the "thiol-transferred antibody." Therefore, the antibody used as a raw material for the production of the thiol-transferred antibody can be defined in the same way as the "antibody" in the "antibody intermediate having an optionally protected bioorthogonal functional group" and the "thiol-transferred antibody."
[0103] The antibody composition of the present invention can be obtained by reacting a thiol-introduced antibody with a compound represented by "leaving group-LR" (Figure 1). In such a reaction, the thiol group in the thiol-introduced antibody binds to the leaving group-bonding atom in L of the compound represented by "leaving group-LR", and the leaving group detaches from the leaving group-bonding atom, resulting in an antibody composition containing an antibody intermediate or its salt (reaction product) and a thiol-introduced antibody or its salt (unreacted product). The molar ratio of the compound represented by "leaving group-LR" or its salt to the thiol-introduced antibody or its salt in the reaction (compound represented by "leaving group-LR" or its salt / thiol-introduced antibody or its salt) is not particularly limited as it varies depending on factors such as the type of compound represented by "leaving group-LR" or its salt and the type of thiol-introduced antibody, but is for example 1 to 100, preferably 2 to 80, and more preferably 3 to 50.
[0104] Such reactions can be carried out as appropriate under mild conditions that do not cause protein denaturation or degradation (e.g., cleavage of amide bonds). For example, such reactions can be carried out at room temperature (e.g., about 15-30°C) in a suitable reaction system, such as a buffer. The pH of the buffer is, for example, 5-9, preferably 5.5-8.5, and more preferably 6.0-8.0. The buffer may contain a suitable catalyst. The reaction time is, for example, 1 minute to 20 hours, preferably 10 minutes to 15 hours, more preferably 20 minutes to 10 hours, and even more preferably 30 minutes to 8 hours. For details on such reactions, see, for example, GJLBernardes et al., Chem. Rev., 115, 2174 (2015); GJLBernardes et al., Chem. Asian. J., 4, 630 (2009); BGDavies et al., Nat. Commun., 5, 4740 (2014); A. Wagner et al., Bioconjugate. Chem., 25, 825 (2014).
[0105] Confirmation of the formation of antibody intermediates or their salts can be performed, depending on the specific molecular weights of the raw materials and products, for example, by reverse-phase HPLC under reducing conditions or by mass spectrometry.
[0106] The antibody composition of the present invention can contain an antibody intermediate or salt thereof having a bioorthogonal functional group, which may be protected, in a high content at a low aggregation rate. The antibody intermediate or salt thereof having a bioorthogonal functional group, which may be protected, can be used in the production of antibody and functional substance conjugates or salts thereof. Therefore, the antibody composition of the present invention The product can efficiently produce antibody and functional substance conjugates or salts thereof under conditions of low aggregation.
[0107] 3. Reagents for the derivatization of thiol-transformed antibodies or their salts This invention provides reagents for the derivatization of thiol-group-introduced antibodies or salts thereof.
[0108] In one embodiment, the reagent of the present invention comprises a compound represented by the following formula (I) or a salt thereof. [ka] (In the formula, X is a halogen atom, Q is either allerene or alkylene. Y is a bond or a divalent group, R is a bioorthogonal functional group that may be protected.
[0109] The halogen atom represented by X in equation (I) is the same as that described above.
[0110] Examples of arylenes represented by Q in formula (I) include phenylene, naphthylene, and anthracenylene, with phenylene and naphthylene being preferred, and phenylene being preferred. Examples of alkylenes represented by Q in formula (I) include linear or branched alkylenes, with linear alkylenes being preferred. Among linear alkylenes, linear alkylenes having 1 to 6 carbon atoms are preferred, and linear alkylenes having 1 to 4 carbon atoms are more preferred.
[0111] The divalent group represented by Y in equation (I) is the same as that described above.
[0112] In certain embodiments, the divalent group represented by Y in formula (I) is -(O-R5) m1 It may also be a group having a main chain structure containing -. R5 and m1 are the same as those described above.
[0113] The bioorthogonal functional group that may be protected, represented by R in formula (I), is the same as that described above.
[0114] In another embodiment, the reagent of the present invention comprises a compound represented by the following formula (II) or a salt thereof. [ka] (In the formula, R1 is an alkyl group, Y is a divalent group, R is a bioorthogonal functional group that may be protected.
[0115] The alkyl group represented by R1 in formula (II) is the same as that described above.
[0116] The divalent group represented by Y in equation (II) is the same as that described above.
[0117] The bioorthogonal functional group that may be protected, represented by R in formula (II), is the same as that described above.
[0118] In yet another embodiment, the reagent of the present invention comprises a compound represented by the following formula (III) or a salt thereof. [ka] (In the formula, Y is a divalent group, R is a bioorthogonal functional group that may be protected.
[0119] The divalent group represented by Y in equation (III) is the same as that described above.
[0120] The bioorthogonal functional group that may be protected, represented by R in formula (III), is the same as that described above.
[0121] In yet another embodiment, the reagent of the present invention comprises a compound represented by the following formula (IV) or a salt thereof. [ka] (In the formula, Y is a divalent group, R is a bioorthogonal functional group that may be protected.
[0122] The divalent group represented by Y in equation (IV) is the same as that described above.
[0123] The bioorthogonal functional group that may be protected, represented by R in formula (IV), is the same as that described above.
[0124] More specifically, the compounds represented by formulas (I) to (IV) may also be the compounds represented by the following formulas (1) to (12). [ka] [ka] (In the formula, k is an integer, either 0 or 1. m is an integer between 1 and 5 (preferably an integer between 1 and 3). m' is an integer between 1 and 5 (preferably an integer between 1 and 3), R2 and R3 are, independently, a hydrogen atom or a methyl atom. R6 is a bio-orthogonal functional group that may be protected. X, R1, Q, and R are the same as those described above.
[0125] The thiol-transferred antibody or its salt derived by the reagent of the present invention is as described above for the thiol-transferred antibody or antibody. For example, the thiol group in the thiol-transferred antibody may be regioselectively bound to an atom in the side chain of an amino acid residue in the constant region of the antibody heavy chain (e.g., an amino acid residue having the easily modifiable side chain described above) (preferably a nitrogen atom in the side chain of a lysine residue) via a linker that does not contain a peptide. The thiol-transferred antibody may also be an IgG antibody. When a human IgG antibody is used as the thiol-transferred antibody, such a lysine residue may be located at one or more positions selected from the group consisting of positions 246 / 248, 288 / 290, and 317 of the human IgG heavy chain in EU numbering.
[0126] The reagent of the present invention can derivatize a thiol-introduced antibody or a salt thereof by reacting with a thiol group in the antibody or a salt thereof (preferably a thiol group introduced via a side chain of a lysine residue).
[0127] The reagents of the present invention may be provided in the form of compositions further comprising other components. Such other components include, for example, solutions and stabilizers (e.g., antioxidants, preservatives). As the solution, aqueous solutions are preferred. Examples of aqueous solutions include water (e.g., distilled water, sterile distilled water, purified water, physiological saline) and buffer solutions (e.g., aqueous phosphoric acid solution, Tris-hydrochloride buffer, carbonic acid-bicarbonate buffer, aqueous boric acid solution, glycine-sodium hydroxide buffer, citrate buffer), but buffer solutions are preferred. The pH of the solution is, for example, 5.0 to 9.0, preferably 5.5 to 8.5. The reagents of the present invention can be provided in liquid or powder form (e.g., lyophilized powder).
[0128] 4. Compounds or their salts The present invention also provides compounds or salts thereof.
[0129] In one embodiment, the compound of the present invention is a compound represented by the following formula (I) or a salt thereof. [ka] (In the formula, X is a halogen atom, Q is either allerene or alkylene. Y is a divalent group, R is a bioorthogonal functional group that may be protected.
[0130] In formula (I), the halogen atom represented by X, the arylene or alkylene represented by Q, the divalent group represented by Y, and the optionally protected bioorthogonal functional group represented by R are the same as those described above.
[0131] In another embodiment, the compound of the present invention is a compound represented by the following formula (II) or a salt thereof. [ka] (In the formula, R1 is an alkyl group, Y is a divalent group, R is a bioorthogonal functional group that may be protected.
[0132] In formula (II), R1 represents an alkyl group, Y represents a divalent group, and R represents The bioorthogonal functional groups that may be protected are the same as those described above.
[0133] In yet another embodiment, the compound of the present invention is a compound represented by the following formula (III) or a salt thereof. [ka] (In the formula, Y is a divalent group, R is a bioorthogonal functional group that may be protected.
[0134] In formula (III), the divalent group represented by Y and the optionally protected bioorthogonal functional group represented by R are the same as those described above.
[0135] In yet another embodiment, the compound of the present invention is a compound represented by the following formula (IV) or a salt thereof. [ka] (In the formula, Y is a divalent group, R is a bioorthogonal functional group that may be protected.
[0136] In formula (IV), the divalent group represented by Y and the optionally protected bioorthogonal functional group represented by R are the same as those described above.
[0137] More specifically, the compounds represented by formulas (I) to (IV) may also be the compounds represented by formulas (2) to (12) above.
[0138] The compounds represented by formulas (I) to (IV) can be obtained by the synthesis reactions described in the examples. For example, such reactions can be carried out in a suitable organic solvent system at a suitable temperature (e.g., about 4 to 90°C). The reaction time is, for example, 1 minute to 20 hours, preferably 10 minutes to 15 hours.
[0139] The formation of the aforementioned series of compounds or their salts can be confirmed by methods such as NMR and mass spectrometry, depending on the specific molecular weights of the raw materials and products. Such compounds or their salts can be purified as appropriate by any method, such as chromatography, solvent extraction, and recrystallization.
[0140] The compound or salt of the present invention is used in the derivatization of thiol-transferred antibodies or salts thereof. It is possible.
[0141] 5. Antibody intermediates or their salts The present invention provides antibody intermediates or salts thereof having bioorthogonal functional groups which may be protected.
[0142] In one embodiment, the antibody intermediate of the present invention is an antibody intermediate having a bioorthogonal functional group which may be protected, represented by the following formula (I'). [ka] (In the formula, Ab is an antibody, S is a sulfur atom, Q is either allerene or alkylene. Y is a bond or a divalent group, R is a bioorthogonal functional group which may be protected. n is an integer between 1 and 8.
[0143] The relationship between the antibody represented by Ab in formula (I') and the adjacent sulfur atom (S) is the same as described above for thiol-introduced antibodies or antibodies. For example, the sulfur atom (S) adjacent to the antibody may be regioselectively bound to an atom in the side chain of an amino acid residue in the constant region of the antibody heavy chain (e.g., an amino acid residue having the easily modifiable side chain described above) (preferably a nitrogen atom in the side chain of a lysine residue) via a linker that does not contain a peptide. The antibody may also be an antibody containing an immunoglobulin unit comprising two heavy chains and two light chains (preferably an antibody containing an immunoglobulin unit comprising two heavy chains and two light chains, and having disulfide bonds between the heavy chains and between the heavy chains and light chains). Furthermore, the antibody may be an IgG antibody. When a human IgG antibody is used as the antibody, such lysine residues may be located at one or more positions selected from the group consisting of positions 246 / 248, 288 / 290, and 317 of the human IgG heavy chain in EU numbering. The positional selectivity and its degree are the same as described above. Positional selectivity can be verified using the method described above.
[0144] n in formula (I') is an integer of 1 to 8, preferably an integer of 1 to 6, more preferably an integer of 1 to 4 (i.e., 1, 2, 3, or 4).
[0145] Examples of the arylene represented by Q in formula (I') include phenylene, naphthylene, and anthracenylene, among which phenylene and naphthylene are preferred, and phenylene is more preferred. Examples of the alkylene represented by Q in formula (I') include linear or branched alkylene, among which linear alkylene is preferred. As the linear alkylene, a linear alkylene having 1 to 6 carbon atoms is preferred, and a linear alkylene having 1 to 4 carbon atoms is more preferred.
[0146] In formula (I'), the divalent group represented by Y and the optionally protected bioorthogonal functional group represented by R are the same as those described above.
[0147] In a specific embodiment, the divalent group represented by Y in formula (I') may be -(O-R5) m1 - and has a main chain structure containing the aforementioned moiety. R5 and m1 are the same as those described above.
[0148] In another embodiment, the antibody intermediate of the present invention is an antibody intermediate having an optionally protected bioorthogonal functional group, which is represented by the following formula (II').
Chemical Formula
[0149] In formula (II'), the antibody represented by Ab, the relationship between the antibody and its adjacent sulfur atom (S), the integer represented by n, the divalent group represented by Y, and the optionally protected bioorthogonal functional group represented by R are the same as those described above.
[0150] In yet another embodiment, the antibody intermediate of the present invention is an antibody intermediate having a bioorthogonal functional group which may be protected, represented by the following formula (III'). [ka] (In the formula, Ab is an antibody, S is a sulfur atom, Y is a bond or a divalent group, R is a bioorthogonal functional group which may be protected. n is an integer between 1 and 8.
[0151] In formula (III'), the antibody represented by Ab, the relationship between the antibody and its adjacent sulfur atom (S), the integer represented by n, the divalent group represented by Y, and the optionally protected bioorthogonal functional group represented by R are the same as those described above.
[0152] In yet another embodiment, the antibody intermediate of the present invention is an antibody intermediate having a bioorthogonal functional group which may be protected, represented by the following formula (IV'). [ka] (In the formula, Ab is an antibody, S is a sulfur atom, Y is a bond or a divalent group, R is a bioorthogonal functional group which may be protected. n is an integer between 1 and 8.
[0153] In formula (IV'), the antibody represented by Ab, the relationship between the antibody and the adjacent sulfur atom (S), the integer represented by n, the divalent group represented by Y, and the optionally protected bioorthogonal functional group represented by R are the same as those described above.
[0154] More specifically, the antibody intermediates represented by formulas (I') to (IV') may be antibody intermediates represented by the following formulas (1') to (12').
Chemical Formula
Chemical Formula
[0155] The aggregation rate of the antibody intermediate or a salt thereof of the present invention may be 5% or less. This is because the modification of the thiol group-introduced antibody with the compound used in the present invention can be carried out under conditions (mild conditions) that cannot cause protein denaturation and degradation (e.g., cleavage of amide bonds), and hardly causes antibody aggregation. The aggregation rate is preferably 4.8% or less, more preferably 4.6% or less, even more preferably 4.4% or less, particularly preferably 4.2% or less, 4.0% or less, 3.8% or less, 3.6% or less, or 3.4% or less. The aggregation rate of the antibody can be determined by size exclusion chromatography (SEC)-HPLC (see Examples and ACS Omega 2020, 5, 7193-7200).
[0156] The antibody intermediate or salt of the present invention may also have high blood stability.
[0157] The antibody intermediate of the present invention can be obtained by reacting a thiol-introduced antibody with a compound represented by formulas (I) to (IV) or a salt thereof (Figure 1). The molar ratio of the compound represented by formulas (I) to (IV) or a salt thereof to the thiol-introduced antibody or a salt thereof in the reaction (compound represented by formulas (I) to (IV) or a salt thereof / thiol-introduced antibody or a salt thereof) is not particularly limited as it varies depending on factors such as the type of compound represented by formulas (I) to (IV) or a salt thereof and the type of thiol-introduced antibody, but is for example 1 to 100, preferably 2 to 80, and more preferably 3 to 50.
[0158] Such reactions can be carried out as appropriate under mild conditions that do not cause protein denaturation or degradation (e.g., cleavage of amide bonds). For example, such reactions can be carried out at room temperature (e.g., about 15-30°C) in a suitable reaction system, such as a buffer. The pH of the buffer is, for example, 5-9, preferably 5.5-8.5, and more preferably 6.0-8.0. The buffer may contain a suitable catalyst. The reaction time is, for example, 1 minute to 20 hours, preferably 10 minutes to 15 hours, more preferably 20 minutes to 10 hours, and even more preferably 30 minutes to 8 hours. For details on such reactions, see, for example, GJLBernardes et al., Chem. Rev., 115, 2174 (2015); GJLBernardes et al., Chem. Asian. J., 4, 630 (2009); BGDavies et al., Nat. Commun., 5, 4740 (2014); A. Wagner et al., Bioconjugate. Chem., 25, 825 (2014).
[0159] Confirmation of the formation of antibody intermediates or their salts can be performed, depending on the specific molecular weights of the raw materials and products, for example, by reverse-phase HPLC under reducing conditions or by mass spectrometry.
[0160] The antibody intermediate of the present invention can be used in the production of antibody and functional substance conjugates or salts thereof.
[0161] 6. Conjugates of antibodies and functional substances or their salts This invention provides antibody and functional substance conjugates or salts thereof.
[0162] In one embodiment, the conjugate of the present invention is a conjugate of an antibody and a functional substance represented by the following formula (I''). [ka] (In the formula, Ab is an antibody, S is a sulfur atom, Q is either allerene or alkylene. Y is a bond or a divalent group, R' is a group produced by the reaction between two bioorthogonal functional groups that can react with each other. Z is a functional substance, n is an integer between 1 and 8.
[0163] The relationship between the antibody represented by Ab in formula (I'') and the adjacent sulfur atom (S) is the same as described above for thiol-introduced antibodies or antibodies. For example, the sulfur atom (S) adjacent to the antibody may be regioselectively bound to an atom in the side chain of an amino acid residue in the constant region of the antibody heavy chain (e.g., an amino acid residue having the easily modifiable side chain described above) (preferably a nitrogen atom in the side chain of a lysine residue) via a linker that does not contain a peptide. The antibody may also be an antibody containing an immunoglobulin unit comprising two heavy chains and two light chains (preferably an antibody containing an immunoglobulin unit comprising two heavy chains and two light chains, and having disulfide bonds between the heavy chains and between the heavy chains and light chains). Furthermore, the antibody may be an IgG antibody. When a human IgG antibody is used as the antibody, such lysine residues may be located at one or more positions selected from the group consisting of positions 246 / 248, 288 / 290, and 317 of the human IgG heavy chain in EU numbering. The positional selectivity and its degree are the same as described above. Positional selectivity can be verified using the method described above.
[0164] In equation (I''), n is an integer between 1 and 8, preferably between 1 and 6, and more preferably between 1 and 4 (i.e., 1, 2, 3, or 4).
[0165] The group produced by the reaction between two mutually reactive bioorthogonal functional groups represented by R' in formula (I'') is a group produced by the reaction between a bioorthogonal functional group held by an antibody intermediate and a bioorthogonal functional group held by a functional substance (where these bioorthogonal functional groups are selected in a mutually reactive combination). Since combinations of two mutually reactive bioorthogonal functional groups are well known, those skilled in the art can appropriately select such combinations to appropriately set up a divalent group that includes a portion produced by the reaction of two mutually reactive bioorthogonal functional groups. Examples of bioorthogonal functional groups that can react with each other include combinations of thiol residues and maleimide residues, combinations of furan residues and maleimide residues, combinations of thiol residues and halocarbonyl residues (where the halogen is replaced by a thiol through a substitution reaction), combinations of alkyne residues (preferably ring groups having a triple bond between carbon atoms, which may be substituted with substituents as described above) and azide residues, combinations of tetrazine residues and alkene residues, combinations of tetrazine residues and alkyne residues, and combinations of thiol residues and other thiol residues (disulfide bond). Therefore, the above portion may be a group produced by the reaction of a thiol residue and a maleimide residue, a group produced by the reaction of a furan residue and a maleimide residue, a group produced by the reaction of a thiol residue and a halocarbonyl residue, a group produced by the reaction of an alkyne residue and an azide residue, or a group produced by the reaction of a tetrazine residue and an alkene residue, or a disulfide group produced by a combination of a thiol residue and another thiol residue. Examples of combinations of bioorthogonal functional groups that can react with each other include combinations of alkyne residues (preferably ring groups having triple bonds between carbon atoms, which may be substituted with substituents as described above) and azides, combinations of thiols and maleimides, combinations of tetrazines and azides, and combinations of furans and maleimides. Preferably, the combination of bioorthogonal functional groups that can react with each other may be a combination of alkyne residues (preferably ring groups having triple bonds between carbon atoms, which may be substituted with substituents as described above) and azides.When a combination of an alkyne residue and an azide is used as two mutually reactive bioorthogonal functional groups, R' is a divalent triazole ring group. When a combination of a ring group having a triple bond between carbon atoms and an azide is used as two mutually reactive bioorthogonal functional groups, R' is a divalent ring group formed by the fusion of the said ring group and a triazole ring. Since the ring group having a triple bond between carbon atoms may be substituted with substituents as described above, the divalent ring group formed by the fusion of the said ring group and a triazole ring may also be substituted with substituents as described above.
[0166] In certain embodiments, the group produced by the reaction between two bioorthogonal functional groups that can react with each other may be a divalent group represented by one of the following structural formulas. [ka] [Here, white and black circles indicate bonding sites. If the white circle bond is connected to an atom on the Ab bond side, the black circle bond may be connected to a Z atom, and if the white circle bond is connected to a Z atom, the black circle bond may be connected to an atom on the Ab bond side.]
[0167] Examples of arylene represented by Q in formula (I'') include phenylene, naphthylene, and anthracenylene, with phenylene and naphthylene being preferred, and phenylene being preferred. Examples of alkylene represented by Q in formula (I'') include linear or branched alkylenes, with linear alkylenes being preferred. Among linear alkylenes, linear alkylenes having 1 to 6 carbon atoms are preferred, and linear alkylenes having 1 to 4 carbon atoms are more preferred.
[0168] In formula (I''), the divalent group represented by Y and the functional substance represented by Z are the same as those described above.
[0169] In certain embodiments, the divalent group represented by Y in formula (I'') is -(O-R5) m1It may also be a group having a main chain structure containing -. R5 and m1 are the same as those described above.
[0170] In another embodiment, the conjugate of the present invention is a conjugate of an antibody and a functional substance represented by the following formula (II''). [ka] (In the formula, Ab is an antibody, S is a sulfur atom, Y is a bond or a divalent group, R' is a group produced by the reaction between two bioorthogonal functional groups that can react with each other. Z is a functional substance, n is an integer between 1 and 8.
[0171] The antibody represented by Ab in formula (II''), the relationship between the antibody and its adjacent sulfur atom (S), the integer represented by n, the divalent group represented by Y, the group produced by the reaction between two mutually reactive bioorthogonal functional groups represented by R', and the functional substance represented by Z are the same as those described above.
[0172] In yet another embodiment, the conjugate of the present invention is a conjugate of an antibody and a functional substance represented by the following formula (III''). [ka] (In the formula, Ab is an antibody, S is a sulfur atom, Y is a bond or a divalent group, R' is a group produced by the reaction between two bioorthogonal functional groups that can react with each other. Z is a functional substance, n is an integer between 1 and 8.
[0173] The antibody represented by Ab in formula (III''), the relationship between the antibody and its adjacent sulfur atom (S), the integer represented by n, the divalent group represented by Y, the group produced by the reaction between two mutually reactive bioorthogonal functional groups represented by R', and the functional substance represented by Z are the same as those described above.
[0174] In yet another embodiment, the conjugate of the present invention is a conjugate of an antibody and a functional substance represented by the following formula (IV''). [ka] (In the formula, Ab is an antibody, S is a sulfur atom, Y is a bond or a divalent group, R' is a group produced by the reaction between two bioorthogonal functional groups that can react with each other. Z is a functional substance, n is an integer between 1 and 8.
[0175] The antibody represented by Ab in formula (IV''), the relationship between the antibody and its adjacent sulfur atom (S), the integer represented by n, the divalent group represented by Y, the group produced by the reaction between two mutually reactive bioorthogonal functional groups represented by R', and the functional substance represented by Z are the same as those described above.
[0176] More specifically, the conjugates represented by equations (I'') to (IV'') may also be the conjugates represented by the following equations (1'') to (12''). [ka] [ka] (In the formula, k is an integer, either 0 or 1. m is an integer between 1 and 5 (preferably an integer between 1 and 3). m' is an integer between 1 and 5 (preferably an integer between 1 and 3), R2 and R3 are, independently, a hydrogen atom or a methyl atom. R6' is a group produced by the reaction between two bioorthogonal functional groups that are reactive with each other. Z' is a functional substance, The S, Q, R', Z, and n adjacent to Ab and Ab are the same as those described above.
[0177] The aggregation rate of the conjugate or salt of the present invention may be 10% or less. The antibody intermediate or salt used in the present invention has an aggregation rate of 5% or less, and the conjugate or salt of the present invention is used to denature and degrade such antibody intermediate or salt of protein. For example, it can be obtained by subjecting the reaction to conditions (mild conditions) that do not cause amide bond cleavage, and thus is less likely to cause antibody aggregation. The aggregation rate is preferably 9% or less, more preferably 8.5% or less, even more preferably 8.0% or less, and particularly preferably 7.5% or less, 7.0% or less, 6.5% or less, 6.0% or less, 5.5% or less, 5% or less, 4.8% or less, 4.6% or less, 4.4% or less, 4.2% or less, 4.0% or less, 3.8% or less, 3.6% or less, or 3.4% or less. The antibody aggregation rate can be measured by size exclusion chromatography (SEC)-HPLC (see Examples and ACS Omega 2020, 5, 7193-7200).
[0178] The conjugate or salt of the present invention can also have high blood stability.
[0179] The conjugate or salt thereof of the present invention can be obtained by reacting the antibody intermediate or salt thereof of the present invention with a functional substance. Such a reaction can be carried out under conditions that do not cause denaturation or degradation of proteins (immunoglobulin / antibody) (e.g., cleavage of amide bonds) (mild conditions as described above). In the reaction, the molar ratio of the functional substance to the antibody intermediate or salt thereof (functional substance / antibody intermediate or salt thereof) is not particularly limited as it varies depending on factors such as the type of antibody intermediate or salt thereof, the type of functional substance, and the reaction time, but is for example 2 or more, preferably 3 or more, and more preferably 5 or more. In order to sufficiently react the functional substance with the thiol group of the antibody intermediate in a short reaction time, a sufficient amount (e.g., an excess amount) of the functional substance relative to the antibody intermediate or salt thereof can be used.
[0180] The formation of the conjugate or its salt can be confirmed by reverse-phase HPLC under reducing conditions or by mass spectrometry, depending on the specific molecular weights of the raw materials and products. The conjugate or its salt can be purified as appropriate by any method, such as chromatography (e.g., affinity chromatography).
[0181] The conjugate or salt of the present invention can be used, for example, as a pharmaceutical or reagent (e.g., a diagnostic agent, a research reagent).
[0182] The conjugate or salt thereof of the present invention may be provided in the form of a pharmaceutical composition. Such a pharmaceutical composition may contain, in addition to the conjugate or salt thereof of the present invention, a pharmaceutically acceptable carrier. Examples of pharmaceutically acceptable carriers include, but are not limited to, excipients such as sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, and calcium carbonate; binders such as cellulose, methylcellulose, hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, and starch; disintegrants such as starch, carboxymethylcellulose, hydroxypropyl starch, sodium bicarbonate, calcium phosphate, and calcium citrate; lubricants such as magnesium stearate, aerosil, talc, and sodium lauryl sulfate; fragrances such as citric acid, menthol, glycyrrhizine ammonium salt, glycine, and orange powder; preservatives such as sodium benzoate, sodium bisulfite, methylparaben, and propylparaben; stabilizers such as citric acid, sodium citrate, and acetic acid; suspending agents such as methylcellulose, polyvinylpyrrolidone, and aluminum stearate; dispersants such as surfactants; diluents such as water, physiological saline, and orange juice; and base waxes such as cocoa butter, polyethylene glycol, and kerosene. The conjugate or salt of the present invention may also have any modifications (e.g., PEGylation) that provide stability.
[0183] Suitable formulations for oral administration include liquid preparations in which an effective amount of ligand is dissolved in a diluent such as water, saline solution, or orange juice, and capsules containing an effective amount of ligand in solid or granular form. These include formulations, sachets or tablets, suspensions in which an effective amount of the active ingredient is suspended in a suitable dispersion medium, and emulsions in which a solution of an effective amount of the active ingredient is dispersed in a suitable dispersion medium and emulsified.
[0184] Pharmaceutical compositions are suitable for parenteral administration (e.g., intravenous injection, subcutaneous injection, intramuscular injection, local injection, intraperitoneal administration). Suitable pharmaceutical compositions for such parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions, which may contain antioxidants, buffers, antibacterial agents, isotonic agents, etc. Also, aqueous and non-aqueous sterile suspensions are examples, which may contain suspending agents, solubilizers, thickeners, stabilizers, preservatives, etc.
[0185] The dosage of a pharmaceutical composition varies depending on the type and activity of the active ingredient, the severity of the disease, the target animal species, the target animal's drug tolerance, body weight, age, etc., but can be set as appropriate. [Examples]
[0186] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.
[0187] Comparative Example 1: Introduction of an azide group by N-(4-azidophenyl)-2-iodo-acetamide [ka]
[0188] In the following comparative examples and examples, the antibody derivative (thiol-modified trastuzumab) described in Examples 81-7 of International Publication No. 2019 / 240287 (WO2019 / 240287A1) was used as the thiol-modified antibody. This antibody derivative has the following structure in which a thiol group is regioselectively introduced into trastuzumab (humanized IgG1 antibody) via the amino group of the side chain of the lysine residue at position 246 or 248 of the antibody heavy chain (the position of the lysine residue follows EU numbering). [ka] (In the above structure, the NH-CH2-CH2-CH2-CH2- extending from the antibody heavy chain corresponds to the side chain of the lysine residue, and the thiol-containing group HS-CH2-CH2-C(=O) is attached to the amino group in the side chain of this lysine residue.)
[0189] To a 50 μM solution of thiol-introduced antibody in buffer (pH 8.0 HEPES buffer), 20 equivalents of N-(4-azidophenyl)-2-iodo-acetamide in DMF solution (12.5 mM) and 50 equivalents of sodium iodide buffer (pH 8.0 HEPES buffer) solution (100 mM) were added. After standing at 37°C for 2 hours, the solution was purified using NAP-5 Columns (GE Healthcare).
[0190] Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was then measured by ESI-TOFMS according to a previously reported method (WO2019 / 240287A1). The thiol-group-introduced antibody used as the starting material showed heavy chain peaks at 50683 and 50845, and a light chain peak at 23439. The product showed heavy chain peaks at 50831 and 50993, where an azide group was introduced into the heavy chain, as well as at 50683 and 50845, the same as the starting material, and a light chain peak at 23439.
[0191] Comparative Example 2: Introduction of azide groups by N-[2-[2-(2-Azidoethoxy)ethoxy]ethyl]-2-iodoaacetamide [ka]
[0192] To a 50 μM solution of thiol-introduced antibody in buffer (pH 8.0 HEPES buffer), 50 equivalents of N-[2-[2-(2-Azidoethoxy)ethoxy]ethyl]-2-iodoacetamide in DMF (31.3 mM) and 50 equivalents of sodium iodide buffer (pH 8.0 HEPES buffer) (100 mM) were added. After standing at 37°C for 2 hours, the solution was purified using NAP-5 Columns (GE Healthcare).
[0193] Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was then measured by ESI-TOFMS according to a previously reported method (WO2019 / 240287A1). The thiol-group-introduced antibody used as the starting material showed heavy chain peaks at 50683 and 50845, and a light chain peak at 23439. The product showed heavy chain peaks at 50896 and 51058, where an azide group was introduced into the heavy chain, as well as at 50683 and 50845, the same as the starting material, and a light chain peak at 23439.
[0194] Example 1: Introduction of azide groups by azide linker (1) [ka]
[0195] To a 20 μM solution of thiol-introduced antibody in buffer (pH 7.4 PBS buffer, 10 mM EDTA), five equivalents of 1.25 mM DMF solution of azidolinker (1, Aldrich) were added, and after standing at room temperature for 1 hour, the solution was purified using NAP-5 Columns (GE Healthcare).
[0196] Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was then measured by ESI-TOFMS according to a previously reported method (WO2019 / 240287A1). The thiol-group-introduced antibody used as the starting material showed heavy chain peaks at 50683 and 50845, and a light chain peak at 23439. The product, in which an azide group was introduced into the heavy chain, showed light chain peaks at 50816 and 50978, as well as at 23439, the same as the starting material.
[0197] Example 2: Introduction of azide groups by azide linker (2) [ka]
[0198] (1) Synthesis of Azidrinker (2) (1-1) Synthesis of 5-azidopentanehydrazide [ka]
[0199] A 10 mL solution of 5-azidopentanoic acid (200 mg, 1.4 mmol) in THF was cooled to 0°C, and N-methylmorpholine (0.32 mL, 2.1 mmol) and isobutyl chloroformate (0.22 mL, 1.7 mmol) were added. After stirring at 0°C for 30 minutes, hydrazine monohydrate (0.087 mL, 2.8 mmol) and DIPEA (0.71 mL, 4.2 mmol) were added. After stirring at room temperature for 16 hours, the mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain 5-(4-azidobutyl)-1,3,4-oxadiazole-2-thiol (111 mg, 0.71 mmol, yield 51%).
[0200] MS(ESI) m / z:158[M+H]
[0201] (1-2) Synthesis of 5-(4-azidobutyl)-1,3,4-oxadiazole-2-thiol [ka]
[0202] To an ethanol solution (7.1 mL) of 5-azidopentanehydrazide (111 mg, 0.71 mmol), carbon disulfide (0.055 mL, 0.92 mmol) and potassium hydroxide (192 mg, 3.4 mmol) were added and the mixture was stirred at 70°C for 16 hours. Then, a 6 M aqueous hydrochloric acid solution was added to adjust the pH of the system to 3.0. After adjustment, liquid-liquid extraction was performed with ethyl acetate, and the crude product obtained by concentrating the organic phase under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain 5-(4-azidobutyl)-1,3,4-oxadiazole-2-thiol (35 mg, 0.18 mmol, yield 25%).
[0203] MS(ESI) m / z:200[M+H]
[0204] (1-3) Synthesis of 2-(4-azidobutyl)-5-methylsulfanyl-1,3,4-oxadiazole [ka]
[0205] To a THF solution (1.8 mL) of 5-(4-azidobutyl)-1,3,4-oxadiazole-2-thiol (35 mg, 0.18 mmol), iodomethane (0.033 mL, 0.53 mmol) and triethylamine (0.074 mL, 0.53 mmol) were added, and the mixture was stirred at room temperature for 16 hours. The crude product obtained by concentrating the reaction mixture under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain 2-(4-azidobutyl)-5-methylsulfanyl-1,3,4-oxadiazole (33 mg, 0.15 mmol, yield 85%).
[0206] MS(ESI) m / z:214[M+H]
[0207] (1-4) Synthesis of Azidrinker (2) [ka]
[0208] A 1.5 mL solution of 2-(4-azidobutyl)-5-methylsulfanyl-1,3,4-oxadiazole (33 mg, 0.15 mmol) in dichloromethane was cooled to 0°C, and mCPBA (0.311 g, 1.3 mmol) was added. After stirring at room temperature for 20 hours, saturated sodium bicarbonate aqueous solution was added, and liquid-liquid extraction was performed with ethyl acetate. The crude product obtained by concentrating the organic layer under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain azid linker (2) (26 mg, 0.11 mmol, yield 71%).
[0209] MS(ESI) m / z:246[M+H]
[0210] (2) Introduction of azide groups by azide linker (2) To a 20 μM solution of thiol-introduced antibody in buffer (pH 7.4 PBS buffer, 10 mM EDTA), five equivalents of 1.25 mM azidide linker (2) in DMF solution were added. After standing at room temperature for 1 hour, the solution was purified using NAP-5 Columns (GE Healthcare).
[0211] Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was then measured by ESI-TOFMS according to a previously reported method (WO2019 / 240287A1). The thiol-group-introduced antibody used as the starting material showed heavy chain peaks at 50683 and 50845, and a light chain peak at 23439. The product, in which an azide group was introduced into the heavy chain, showed light chain peaks at 50846 and 51008, as well as at 23439, the same as the starting material.
[0212] Example 3: Introduction of azide groups by azide linker (3) [ka]
[0213] (1) Synthesis of Azidrinker (3) (1-1) Synthesis of 2-(4-azidophenyl)-5-methylsulfanyl-1,3,4-oxadiazole [ka]
[0214] To a 3.0 mL solution of trifluoroacetate of 4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)aniline (48 mg, 0.15 mmol) in dichloromethane, 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (137 mg, 0.48 mmol) and DMAP (86 mg, 0.70 mmol) were added, and the mixture was stirred at 50°C for 16 hours. The crude product obtained by concentrating the reaction mixture under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain 2-(4-azidophenyl)-5-methylsulfanyl-1,3,4-oxadiazole (26 mg, 0.11 mmol, yield 73%).
[0215] MS(ESI) m / z:234[M+H]
[0216] (1-2) Synthesis of Azidrinker (3) [ka] A 1.1 mL solution of 2-(4-azidophenyl)-5-methylsulfanyl-1,3,4-oxadiazole (26 mg, 0.11 mmol) in dichloromethane was cooled to 0°C, and mCPBA (113 mg, 0.45 mmol) was added. After stirring at room temperature for 20 hours, saturated sodium bicarbonate aqueous solution was added, and liquid-liquid extraction was performed with ethyl acetate. The crude product obtained by concentrating the organic layer under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain azid linker (3) (23 mg, 0.086 mmol, yield 78%).
[0217] MS(ESI) m / z:266[M+H]
[0218] (2) Introduction of azide groups by azide linker (3) The thiol group-introduced antibody was reacted with the azid linker (3) in the same manner as described in Example 2(2).
[0219] Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was then measured by ESI-TOFMS according to a previously reported method (WO2019 / 240287A1). The thiol-group-introduced antibody used as the starting material showed heavy chain peaks at 50683 and 50845, and a light chain peak at 23439. The product, in which an azide group was introduced into the heavy chain, showed light chain peaks at 50841 and 51002, as well as at 23439, the same as the starting material.
[0220] Example 4: Introduction of azide groups by azide linker (4) [ka]
[0221] (1) Synthesis of Azidrinker (4) (1-1) Synthesis of tert-butyl N-[4-(hydrazinecarbonyl)phenyl]carbamate [ka]
[0222] A THF solution (8.4 mL) of 4-(tert-butoxycarbonylamino)benzoic acid (200 mg, 0.84 mmol) was cooled to 0°C, and N-methylmorpholine (0.14 mL, 1.3 mmol) and isobutyl chloroformate (0.13 mL, 1.0 mmol) were added. After stirring at 0°C for 30 minutes, hydrazine monohydrate (0.078 mL, 2.5 mmol) and DIPEA (0.30 mL, 1.7 mmol) were added. After stirring at room temperature for 16 hours, the mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain tert-butyl N-[4-(hydrazinecarbonyl)phenyl]carbamate (187 mg, 0.74 mmol, yield 88%).
[0223] MS(ESI) m / z:252[M+H]
[0224] Synthesis of (1-2) tert-butyl N-[4-(5-sulfanyl-1,3,4-oxadiazol-2-yl)phenyl]carbamate [ka]
[0225] To an ethanol solution (7.4 mL) of tert-butyl N-[4-(hydrazinecarbonyl)phenyl]carbamate (187 mg, 0.74 mmol), carbon disulfide (0.058 mL, 0.97 mmol) and potassium hydroxide (125 mg, 2.2 mmol) were added and the mixture was stirred at 75°C for 16 hours. Then, a 6 M aqueous hydrochloric acid solution was added to adjust the pH of the system to 3.0. After adjustment, liquid-liquid extraction was performed with ethyl acetate, and the crude product obtained by concentrating the organic phase under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain tert-butyl N-[4-(5-sulfanyl-1,3,4-oxadiazol-2-yl)phenyl]carbamate (99 mg, 0.34 mmol, yield 45%).
[0226] MS(ESI) m / z:294[M+H]
[0227] Synthesis of (1-3)tert-butyl N-[4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)phenyl]carbamate [ka]
[0228] A THF solution (3.4 mL) of tert-butyl N-[4-(5-sulfanyl-1,3,4-oxadiazol-2-yl)phenyl]carbamate (99 mg, 0.34 mmol) was cooled to 0°C, and iodomethane (0.063 mL, 1.0 mmol) and triethylamine (0.14 mL, 1.0 mmol) were added. The mixture was stirred at room temperature for 3 hours. The crude product obtained by concentrating the reaction mixture under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain tert-butyl N-[4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)phenyl]carbamate (88 mg, 0.29 mmol, yield 84%).
[0229] MS(ESI) m / z:308[M+H]
[0230] Synthesis of (1-4)4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)aniline [ka]
[0231] Trifluoroacetic acid (2.9 mL) was added to a solution of tert-butyl N-[4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)phenyl]carbamate (88 mg, 0.29 mmol) in dichloromethane (2.9 mL), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain the trifluoroacetate salt of 4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)aniline (93 mg, 0.29 mmol, yield 100%).
[0232] Synthesis of (1-5)2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]-N-[4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)phenyl]acetamide [ka]
[0233] Dichloromethyl 4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)aniline trifluoroacetate (57 mg, 0.18 mmol) 1.8 mL of tan solution was mixed with 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]acetic acid (102 mg, 0.43 mmol), EDCI (115 mg, 0.60 mmol), DMAP (9.4 mg, 0.077 mmol), and triethylamine (0.114 mL, 0.82 mmol). After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]-N-[4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)phenyl]acetamide (73 mg, 0.17 mmol, yield 94%).
[0234] MS(ESI) m / z:423[M+H]
[0235] (1-6) Synthesis of Azidrinker (4) [ka]
[0236] A 1.7 mL solution of 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]-N-[4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)phenyl]acetamide (73 mg, 0.17 mmol) in dichloromethane was cooled to 0°C, and mCPBA (185 mg, 0.75 mmol) was added. After stirring at room temperature for 20 hours, saturated sodium bicarbonate aqueous solution was added, and liquid-liquid extraction was performed with ethyl acetate. The crude product obtained by concentrating the organic layer under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain azid linker (4) (1.2 mg, 0.0026 mmol, yield 1.8%).
[0237] MS(ESI) m / z:455[M+H]
[0238] (2) Introduction of azide groups by azide linker (4) The thiol group-introduced antibody was reacted with the azid linker (4) in the same manner as described in Example 2(2).
[0239] Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was then measured by ESI-TOFMS according to a previously reported method (WO2019 / 240287A1). The thiol-group-introduced antibody used as the starting material showed heavy chain peaks at 50683 and 50845, and a light chain peak at 23439. The product showed azide groups introduced into the heavy chain at 51057 and 51219, and a light chain peak at 23439, the same as the starting material.
[0240] Example 5: Introduction of azide groups by azide linker (5) [ka]
[0241] (1) Synthesis of Azidrinker (5) Synthesis of (1-1)4-(5-sulfanyl-1,3,4-oxadiazol-2-yl)benzoic acid [ka]
[0242] To a 10 mL solution of 4-tert-butoxycarbonylbenzoic acid (307.0 mg, 1.38 mmol) in dichloromethane, 0.0558 mL, 1.79 mmol, EDCI (411.1 mg, 2.14 mmol), DMAP (18.1 mg, 0.14 mmol), and triethylamine (0.462 mL, 3.34 mmol) were added. After stirring at room temperature for 16 hours, the mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography to obtain a mixture of tert-butyl 4-(hydrazinecarbonyl)benzoate.
[0243] To a 10 mL ethanol solution of the obtained mixture, carbon disulfide (0.0471 mL, 0.78 mmol) and potassium hydroxide (103.7 mg, 1.80 mmol) were added, and the mixture was stirred at 70°C for 16 hours. Then, a 6 M aqueous hydrochloric acid solution was added to adjust the pH of the system to 3.0. After adjustment, liquid-liquid extraction was performed with ethyl acetate, and the crude product obtained by concentrating the organic phase under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain 4-(5-sulfanyl-1,3,4-oxadiazol-2-yl)benzoic acid (72.9 mg, 0.33 mmol, 2-step yield 24%).
[0244] MS(ESI) m / z:223[M+H]
[0245] Synthesis of (1-2)4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)benzoic acid [ka]
[0246] A THF solution (3.3 mL) of 4-(5-sulfanyl-1,3,4-oxadiazol-2-yl)benzoic acid (72.9 mg, 0.33 mmol) was cooled to 0°C, and iodomethane (0.616 mL, 0.99 mmol) and triethylamine (0.228 mL, 1.60 mmol) were added. The mixture was stirred at room temperature for 3 hours. The crude product obtained by concentrating the reaction mixture under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain 4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)benzoic acid (66.2 mg, 0.28 mmol, yield 88%).
[0247] MS(ESI) m / z:237[M+H]
[0248] (1-3)N-[2-[2-[2-[2-[(4-azidobenzoyl)amino]ethoxy]ethoxy]ethoxy]ethyl]-4-(5-methy Synthesis of lsulfanyl-1,3,4-oxadiazol-2-yl)benzamide [ka]
[0249] To a 2.8 mL solution of 4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)benzoic acid (66.2 mg, 0.28 mmol) in dichloromethane, N-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl]-4-azido-benzamide (0.190 mg, 0.42 mmol), EDCI (88.5 mg, 0.46 mmol), DMAP (7.2 mg, 0.059 mmol), and triethylamine (0.116 mL, 0.84 mmol) were added. After stirring at room temperature for 5 hours, the reaction mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain N-[2-[2-[2-[2-[(4-azidobenzoyl)amino]ethoxy]ethoxy]ethoxy]ethyl]-4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)benzamide (104 mg, 0.19 mmol, yield 67%).
[0250] MS(ESI) m / z:556[M+H]
[0251] (1-4) Synthesis of Azidrinker (5) [ka]
[0252] A 1.9 mL solution of N-[2-[2-[2-[2-[(4-azidobenzoyl)amino]ethoxy]ethoxy]ethoxy]ethyl]-4-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)benzamide (104 mg, 0.19 mmol) in dichloromethane was cooled to 0°C, and mCPBA (195.4 mg, 0.79 mmol) was added. After stirring at room temperature for 20 hours, saturated sodium bicarbonate aqueous solution was added, and liquid-liquid extraction was performed with ethyl acetate. The crude product obtained by concentrating the organic layer under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain azid linker (5) (84.8 mg, 0.14 mmol, yield 76%).
[0253] MS(ESI) m / z:588[M+H]
[0254] (2) Introduction of azide groups by azide linker (5) The thiol group-introduced antibody was reacted with the azid linker (5) in the same manner as described in Example 2(2).
[0255] Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was then measured by ESI-TOFMS according to a previously reported method (WO2019 / 240287A1). The thiol-group-introduced antibody used as the starting material showed heavy chain peaks at 50683 and 50845, and a light chain peak at 23439. The product, in which an azide group was introduced into the heavy chain, showed light chain peaks at 51189 and 51350, as well as at 23439, the same as the starting material.
[0256] Example 6: Introduction of azide groups by azide linker (6) [ka]
[0257] (1) Synthesis of Azidrinker (6) [ka]
[0258] N-Succinimidyl 3-(2-Pyridyldithio)propionate (55.2 mg, 0.177 mmol) was dissolved in CH2Cl2 (2.0 mL), and 11-Azido-3,6,9-trioxaundecan-1-amine (35 μL, 0.177 mmol) was added and the mixture was stirred at room temperature for 18 hours. After confirming the reaction by LC / MS, the solution was dissolved in a 0.05% aqueous trifluoroacetic acid solution and subjected to reverse-phase high-performance liquid chromatography using octadodecyl group chemically bonded silica gel as a packing material. Elution was performed with a mixed solution of water and acetonitrile containing 0.05% trifluoroacetic acid, and each fraction was examined by LC-MS. The fraction containing the product was collected, concentrated under reduced pressure to remove acetonitrile, and then freeze-dried to obtain azidolinker (6) (72.2 mg, 0.173 mmol).
[0259] 1 H NMR (400MHz, Chloroform-d) δ=8.55(s,1H),7.78(s,1H),7.22(s,1H),6.73(s,1H),3.76-3.63(m,10H),3.60(dd,J=5.6,4.5, 2H),3.49(q,J=5.2,2H),3.41(t,J=5.0,2H),3.13(tt,J=7.0,2.4,2H),2.66(td,J=6.9,2.2,2H). MS(ESI)m / z: z=1 416[M+H] +
[0260] (2) Introduction of azide groups by azide linker (6) The thiol-modified antibody was reacted with the azid linker (6) reagent in the same manner as described in Example 2(2). The reaction mixture was replaced with 20 mM ammonium acetate buffer, and the mass was measured by ESI-TOFMS according to the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732). A peak of 149009, in which two azide groups were introduced into the antibody, was confirmed.
[0261] Example 7: Introduction of azide groups by azide linker (7) [ka]
[0262] (1) Synthesis of Azidrinker (7) [ka]
[0263] 4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid (100.0 mg, 0.39 mmol) was dissolved in THF (3.0 mL), and 11-Azido-3,6,9-trioxaundecan-1-amine (77 μL, 0.39 mmol), DCC (97.0 mg, 0.47 mmol), and NHS (54.0 g, 0.47 mmol) were added. The mixture was stirred at room temperature for 18 hours. After confirming the reaction by LC / MS, the solution was dissolved in a 0.05% aqueous trifluoroacetic acid solution and subjected to reverse-phase high-performance liquid chromatography using octadodecyl group chemically bonded silica gel as a packing material. Elution was performed with a mixed solution of water and acetonitrile containing 0.05% trifluoroacetic acid, and each fraction was examined by LC-MS. The fraction containing the product was collected, concentrated under reduced pressure to remove acetonitrile, and then freeze-dried to obtain azidlinker (7) (39.9 mg, 0.087 mmol).
[0264] 1 H NMR(400MHz,Chloroform-d)δ=8.52(d,J=5.0,1H),7.81(d,J=8.2,1H),7.72(t,J=7.9,1H),7.17(t,J=6.2,1H),6.15(s,1H), 3.76-3.62(m,10H),3.57(dd,J=5.6,4.6,2H),3.44(dt,J=15.2,5.1,4H),2.42-2.27(m,2H),2.06-1.94(m,2H),1.33(s,6H). MS(ESI)m / z: z=1 458[M+H] +
[0265] (2) Introduction of azide groups by azide linker (7) The thiol group-introduced antibody can be reacted with the azid linker (7) reagent in the same manner as described in Example 2(2).
[0266] Example 8: Introduction of DBCO group by alkyne linker (8) [ka]
[0267] (1) Synthesis of alkyne linker (8) [ka]
[0268] To a 1 mL solution of 3-Amino-1-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-1-propanone (20 mg, 0.072 mmol) in dichloromethane, diisopropylcarbodiimide (10.9 mg, 0.087 mmol) and bromoacetylbenzoic acid (21 mg, 0.087 mmol) were added at room temperature. After stirring at room temperature for 16 hours, the mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain alkyne linker (8) (12.3 mg, 0.25 mmol, yield 34%).
[0269] MS(ESI) m / z:501[M+H]
[0270] (2) Introduction of DBCO group by alkyne linker (8) The thiol-introduced antibody was reacted with alkyne linker (7) in the same manner as described in Example 2(2). Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was then measured by ESI-TOFMS according to previously reported information (WO2019 / 240287A1). The starting thiol-introduced antibody showed heavy chain peaks at 50683 and 50845 and a light chain peak at 23439. The product showed azide groups introduced into the heavy chain at 51109 and 51270, and a light chain peak at 23439, the same as the starting material.
[0271] Example 9: Introduction of DBCO group by alkyne linker (9) [ka]
[0272] Ten equivalents of the above alkyne linker (9, manufactured by Tokyo Chemical Industry Co., Ltd.) were reacted using the same method as described in Example 2(2). Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was measured by ESI-TOFMS according to previously reported method (WO2019 / 240287A1). The thiol-group-introduced antibody used as the starting material showed heavy chain peaks at 50683 and 50845 and a light chain peak at 23439. The product showed azide groups introduced into the heavy chain at 51123 and 51291, and a light chain peak at 23439, the same as the starting material.
[0273] Example 10: Introduction of DBCO group by alkyne linker (10) [ka]
[0274] Ten equivalents of the above alkyne linker (10) were reacted using the same method as described in Example 2(2). Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was measured by ESI-TOFMS according to previously reported method (WO2019 / 240287A1). The thiol-group-introduced antibody used as the starting material showed heavy chain peaks at 50683 and 50845 and a light chain peak at 23439. The product showed azide groups introduced into the heavy chain at 51371 and 51532, and a light chain peak at 23439, the same as the starting material.
[0275] Example 11: Introduction of DBCO group by alkyne linker (11) [ka]
[0276] (1) Synthesis of alkyne linker (11) [ka]
[0277] To a 1 mL solution of 3-Amino-1-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-1-propanone (14 mg, 0.051 mmol) in dichloromethane, WSC (15 mg, 0.079 mmol), HOBT (15 mg, 0.111 mmol), triethylamine (12 μL, 0.162 mmol), DMAP (0.5 mg, 0.004 mmol), and 3-pyridyldithiopropionic acid (11 mg, 0.050 mmol) were added at room temperature. After stirring at room temperature for 3 hours, the mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain alkyne linker (10) (4.2 mg, 0.0096 mmol, yield 19%).
[0278] MS(ESI) m / z:501[M+H]
[0279] (2) Introduction of DBCO group by alkyne linker (11) The thiol-transferred antibody was reacted with the above alkyne linker (11) in the same manner as described in Example 2(2). The reaction mixture was replaced with 20 mM ammonium acetate buffer, and the method described in a previous report (Anal. Chem., 2019, 91, 20, 12724-12732) was followed. Following the guidelines, the mass was measured by ESI-TOFMS, and a peak of 149151 was identified, in which two azide groups were introduced into the antibody.
[0280] Example 12: Measurement of aggregation rate of bioorthogonal functional group-introduced antibodies by SEC HPLC The agglutination rates of the bioorthogonal functional group-introduced antibodies synthesized in Comparative Examples 1 and 2 and Examples 1 to 6 and 8 to 11 were measured under the following conditions, in accordance with previously reported information (ACS Omega 2020, 5, 7193-7200).
[0281] Measurement system: 1260 HPLC system (manufactured by Agilent) Column: Agilent AdvanceBio SEC 300Å 2.7μm, 4.6mm × 150mm Flow rate: 0.25mL / min Eluent: 100 mM sodium dihydrogen phosphate / sodium hydrogen phosphate, 250 mM sodium chloride aqueous solution (pH 6.8), 10% v / v isopropanol Detector: UV (280nm)
[0282] [Table 1]
[0283] As a result, the aggregation rate of the bioorthogonal functional group-introduced antibody obtained using the compound in the example was less than 3.5%, which was lower than the aggregation rate of the bioorthogonal functional group-introduced antibody obtained using the compound in the comparative example (Table 1).
[0284] Example 13: Measurement of the proportion of unreacted heavy chains by reverse-phase HPLC under reducing conditions (1) Preparation of the measurement sample The product was then mixed with an aqueous solution of DL-dithiotrerol (prepared by adding a 1M aqueous solution of DL-dithiotrerol to an 8M aqueous solution of guanidine hydrochloride) and heated at 80°C for 10 minutes.
[0285] (2) Analysis by reversed-phase HPLC Reverse-phase HPLC analysis was performed on the bioorthogonal functional group-introduced antibodies synthesized in Comparative Examples 1 and 2 and Examples 1-5 and 8, 9, and 10, according to a previously published report (Anal. Chem., 2019, 91, 20, 12724-12732). The measurements were performed under the following conditions.
[0286] Measurement system: 1260 HPLC system (manufactured by Agilent) Column: Agilent AdvanceBio RP-mAb Diphenyl 3.5μm, 2.1mm × 100mm Gradient: Linear gradient of eluent A / B Flow rate: 0.4mL / min Eluent A: Water, 0.1% v / v trifluoroacetic acid Eluent B: Acetonitrile, 0.1% v / v trifluoroacetic acid Detector: UV (280nm)
[0287] The proportion of the reacting heavy chain was calculated by (peak area of unreacted heavy chain) / (peak area of all heavy chains of the antibody).
[0288] [Table 2]
[0289] The results in Table 2 above clearly show that the bioorthogonal functional group-introduced antibodies synthesized in Examples 1-5 and 8, 9, and 10 had a conversion rate of over 85% from the thiol-introduced antibodies used as raw materials.
[0290] Furthermore, in the case of compounds having disulfide bonds, such as those in Examples 6 and 11, the disulfide bonds are cleaved by DTT during the pretreatment step for reversed-phase HPLC measurement, and the compounds are converted into thiol-group-introduced antibodies, which are the raw materials. Therefore, the percentage of unreacted heavy chains cannot be determined by this method. Accordingly, the percentage of unreacted heavy chains for the compounds in Examples 6 and 11 was determined in the following example.
[0291] Example 14: Measurement of the percentage of unreacted thiol-transferred antibodies by ESI-TOFMS (1) Glycan cleavage of antibodies with bioorthogonal functional groups The bioorthogonal functional group-introduced antibodies synthesized in Examples 6 and 11 were subjected to glycosylation and post-processing using PNGase F (New England BioLabs, catalog number P0704) according to the manufacturer's protocol and previously reported method (WO2019240288A1). HIC-HPLC analysis was performed.
[0292] (2) Measurement of the percentage of unreacted antibodies by ESI-TOFMS analysis of glycosylation cleavage products and DAR calculator. The mass of the glycosylation cells obtained in (1) was measured by ESI-TOFMS according to the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732). Table 3 shows the percentage of unreacted antibodies calculated from the DAR peak and %Area using a DAR calculator (Agilent software) for the obtained MS data.
[0293] The percentage of unreacted antibodies was calculated using the following formula. The percentage of unreacted antibodies (%) = (A + B / 2) / (A + B + C) A: Peak area of the mass number corresponding to the raw material thiol-introduced antibody (compound 28) B: Peak area corresponding to the mass number in which one bioorthogonal functional group has been introduced into the raw material thiol-introduced antibody (compound 28). C: Peak area corresponding to the mass number in which two bioorthogonal functional groups have been introduced into the raw material thiol-introduced antibody (compound 28).
[0294] [Table 3]
[0295] From the results in Table 3 above, it was revealed that in the synthesis of antibody derivatives using the compounds of Examples 6 and 11, the antibody derivatives into which bioorthogonal functional groups were introduced achieved a conversion rate of over 90% from the starting thiol-modified antibody.
[0296] Example 15: Synthesis of ADCs and ADC mimics by click reaction with bioorthogonal functional group-introduced antibodies (1) Synthesis of ADC by click reaction In accordance with previously reported information (WO2019 / 240287A1 and WO2019 / 240288A1), 7 equivalents of a 5 mM DMF solution of DBCO-VC-PAB-MMAE (ABZENA) were added to the azide-introduced trastuzumab obtained in Examples 1-6. After stirring at room temperature for 20 hours, the mixture was purified using NAP-5 Columns (GE Healthcare) to obtain ADC.
[0297] (2) Synthesis of ADC mimics by click reaction Following previous reports (WO2019 / 240287A1 and WO2019 / 240288A1), Carboxyrhodamine 110-PEG4-DBCO (Broadpharm) was added to the azide-modified trastuzumab obtained in Examples 1-6 to obtain an ADC mimic.
[0298] Similarly, to the DBCO-modified trastuzumab obtained in Examples 8-11, carboxyrhodamine 110-PEG3-azide (Broadpharm) was added to obtain an ADC mimic.
[0299] Example (3) Analysis of ADC and ADC mimic ESI-TOFMS analysis of the ADC synthesized in Example 13(1) and the ADC mimic synthesized in Example 13(2) was performed according to previously reported information (WO2019 / 240287A1), and it was confirmed that the DAR was 2.
[0300] Example 16: Evaluation of ADC mimics by stability testing using rat plasma The blood stability of the various ADC mimics synthesized in Example 15(2) was evaluated. Specifically, the blood stability of the ADC mimics was evaluated by analyzing the amount of fluorescent molecules detached from the ADC mimics when they were incubated in rat blood, as described below.
[0301] (1) Synthesis of control ADC mimic The following azide antibody, as previously reported (WO2019 / 240287A1), was prepared according to Example 15(2) using Carboxyrhodamine110-PEG4-DBCO(Broad It was reacted with a pharm product and then directed to the ADC mimic. [ka]
[0302] (2) Plasma stability test 700 μL of rat plasma (Charles River) was mixed with ADC mimic to a concentration of 0.1 mg / mL, and then sterile filtered. This solution was dispensed into six Eppendorf tubes in 50 μL portions. Three of the six samples were stored in an incubator set to 37°C for 4 days. The remaining three were stored in a freezer at -80°C for the same period. 100 μL of acetonitrile was added to each sample, and the mixture was vortexed and then centrifuged to obtain a precipitate. The supernatant solution was collected and analyzed by HPLC.
[0303] (3) Analysis of the amount of detached fluorescent molecules using HPLC analysis The measurement involved measuring the fluorescence molecular weight lost from the ADC mimic using liquid chromatography / fluorescence detection. Three samples stored in a freezer (-80°C) for 96 hours in Example 16(1) were designated as Day=0, and three samples stored at 37°C for 96 hours in Example 14(1) were designated as Day=4. The difference in fluorescence intensity between Day=4 and Day=0 was analyzed.
[0304] The results were evaluated as shown in the table below. As a control, the fluorescence intensity of the example compounds was compared using the ADC mimic synthesized in Example 16(1), and the ratio of the relative decrease rates was calculated using the following formula (A).
[0305] Example: Increase in fluorescence intensity of fluorescent molecules detached from ADC mimic = [(Fluorescence intensity on Day 4) - (Fluorescence intensity on Day 0)]
[0306] The increase in fluorescence intensity of the fluorescent molecule that was removed from the control ADC mimic = [(Fluorescence intensity on Day 4) - (Fluorescence intensity on Day 0)]
[0307] Ratio of increase = Increase in fluorescence intensity of Example ADC mimic / Increase in fluorescence intensity of Control ADC mimic
[0308] [Table 4]
[0309] As a result, the ADC mimics synthesized in Examples 15(1) and (2) were all more than 10 times more stable than the control synthesized in Example 16(1).
[0310] Example 17: Synthesis of antibody-protein complexes by click reaction with bioorthogonal functional group-introduced antibodies (1) Linker introduction into protein Six equivalents of DMF solution of N-Hydroxysuccinimidyl-4-azidobenzoate were added to lysozyme (pH 7.4 PBS buffer solution), and the mixture was stirred at room temperature for 3 hours. The solution was then purified using NAP-5 Columns (GE Healthcare) to obtain azide-modified lysozyme. Mass measurement by ESI-TOFMS according to the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732) revealed a peak of 14450, indicating the introduction of the azide group into the lysozyme.
[0311] Furthermore, azide groups were introduced into bovine serum albumin using a similar method. Mass measurements by ESI-TOFMS revealed a peak of 66579, indicating that azide groups had been introduced into the bovine serum albumin.
[0312] (2) Synthesis of antibody-protein complexes by click reaction Following previous reports (WO2019 / 240287A1 and WO2019 / 240288A1), azide-modified lysozyme synthesized in Example 17(1) was added to the alkyne-modified trastuzumab obtained in Example 8 to obtain a trastuzumab-lysozyme complex. Mass measurement by ESI-TOFMS according to the method described in previous report (Anal. Chem., 2019, 91, 20, 12724-12732) revealed a peak of 178610, in which two lysozyme molecules were introduced into the trastuzumab.
[0313] Furthermore, using a similar method, bovine serum albumin synthesized in Example 17(1) was added to the alkyne-introduced trastuzumab obtained in Example 8 to obtain a trastuzumab-lysozyme complex. Following the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732), the mass was measured by ESI-TOFMS, and a peak of 283466 was confirmed, indicating that two bovine serum albumin molecules had been introduced into the trastuzumab.
[0314] Using a similar method, the alkyne-transformed trastuzumab obtained in Example 9 was combined with the azide-transformed lysozyme synthesized in Example 17(1) to obtain a trastuzumab-lysozyme complex. Following the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732), the mass was measured by ESI-TOFMS, and it was found that trastuzumab was combined with lysozyme. A peak of 178669 was observed, with two instances of the character "ム" introduced.
[0315] Using a similar method, the alkyne-modified trastuzumab obtained in Example 10 was combined with azide-modified lysozyme synthesized in Example 17(1) to obtain a trastuzumab-lysozyme complex. Following the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732), the mass was measured by ESI-TOFMS, and a peak of 179154, in which two lysozyme molecules were introduced into the trastuzumab, was confirmed.
[0316] Using a similar method, the alkyne-modified trastuzumab obtained in Example 11 was combined with azide-modified lysozyme synthesized in Example 17(1) to obtain a trastuzumab-lysozyme complex. Following the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732), the mass was measured by ESI-TOFMS, and a peak of 178647, in which two lysozyme molecules were introduced into the trastuzumab, was confirmed.
[0317] Example 18: Introduction of bioorthogonal functional groups at the Lys288 / 290 position (18-1) Synthesis of compounds having affinity substances, cleavage moieties, and reactive groups for soluble proteins (peptide thioester linker conjugates - thiophenol activated compounds), and modification of the anti-HER2 antibody trastuzumab using said compounds and analysis thereof. (18-1-1) Synthesis of IgG1 Fc-binding peptide The peptide Ac-FNMQCQRRFYEALHDPNLNEEQRNARIRSIKDDC-NH2 (SEQ ID NO: 4), an affinity substance for soluble proteins, was synthesized by Fmoc solid-phase synthesis. A CEM Liberty Blue peptide synthesizer was used. All reagents were manufactured by Watanabe Chemical Industries. The resin used was Fmoc-NH-SAL-PEG. Resin,HL, arginine (R), cysteine (C), and histidine (H) were double-coupled. Resin was cleaved in a solution of trifluoroacetic acid:water:triisopropylsilane:ethanedithiol = 94:2.5:1.0:2.5 with stirring for 3 hours. After cleavage, Resin was removed by filtration, and trifluoroacetic acid was removed. Diethyl ether was added to the resulting crystals to precipitate with ether, and the resulting white crystals were recovered by filtration. This was dissolved in a 0.1% aqueous trifluoroacetic acid solution and subjected to reverse-phase high-performance liquid chromatography using octadodecyl group chemically bonded silica gel as a packing material. Elution was performed with a mixed solution of water and acetonitrile containing 0.1% trifluoroacetic acid, and each fraction was identified by LC-MS. The fraction containing the product was recovered, concentrated under reduced pressure to remove only acetonitrile, and then freeze-dried.
[0318] Formation of intramolecular disulfide bonds at positions 5 and 34 of (18-1-2)Ac-FNMQCQRRFYEALHDPNLNEEQRNARIRSIKDDC-NH2 (SEQ ID NO: 4) The peptide synthesized in (18-1-1) was dissolved in DMSO, and 0.1 M Tris-HCl pH 8.0 was added. Oxidized glutathione was added to this solution, and the mixture was stirred at room temperature for 20 hours. The reaction was stopped by adding 2 M aqueous trifluoroacetic acid to the reaction solution, and this was dissolved in 0.05% aqueous trifluoroacetic acid. The mixture was subjected to reverse-phase high-performance liquid chromatography using octadodecyl group chemically bonded silica gel as a packing material, and eluted with a mixed solution of water and acetonitrile containing 0.05% trifluoroacetic acid. Each fraction was identified by LC-MS. The fraction containing the product was collected, concentrated under reduced pressure to remove acetonitrile, and then freeze-dried to obtain the target product (20.0 mg, 4.70 μmol).
[0319] MS(ESI)m / z: z=4 1063.65[M+4H] 4+ ,z=5 851.15[M+5H] 5+
[0320] (18-1-3) Synthesis of Thioester Linkers (18-1-3-1) [ka] 3,3'-Dithiodipropionic Acid (1 g, 5.0 mmol) was dissolved in THF (10 mL), and DMF (100 μL) and Oxalyl Chloride (1.5 mL, 15.0 mmol) were added at 0°C for 15 minutes, followed by stirring at room temperature for 1 hour. Then, Benzenethiol (1.53 mL, 15.0 mmol), Pyridine (4 mL, 50 mmol), and CH2Cl2 (10 mL) were added at 0°C, and the mixture was stirred at room temperature for 3 hours. After confirming the reaction by TLC (hexane / ethyl acetate = 5 / 1), the crystals were removed, and the mixture was extracted with ethyl acetate and 1 M hydrochloric acid aqueous solution. The organic layer was then concentrated. Elution was performed with a mixed solution of hexane and ethyl acetate, and each fraction was confirmed by TLC (hexane / ethyl acetate = 5 / 1). The fraction containing the product was collected, concentrated under reduced pressure to remove the organic solvent, and then vacuum dried to obtain the above compound (1.2 g, 3.04 mmol).
[0321] (18-1-3-2) [ka]
[0322] The compound synthesized in (18-1-3-1) (1.2 g, 3.04 mmol) was dissolved in a mixed solvent of DMF / H2O=5 / 1, and TCEP·HCl (1.74 g, 6.08 mmol) was added and the mixture was stirred at room temperature for 1 hour. After confirming the reaction by TLC (hexane / ethyl acetate=5 / 1), the organic layer was extracted with ethyl acetate and water, and then concentrated. Elution was performed with a mixed solution of hexane and ethyl acetate, and each fraction was confirmed by TLC (hexane / ethyl acetate=5 / 1). The fraction containing the product was recovered, concentrated under reduced pressure to remove the organic solvent, and then vacuum dried to obtain the above compound (1.18 g, 6.5 mmol).
[0323] (18-1-3-3) [ka] The compound synthesized in (18-1-3-2) (200 mg, 1.10 mmol) was dissolved in acetonitrile (2.0 mL), and glutaric anhydride (125.5 mg, 1.10 mmol), DMAP (6.72 mg, 0.06 mmol), and pyridine (0.22 mL) were added and the mixture was stirred at room temperature for 4 hours. After confirming the reaction by TLC (dichloromethane / methanol = 10 / 1), the organic layer was extracted with ethyl acetate and 0.5 M HCl, and the organic layer was concentrated. Elution was performed with a mixed solution of dichloromethane and methanol, and each fraction was confirmed by TLC (dichloromethane / methanol = 10 / 1). The fraction containing the product was collected, concentrated under reduced pressure to remove the organic solvent, and then vacuum dried to obtain the above compound (135 mg, 0.45 mmol).
[0324] (18-1-3-4) [ka]
[0325] The compound synthesized in (18-1-3-3) (134 mg, 0.45 mmol) was dissolved in CH2Cl2 (2.25 mL) and triethylamine (157 μL, 1.13 mmol). Pentafluorophenyltrifluoroacetic acid (154 μL, 0.90 mmol) was added at 0°C and the mixture was stirred for 1 hour. After confirming the reaction by TLC (hexane / ethyl acetate = 3 / 1), the reaction solution was concentrated. The product was eluted with a mixed solution of hexane and ethyl acetate, and each fraction was identified by TLC (hexane / ethyl acetate = 3 / 1). The fraction containing the product was recovered, concentrated under reduced pressure to remove the organic solvent, and then vacuum dried to obtain the above compound (96 mg, 0.20 mmol).
[0326] 1 H NMR (400 MHz, Chloroform-d) δ = 7.44 (s, 5H), 3.23 (t, J=6.9, 2H), 3.01 (t, J=6.9, 2H), 2.77 (dt, J=14.5, 7.3, 4H), 2.16 (t, J=7.3, 2H).
[0327] (18-1-4) Peptide-linker binding [ka] Both of the above amino acid sequences are the same as the amino acid sequence of Sequence ID No. 4.
[0328] Ac-FNMQCQRRFYEALHDPNLNEEQRNARIRSIKDDC-NH2 (SEQ ID NO: 4) (30.0 mg, 7.06 μmol, where the 5th and 34th cysteine groups each form intramolecular disulfide bonds), synthesized in (18-1-2), was dissolved in N,N-dimethylformamide (1.00 mL), and the thioester linker synthesized in (1-3) (96.0 mg, 201 μmol) was added. The mixture was stirred at room temperature for 24 hours. This was then dissolved in a 0.05% aqueous trifluoroacetic acid solution and the octadodecyl group chemical bond was formed. The product was subjected to reverse-phase high-performance liquid chromatography using silica gel as a packing material, and eluted with a mixed solution of water and acetonitrile containing 0.05% trifluoroacetic acid. Each fraction was examined by LC-MS. The fraction containing the product was recovered, concentrated under reduced pressure to remove acetonitrile, and then freeze-dried to obtain the peptide thioester linker-thiophenol activated product (15.8 mg, 3.48 μmol).
[0329] MS(ESI)m / z:z=4 1136.80[M+4H] 4+
[0330] (18-1-5) Specific modification of the anti-HER2 IgG antibody trastuzumab and analysis by ESI-TOFMS The peptide linker compound synthesized in (18-1-4) was dissolved in dimethyl sulfoxide to a concentration of 10 mM. 500 μg of the anti-HER2 antibody trastuzumab (Chugai Pharmaceutical) was dissolved in 200 μL (20 μM) of HEPES buffer (pH 8.2), and 3.38 μL (10 equivalents relative to the antibody) of 10 mM peptide reagent was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was replaced with 20 mM ammonium acetate buffer, and the mass was measured by ESI-TOFMS. The starting material trastuzumab showed a peak at 148223. The product showed peaks at 152660 (with one binding peptide), 157093 (with two binding peptides), and 161528 (with three binding peptides).
[0331] (18-1-6) Confirmation of heavy chain selectivity of trastuzumab-specifically modified compounds by ESI-TOFMS analysis under reducing conditions. To the antibody-peptide conjugate prepared in (18-1-5), 2 μL of 100 mM tris(2-carboxyethyl)phosphine hydrochloride solution (equal volume to the antibody) was added and the mixture was stirred at room temperature for 15 minutes. Mass measurement by ESI-TOFMS revealed that the starting material trastuzumab had a heavy chain peak at 50596 and a light chain peak at 23439, while the product had a heavy chain with one linker introduced at 55033 and a light chain with the same peak at 23439 as the starting material.
[0332] (18-1-7) Confirmation of peptide / antibody binding ratio of trastuzumab-specifically modified forms using a DAR calculator. Table 5 shows the results of confirming the peptide / antibody binding ratio using a DAR calculator (Agilent software) for the MS data analyzed in (18-1-5). The average peptide / antibody binding ratio calculated from the DAR peak and %Area in Table 5 was 2.0. Therefore, the formation of an antibody intermediate represented by the following structural formula (average peptide / antibody binding ratio of 2.0) was confirmed.
[0333] [ka] [Here, Ig represents an immunoglobulin unit (IgG) containing two heavy chains and two light chains, and forms amide bonds with two adjacent carbonyl groups (C=O) via amino groups in the side chains of lysine residues located at positions 288 / 290 in the two heavy chains according to Eu numbering.] Y represents the affinity peptide represented by the amino acid sequence of SEQ ID NO: 4. The average bond ratio r between Ig and the two adjacent carbonyl groups (C=O) is 2.0.
[0334] [Table 5]
[0335] (18-1-8) Production of thiol group-introduced antibody derivatives by cleavage of thioester groups To the antibody intermediate obtained in (18-1-7), a hydroxylamine solution was added according to the previously reported (WO2019240287A1), and the mixture was allowed to stand at room temperature for 1 hour. After 2 hours, the mixture was replaced with 20 mM PBS buffer and 10 mM EDTA (pH 7.4) to obtain the thiol-introduced antibody derivative. Mass measurement by ESI-TOFMS revealed a peak at 148409, where the cleavage reaction had progressed.
[0336] [ka] [Here, Ig represents an immunoglobulin unit (IgG) containing two heavy chains and two light chains, and forms amide bonds with two adjacent carbonyl groups (C=O) via amino groups in the side chains of lysine residues located at positions 288 / 290 in the two heavy chains according to Eu numbering.] The average bond ratio r between Ig and the two adjacent carbonyl groups (C=O) is 2.0.
[0337] (18-1-9) Peptide mapping by trypsin treatment Peptide mapping was performed on the trastuzumab thiol derivatives obtained in (1-8) using the following procedure.
[0338] (18-1-9-1) Trypsin treatment of trastuzumab thiol derivatives In a 1.5 mL low-adsorption microtest tube, 10 μL of sample solution, 50 mM ammonium bicarbonate buffer, and 10 μL of 20 mM dithiothreitol aqueous solution dissolved in 40% trifluoroethanol were added and incubated at 65°C for 1 hour. Then, 10 μL of 50 mM iodoacetamide aqueous solution was added and the mixture was reacted at room temperature for 30 minutes under light protection. After the reaction, 40 μL of 50 mM ammonium bicarbonate buffer was added and stirred, and 10 μL of 20 ng / μL trypsin aqueous solution was added and enzymatic digestion was carried out at 37°C for 16 hours. After digestion, 2 μL of 20% trifluoroacetic acid aqueous solution was added to stop the reaction, and LC-MS / MS measurement was performed.
[0339] (18-1-9-2) LC-MS / MS measurement of trastuzumab (Analyzer) Nano HPLC: EASY-nLC 1000 (Thermo Fisher Scientific) Mass spectrometer: Tribrid mass spectrometer Orbitrap Fusion (Thermo Fisher Scientific)
[0340] (HPLC analysis conditions) Trap column: Acclaim PepMap (registered trademark) 100, 75 μm x 2 CM (Thermo Fisher Scientific) Analysis column: ESI-column (NTCC-360 / 75-3-125, 75μm×12.5cm, 3μm (Nikkyo Technos)) Mobile phase A: 0.1% formic acid aqueous solution Mobile phase B: 0.1% formic acid, acetonitrile solution Loading solution: 0.1% trifluoroacetic acid aqueous solution Flow rate: 300nL / min Sample injection volume: 1 μL Gradient conditions (B%): 2% (0.0-0.5 min), 2% → 30% (0.5-23.5 min), 30% → 75% (23.5-25.5 min), 75% (25.5-35.0 min)
[0341] (Mass spectrometer analysis conditions) Ionization method: ESI, Positive mode Scan type: Data-dependent acquisition Activation Type: Collision Induced Dissociation (CID) Data acquisition is performed using the included software, Xcalibur 3.0 (Thermo Fisher Scientific) and Thermo Orbitrap Fusion Tune. The test was performed using Application 2.0 (Thermo Fisher Scientific).
[0342] (18-1-9-3) Analysis of modification sites of trastuzumab Modification site analysis of LC-MS / MS measurement results was performed using BioPharma Finder 3.0 (Thermo Fisher Scientific). Analysis using BioPharma Finder was performed with the S / N Threshold set to 1 and the MS Noise Level set to 0.01% of the peak top intensity. The digestive enzyme was set to Trypsin and the Specificity to High. For Static Modification, Carbamidomethyl (+57.021 Da) was selected as modification of the cysteine residue by iodoacetamide. For Dynamic Modifications, oxidation of the methionine residue (+15.995 Da) and a modified lysine residue (thiol introduced after Carbamidomethylation by iodoacetamide (+145.019 Da)) were selected. Furthermore, filters were set to include only those with a Confidence Score of 80 or higher, a Mass Accuracy of 5 ppm or less at the time of peptide identification, and for which MS / MS was observed. Regarding the residue numbers of lysine residues, those on the heavy chain VH domain and light chain are represented by the sequence number (i.e., the N-terminal amino acid is considered the first; the same applies hereafter), while those on the heavy chain CH1, CH2, and CH3 domains are represented using EU numbering. Furthermore, the amino acid sequences (1) and (2) shown in Figure 6 were used as data for searching for modified sites.
[0343] (18-1-9-4) Analysis results of modification sites of trastuzumab by LC-MS / MS Analysis using LC-MS / MS revealed the MS spectrum (measured value: m / z 577.03606, theoretical value: 577.03557, quadrivalent) of the peptide fragment FNWYVDGVEVHNAKTKPR (SEQ ID NO: 3), which consists of 18 amino acid residues including a lysine residue modification site (thiol derivative (+145.019Da)) induced by trypsin digestion of trastuzumab (iodoacetamide-mediated carbon methylation). (Figure 7) The CID spectrum confirmed a product ion with m / z 682.13 (theoretical value: 682.01), corresponding to trivalent y16, indicating modification of the lysine residue at position 288 or 290 in the EU numbering of the heavy chain (Figure 8). Analysis using BioPharma Finder showed that modifications to the lysine residue at positions 288 or 290 occurred with high selectivity (Figure 9). These results indicate that in the trastuzumab thiol derivative obtained in (18-1-8) above, regioselective conjugation occurs on the antibody heavy chain at Lys288 and Lys290 in the EU numbering.
[0344] (18-2-1) Synthesis of Thioester Linkers (18-2-1-1) [ka]
[0345] The compound synthesized in (18-1-3-2) (295 mg, 1.62 mmol) was dissolved in CH2Cl2 (13.5 mL), and 3-(tert-Butoxycarbonyl)benzoic acid (300 mg, 1.35 mmol), DIPEA (700 μL, 2.03 mmol), and PyBOP (843 mg, 1.62 mmol) were added and the mixture was stirred at room temperature for 1 hour. After confirming the reaction by TLC (hexane / ethyl acetate = 5 / 1), the reaction solution was concentrated. Elution was performed with a mixed solution of hexane and ethyl acetate, and each fraction was confirmed by TLC (hexane / ethyl acetate = 5 / 1). The fraction containing the product was collected, concentrated under reduced pressure to remove the organic solvent, and then vacuum dried to obtain the above compound (259 mg, 0.64 mmol).
[0346] (18-2-1-2) [ka]
[0347] The compound synthesized in (18-2-1-1) (259 mg, 0.64 mmol) was dissolved in a CH2Cl2 / TFA=1 / 1 mixed solution and stirred at room temperature for 1 hour. After confirming that the solution had fallen to the origin using TLC (hexane / ethyl acetate=5 / 1), the reaction solution was concentrated and then vacuum dried to obtain the above compound (227 mg, 0.66 mmol).
[0348] (18-2-1-3) [ka]
[0349] To the compound synthesized in (18-2-1-2) (227 mg, 0.66 mmol), add CH2Cl2 (3.3 mL) and triethylamine (230 μL, 1.65 mmol) and dissolve. The reaction was carried out by adding pentafluorophenyltrifluoroacetic acid (225 μL, 1.32 mmol) at 0°C and stirring for 1 hour. After confirming the reaction by TLC (hexane / ethyl acetate = 3 / 1), the reaction solution was concentrated. Elution was performed with a mixed solution of hexane and ethyl acetate, and each fraction was confirmed by TLC (hexane / ethyl acetate = 3 / 1). The fraction containing the product was recovered, the organic solvent was removed by concentration under reduced pressure, and then vacuum drying was performed to obtain the above compound (175.3 mg, 0.34 mmol). 1 H NMR (400 MHz, Chloroform-d) δ = 8.79 (t, J=1.8, 1H), 8.43 (dt, J=7.8, 1.5, 1H), 8.30 (dt, J=7.9, 1.5, 1H), 7.70 (t, J=7.8, 1H), 7.45 (s, 4H), 3.45 (t, J=6.9, 2H), 3.14 (t, J=6.9, 2H).
[0350] (18-2-2) Peptide-linker binding [ka] Both of the above amino acid sequences are the same as the amino acid sequence of Sequence ID No. 4.
[0351] Ac-FNMQCQRRFYEALHDPNLNEEQRNARIRSIKDDC-NH2 (SEQ ID NO: 4) (30.0 mg, 7.06 μmol, where the 5th and 34th cysteine groups each form intramolecular disulfide bonds), synthesized in (18-1-2), was dissolved in N,N-dimethylformamide (1.00 mL), a linker (72.0 mg, 141 μmol) was added, and the mixture was stirred at room temperature for 24 hours. This was dissolved in a 0.05% aqueous trifluoroacetic acid solution and subjected to reverse-phase high-performance liquid chromatography using octadodecyl group chemically bonded silica gel as a packing material. Elution was performed with a mixed solution of water and acetonitrile containing 0.05% trifluoroacetic acid, and each fraction was identified by LC-MS. The fraction containing the product was recovered, concentrated under reduced pressure to remove acetonitrile, and then freeze-dried to obtain the peptide thioester linker-thiophenol activated product (10.0 mg, 2.19 μmol).
[0352] MS(ESI)m / z: z=4 1145.6[M+4H] 4+
[0353] (18-2-3) Specific modification of the anti-HER2 antibody trastuzumab and analysis by ESI-TOFMS The peptide linker compound synthesized in (18-2-2) was dissolved in dimethyl sulfoxide to a concentration of 10 mM. 500 μg of the anti-HER2 antibody trastuzumab (Chugai Pharmaceutical) was dissolved in 200 μL (20 μM) of 50 mM HEPES buffer (pH 8.2), and 3.38 μL (10 equivalents relative to the antibody) of 10 mM peptide reagent was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was replaced with 20 mM ammonium acetate buffer. Mass measurement by ESI-TOFMS revealed a peak at 148223 for the starting material, trastuzumab. Peaks were observed in 152691, where one peptide was introduced; 157163, where two binding peptides were introduced; and 161634, where three binding peptides were introduced.
[0354] (18-2-4) Confirmation of heavy chain selectivity of trastuzumab-specifically modified compounds by ESI-TOFMS analysis under reducing conditions. To the antibody-peptide conjugate prepared in (18-2-3), 2 μL of 100 mM tris(2-carboxyethyl)phosphine hydrochloride solution (equal volume to the antibody) was added and the mixture was stirred at room temperature for 15 minutes. Mass measurement by ESI-TOFMS revealed that the starting material trastuzumab had a heavy chain peak at 50596 and a light chain peak at 23439. The reactant had a heavy chain with one linker introduced (55067) and a light chain with the same peak at 23439 as the starting material.
[0355] (18-2-5) Confirmation of peptide / antibody binding ratio of trastuzumab-specifically modified compounds using a DAR calculator. Table 6 shows the results of confirming the peptide / antibody binding ratio using a DAR calculator (Agilent software) for the MS data analyzed in (18-2-3). The average peptide / antibody binding ratio calculated from the DAR peak and %Area in Table 6 was 2.0. Therefore, the formation of an antibody intermediate represented by the following structural formula (average peptide / antibody binding ratio of 2.0) was confirmed.
[0356] [ka] [Here, Ig represents an immunoglobulin unit (IgG) containing two heavy chains and two light chains, and forms amide bonds with two adjacent carbonyl groups (C=O) via amino groups in the side chains of lysine residues located at positions 288 / 290 in the two heavy chains according to Eu numbering.] Y represents the affinity peptide represented by the amino acid sequence of SEQ ID NO: 4. The average bond ratio r between Ig and the two adjacent carbonyl groups (C=O) is 2.0.
[0357] [Table 6]
[0358] (18-2-6) Production of thiol group-introduced antibody derivatives by cleavage of thioester groups The thiol-introduced antibody derivative described in (18-1-8) was obtained by subjecting the antibody intermediate obtained in (18-2-5) to the thioester group cleavage reaction described in (18-1-8).
[0359] (18-2-7) Peptide mapping by trypsin treatment The trastuzumab thiol derivative obtained in (18-2-6) was subjected to the following procedure. We did a mini-dimension mapping.
[0360] (18-2-7-1) Trypsin treatment of trastuzumab thiol derivatives The trastuzumab thiol transderm obtained in (18-2-6) was treated with trypsin in the same manner as in (18-1-9-1).
[0361] (18-2-7-2) LC-MS / MS measurement of trastuzumab LC-MS / MS measurements were performed under the same conditions as in (18-1-9-2).
[0362] (18-2-7-3) Analysis of modification sites of trastuzumab The analysis was performed in the same manner as in (18-1-9-3).
[0363] (18-2-7-4) Analysis results of modification sites of trastuzumab by LC-MS / MS Analysis using LC-MS / MS revealed the MS spectrum (measured value: m / z 577.03571, theoretical value: 577.03557, quadrivalent) of the peptide fragment FNWYVDGVEVHNAKTKPR (SEQ ID NO: 3), which consists of 18 amino acid residues including a lysine residue modification site (thiol derivative (+145.019Da)) induced by trypsin digestion of trastuzumab (measured value: m / z 577.03571, theoretical value: 577.03557, quadrivalent) (Figure 10). The CID spectrum confirmed a product ion with m / z 682.41 (theoretical value: 682.01), corresponding to trivalent y16, indicating modification of the lysine residue at position 288 or 290 in the EU numbering of the heavy chain (Figure 11). Furthermore, analysis using BioPharma Finder showed that the modification of the lysine residue at position 288 or 290 occurred with high selectivity (Figure 12). These results indicate that in the trastuzumab thiol derivative obtained in (18-2-6) above, regioselective conjugation occurs on the antibody heavy chain at Lys288 and Lys290 in the EU numbering.
[0364] (18-3-1) Synthesis of Thioester Linkers (18-3-1-1) [ka]
[0365] The compound synthesized in (18-1-3-2) (220 mg, 1.21 mmol) was dissolved in CH2Cl2 (12.0 mL), and Adipic Acid (530 mg, 3.63 mmol), DIPEA (314 μL, 1.82 mmol), and PyBOP (755 mg, 1.45 mmol) were added and the mixture was stirred at room temperature for 1 hour. After confirming the reaction by TLC (dichloromethane / methanol = 10 / 1), the reaction solution was concentrated. Elution was performed with a mixed solution of dichloromethane and methanol, and each fraction was confirmed by TLC (dichloromethane / methanol = 10 / 1). The fraction containing the product was collected, concentrated under reduced pressure to remove the organic solvent, and then vacuum dried to obtain the above compound (205 mg, 0.63 mmol).
[0366] (18-3-1-2) [ka]
[0367] The compound synthesized in (18-3-1-1) (205 mg, 0.63 mmol) was dissolved in CH2Cl2 (3.15 mL) and triethylamine (220 μL, 1.58 mmol). Pentafluorophenyltrifluoroacetic acid (215 μL, 1.26 mmol) was added at 0°C and the mixture was stirred for 1 hour. After confirming the reaction by TLC (hexane / ethyl acetate = 3 / 1), the reaction solution was concentrated. The product was eluted with a mixed solution of hexane and ethyl acetate, and each fraction was identified by TLC (hexane / ethyl acetate = 3 / 1). The fraction containing the product was collected, the organic solvent was removed by concentration under reduced pressure, and then the mixture was vacuum-dried to obtain the above compound (200 mg, 0.41 mmol).
[0368] 1 H NMR (400 MHz, Chloroform-d) δ = 7.44 (s, 5H), 3.20 (t, J=7.0, 2H), 3.00 (t, J=6.9, 2H), 2.66 (dt, J=28.3, 7.4, 5H), 1.79 (ddt, J=20.4, 15.2, 7.5, 5H), 1.57-1.38 (m, 3H).
[0369] (18-3-2) Binding of peptides and linkers [ka] Both of the above amino acid sequences are the same as the amino acid sequence of Sequence ID No. 4.
[0370] Ac-FNMQCQRRFYEALHDPNLNEEQRNARIRSIKDDC-NH2 (SEQ ID NO: 4) (30.0 mg, 7.06 μmol, where the 5th and 34th cysteine groups each form intramolecular disulfide bonds), synthesized in (18-1-2), was dissolved in N,N-dimethylformamide (1.00 mL), a linker (69.0 mg, 141 μmol) was added, and the mixture was stirred at room temperature for 24 hours. This was dissolved in a 0.05% aqueous trifluoroacetic acid solution and subjected to reverse-phase high-performance liquid chromatography using octadodecyl group chemically bonded silica gel as a packing material. Elution was performed with a mixed solution of water and acetonitrile containing 0.05% trifluoroacetic acid, and each fraction was identified by LC-MS. The fraction containing the product was recovered, concentrated under reduced pressure to remove acetonitrile, and then freeze-dried to obtain the peptide thioester linker-thiophenol activated product (7.5 mg, 1.65 μmol).
[0371] MS(ESI)m / z: z=4 1140.50[M+4H] 4+
[0372] (18-3-3) Specific modification of the anti-HER2 antibody trastuzumab and analysis by ESI-TOFMS The peptide linker compound synthesized in (18-3-2) was dissolved in dimethyl sulfoxide to a concentration of 10 mM. 500 μg of the anti-HER2 antibody trastuzumab (Chugai Pharmaceutical) was dissolved in 200 μL (20 μM) of 50 mM HEPES buffer (pH 8.2), and 3.38 μL (10 equivalents relative to the antibody) of 10 mM peptide reagent was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was replaced with 20 mM ammonium acetate buffer. Mass measurement by ESI-TOFMS revealed a peak at 148223 for the starting material trastuzumab. Peaks were also observed at 152676 (with one binding peptide), 157126 (with two binding peptides), and 161572 (with three binding peptides).
[0373] (18-3-4) Confirmation of heavy chain selectivity of trastuzumab-specific modifiers by ESI-TOFMS analysis under reducing conditions. To the antibody-peptide conjugate prepared in (18-3-3), 2 μL of 100 mM tris(2-carboxyethyl)phosphine hydrochloride solution (equal volume to the antibody) was added and the mixture was stirred at room temperature for 15 minutes. Mass measurement by ESI-TOFMS revealed that the starting material trastuzumab showed a heavy chain peak at 50596 and a light chain peak at 23439. The reactant showed a heavy chain with one linker introduced (55048) and a light chain with the same peak at 23439 as the starting material.
[0374] (18-3-5) Confirmation of peptide / antibody binding ratio of trastuzumab-specifically modified forms using a DAR calculator. Table 7 shows the results of confirming the peptide / antibody binding ratio using a DAR calculator (Agilent software) for the MS data analyzed in (18-3-3). The average peptide / antibody binding ratio calculated from the DAR peak and %Area in Table 7 was 1.9. Therefore, the formation of an antibody intermediate represented by the following structural formula (average peptide / antibody binding ratio of 1.9) was confirmed.
[0375] [ka] [Here, Ig represents an immunoglobulin unit (IgG) containing two heavy chains and two light chains, and forms amide bonds with two adjacent carbonyl groups (C=O) via amino groups in the side chains of lysine residues located at positions 288 / 290 in the two heavy chains according to Eu numbering.] Y represents the affinity peptide represented by the amino acid sequence of SEQ ID NO: 4. The average bond ratio r between Ig and the two adjacent carbonyl groups (C=O) is 1.9.
[0376] [Table 7]
[0377] (18-3-6) Production of thiol group-introduced antibody derivatives by cleavage of thioester groups The thiol-introduced antibody derivative described in (18-1-8) was obtained by subjecting the antibody intermediate obtained in (18-3-5) to the thioester group cleavage reaction described in (18-1-8).
[0378] (18-4-1) Synthesis of Thioester Linkers (18-4-1-1) [ka]
[0379] tBu-3-Sulfanylpropanoate (500 mg, 3.08 mmol) was dissolved in tetrahydrofuran (7 mL), triethylamine (0.64 mL, 4.62 mmol) was added, and then malonyl chloride (0.15 mg, 1.54 mmol) was added at 0°C and the mixture was stirred for 3 hours. After confirming the reaction by TLC (hexane / ethyl acetate = 5 / 1), the reaction solution was concentrated. Elution was performed with a mixed solution of hexane and ethyl acetate, and each fraction was confirmed by TLC (hexane / ethyl acetate = 5 / 1). The fraction containing the product was collected, concentrated under reduced pressure to remove the organic solvent, and then vacuum dried to obtain the above compound (104 mg, 0.26 mmol).
[0380] (18-4-1-2) [ka]
[0381] The compound synthesized in (18-4-1-1) (104 mg, 0.26 mmol) was dissolved in a CH2Cl2 / TFA=1 / 1 mixed solution and stirred at room temperature for 1 hour. After confirming that the solution had fallen to the origin using TLC (hexane / ethyl acetate=5 / 1), the reaction solution was concentrated and then vacuum dried to obtain the above compound (104 mg, 0.37 mmol).
[0382] (18-4-1-3) [ka]
[0383] The compound synthesized in (18-4-1-2) (104 mg, 0.37 mmol) was dissolved in CH2Cl2 (1.85 mL) and triethylamine (130 μL, 0.93 mmol). N-SuccinimidylTrifluoroacetate (156 mg, 0.74 mmol) was added at 0°C and the mixture was stirred for 1 hour. After confirming the reaction by TLC (hexane / ethyl acetate = 1 / 1), the reaction solution was concentrated. The product was eluted with a mixed solution of hexane and ethyl acetate, and each fraction was identified by TLC (hexane / ethyl acetate = 1 / 1). The fraction containing the product was collected, concentrated under reduced pressure to remove the organic solvent, and then vacuum dried to obtain the above compound (66.8 mg, 0.14 mmol).
[0384] 1 H NMR (400 MHz, Chloroform-d) δ = 3.84 (s, 2H), 3.28 (t, J=6.9, 2H), 3.19 (t, J=6.8, 2H), 3.00 (t, J=6.8, 2H), 2.74 (t, J=6.8, 2H).
[0385] (18-4-2) Peptide-linker binding [ka] Both of the above amino acid sequences are the same as the amino acid sequence of Sequence ID No. 4.
[0386] Ac-FNMQCQRRFYEALHDPNLNEEQRNARIRSIKDDC-NH2 (SEQ ID NO: 4) (29.7 mg, 7.00 μmol, where the 5th and 34th cysteine groups each form intramolecular disulfide bonds), synthesized in (18-1-2), was dissolved in N,N-dimethylformamide (1.00 mL), a linker (66.8 mg, 0.14 mmol) was added, and the mixture was stirred at room temperature for 4 hours. This was dissolved in a 0.05% aqueous trifluoroacetic acid solution and subjected to reverse-phase high-performance liquid chromatography using octadodecyl group chemically bonded silica gel as a packing material. Elution was performed with a mixed solution of water and acetonitrile containing 0.05% trifluoroacetic acid, and each fraction was identified by LC-MS. The fraction containing the product was recovered, concentrated under reduced pressure to remove acetonitrile, and then freeze-dried to obtain the peptide thioester linker-NHS activated product (13 mg, 2.82 μmol).
[0387] MS(ESI)m / z: z=4 1153.10[M+4H] 4+
[0388] (18-4-3) Specific modification of the anti-HER2 antibody trastuzumab and analysis by ESI-TOFMS The peptide linker compound synthesized in (18-4-2) was dissolved in dimethyl sulfoxide to a concentration of 10 mM. 500 μg of the anti-HER2 antibody trastuzumab (Chugai Pharmaceutical) was dissolved in 200 μL (20 μM) of 50 mM HEPES buffer (pH 8.2), and 3.38 μL (10 equivalents relative to the antibody) of 10 mM peptide reagent was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was replaced with 20 mM ammonium acetate buffer. Mass measurement by ESI-TOFMS revealed a peak at 148223 for the starting material trastuzumab. Peaks were also observed at 152722 (with one binding peptide), 157215 (with two binding peptides), and 161708 (with three binding peptides).
[0389] (18-4-4) Confirmation of heavy chain selectivity of trastuzumab-specifically modified trastuzumab by ESI-TOFMS analysis under reduction conditions. To the antibody-peptide conjugate prepared in (18-4-3), 2 μL of 100 mM tris(2-carboxyethyl)phosphine hydrochloride solution (equal volume to the antibody) was added and the mixture was stirred at room temperature for 15 minutes. Mass measurement by ESI-TOFMS revealed that the starting material trastuzumab showed a heavy chain peak at 50594 and a light chain peak at 23439. The reactant showed a heavy chain with one linker introduced (55091) and a light chain with the same peak at 23439 as the starting material.
[0390] (18-4-5) Confirmation of peptide / antibody binding ratio of trastuzumab-specifically modified forms using a DAR calculator. Table 8 shows the results of confirming the peptide / antibody binding ratio using a DAR calculator (Agilent software) for the MS data analyzed in (18-4-3). The average peptide / antibody binding ratio calculated from the DAR peak and %Area in Table 8 was 1.8. Therefore, the formation of an antibody intermediate represented by the following structural formula (average peptide / antibody binding ratio of 1.8) was confirmed.
[0391] [ka] [Here, Ig represents an immunoglobulin unit (IgG) containing two heavy chains and two light chains, and forms amide bonds with two adjacent carbonyl groups (C=O) via amino groups in the side chains of lysine residues located at positions 288 / 290 in the two heavy chains according to Eu numbering.] Y represents the affinity peptide represented by the amino acid sequence of SEQ ID NO: 4. The average bond ratio r between Ig and the two adjacent carbonyl groups (C=O) is 1.8.
[0392] [Table 8]
[0393] (18-4-6) Production of thiol group-introduced antibody derivatives by cleavage of thioester groups The thiol-introduced antibody derivative described in (18-1-8) was obtained by subjecting the antibody intermediate obtained in (18-4-5) to the thioester group cleavage reaction described in (18-1-8).
[0394] (18-5-1) Binding of peptides and linkers [ka] Both of the above amino acid sequences are the same as the amino acid sequence of Sequence ID No. 5.
[0395] Ac-FNMQCQRRFYEALHDPNLNEEQRNARIRSIKEDC-NH2 (SEQ ID NO: 5) (30.0 mg, 7.06 μmol, where the 5th and 34th cysteine molecules each form intramolecular disulfide bonds) synthesized by the method described in (18-1-1) was linked with a linker in the same manner as in Example 2 (2-2) to obtain the peptide thioester linker linked product - thiophenol activated product (10.0 mg, 2.19 μmol).
[0396] MS(ESI)m / z: z=4 1145.6[M+4H] 4+
[0397] (18-5-2) Specific modification of the anti-HER2 antibody trastuzumab and analysis by ESI-TOFMS The peptide linker compound synthesized in (18-5-1) was dissolved in dimethyl sulfoxide to a concentration of 10 mM. 500 μg of the anti-HER2 antibody trastuzumab (Chugai Pharmaceutical) was dissolved in 200 μL (20 μM) of 50 mM HEPES buffer (pH 8.2), and 3.38 μL (10 equivalents relative to the antibody) of 10 mM peptide reagent was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was replaced with 20 mM ammonium acetate buffer. Mass measurement by ESI-TOFMS revealed a peak at 148223 for the starting material trastuzumab. Peaks were also observed at 152707 (with one binding peptide), 157188 (with two binding peptides), and 161676 (with three binding peptides).
[0398] (18-5-3) Confirmation of heavy chain selectivity of trastuzumab-specifically modified compounds by ESI-TOFMS analysis under reducing conditions. To the antibody-peptide conjugate prepared in (18-5-2), 2 μL of 100 mM tris(2-carboxyethyl)phosphine hydrochloride solution (equal volume to the antibody) was added and the mixture was stirred at room temperature for 15 minutes. Mass measurement by ESI-TOFMS revealed that the starting material trastuzumab showed a heavy chain peak at 50596 and a light chain peak at 23439. The reactant showed a heavy chain with one linker introduced (55077) and a light chain with the same peak at 23439 as the starting material.
[0399] (18-5-4) Confirmation of peptide / antibody binding ratio of trastuzumab-specifically modified forms using a DAR calculator. Table 9 shows the results of confirming the peptide / antibody binding ratio using a DAR calculator (Agilent software) for the MS data analyzed in (5-2). The average peptide / antibody binding ratio calculated from the DAR peak and %Area in Table 9 was 2.0. Therefore, the formation of an antibody intermediate represented by the following structural formula (average peptide / antibody binding ratio of 2.0) was confirmed.
[0400] [ka] [Here, Ig represents an immunoglobulin unit (IgG) containing two heavy chains and two light chains, and forms amide bonds with two adjacent carbonyl groups (C=O) via amino groups in the side chains of lysine residues located at positions 288 / 290 in the two heavy chains according to Eu numbering.] Y represents the affinity peptide represented by the amino acid sequence of SEQ ID NO: 5. The average bond ratio r between Ig and the two adjacent carbonyl groups (C=O) is 2.0.
[0401] [Table 9]
[0402] (18-5-5) Production of thiol group-introduced antibody derivatives by cleavage of thioester groups The thiol-introduced antibody derivative described in (18-1-8) was obtained by subjecting the antibody intermediate obtained in (18-5-4) to the thioester group cleavage reaction described in (18-1-8).
[0403] (18-6-1) Binding of peptides and linkers [ka] Both of the above amino acid sequences are the same as the amino acid sequence of Sequence ID No. 6.
[0404] Ac-FNMQCQRRFYEALHDPNLNEEQRNARIRSIKEEC-NH2 (SEQ ID NO: 6) (30.0 mg, 7.06 μmol, where the 5th and 34th cysteine groups each form intramolecular disulfide bonds) synthesized by the method described in (18-1-1) was linked with a linker in the same manner as in (18-2-2) to obtain the peptide thioester linker linked product - thiophenol activated product (22.2 mg, 4.82 μmol).
[0405] MS(ESI)m / z: z=4 1152.4[M+4H] 4+
[0406] (18-6-2) Specific modification of the anti-HER2 antibody trastuzumab and analysis by ESI-TOFMS The peptide linker compound synthesized in (18-6-1) was dissolved in dimethyl sulfoxide to a concentration of 10 mM. 500 μg of the anti-HER2 antibody trastuzumab (Chugai Pharmaceutical) was dissolved in 200 μL (20 μM) of 50 mM HEPES buffer (pH 8.2), and 3.38 μL (10 equivalents relative to the antibody) of 10 mM peptide reagent was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was replaced with 20 mM ammonium acetate buffer. Mass measurement by ESI-TOFMS revealed a peak at 148223 for the starting material trastuzumab. Peaks were also observed at 152720 (with one binding peptide), 157216 (with two binding peptides), and 161716 (with three binding peptides).
[0407] (18-6-3) Confirmation of heavy chain selectivity of trastuzumab-specifically modified compounds by ESI-TOFMS analysis under reducing conditions. To the antibody-peptide conjugate prepared in (18-6-2), 2 μL of 100 mM tris(2-carboxyethyl)phosphine hydrochloride solution (equal volume to the antibody) was added and the mixture was stirred at room temperature for 15 minutes. Mass measurement by ESI-TOFMS revealed that the starting material trastuzumab showed a heavy chain peak at 50596 and a light chain peak at 23439. The reactant showed a heavy chain with one linker introduced (55091) and a light chain with the same peak at 23439 as the starting material.
[0408] (18-6-4) Confirmation of peptide / antibody binding ratio of trastuzumab-specifically modified forms using a DAR calculator. Table 10 shows the results of confirming the peptide / antibody binding ratio using a DAR calculator (Agilent software) for the MS data analyzed in (18-6-2). The average peptide / antibody binding ratio calculated from the DAR peak and %Area in Table 10 was 2.0. Therefore, the formation of an antibody intermediate represented by the following structural formula (average peptide / antibody binding ratio of 2.0) was confirmed.
[0409] [ka] [Here, Ig represents an immunoglobulin unit (IgG) containing two heavy chains and two light chains, and forms amide bonds with two adjacent carbonyl groups (C=O) via amino groups in the side chains of lysine residues located at positions 288 / 290 in the two heavy chains according to Eu numbering.] Y represents the affinity peptide represented by the amino acid sequence of SEQ ID NO: 6. The average bond ratio r between Ig and the two adjacent carbonyl groups (C=O) is 2.0.
[0410] [Table 10]
[0411] (18-6-5) Production of thiol group-introduced antibody derivatives by cleavage of thioester groups The thiol-introduced antibody derivative described in (18-1-8) was obtained by subjecting the antibody intermediate obtained in (18-6-4) to the thioester group cleavage reaction described in (18-1-8).
[0412] (18-7-1) Binding of peptides and linkers [ka] Both of the above amino acid sequences are the same as the amino acid sequence of Sequence ID No. 7.
[0413] Ac-NMQCQRRFYEALHDPNLNEEQRNARIRSIKEEC-NH2 (SEQ ID NO: 7) (30.0 mg, 7.06 μg) synthesized by the method described in (18-1-1). A linker was attached to (18-2-2) in the same manner as in (18-2-2), where the 5th and 34th cysteine molecules each form an intramolecular disulfide bond, to obtain the peptide thioester linker-thiophenol activated product (12.0 mg, 2.69 μmol).
[0414] MS(ESI)m / z:z=4 1115.8[M+4H] 4+
[0415] (18-7-2) Specific modification of the anti-HER2 antibody trastuzumab and analysis by ESI-TOFMS The peptide linker compound synthesized in (18-7-1) was dissolved in dimethyl sulfoxide to a concentration of 10 mM. 500 μg of the anti-HER2 antibody trastuzumab (Chugai Pharmaceutical) was dissolved in 200 μL (20 μM) of 50 mM HEPES buffer (pH 8.2), and 3.38 μL (10 equivalents relative to the antibody) of 10 mM peptide reagent was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was replaced with 20 mM ammonium acetate buffer. Mass measurement by ESI-TOFMS revealed a peak at 148223 for the starting material trastuzumab. Peaks at 152573 (with one binding peptide introduced) and 156927 (with two binding peptide introduced) were also observed.
[0416] (18-7-3) Confirmation of heavy chain selectivity of trastuzumab-specifically modified compounds by ESI-TOFMS analysis under reducing conditions. To the antibody-peptide conjugate prepared in (18-7-2), 2 μL of 100 mM tris(2-carboxyethyl)phosphine hydrochloride solution (equal volume to the antibody) was added and the mixture was stirred at room temperature for 15 minutes. Mass measurement by ESI-TOFMS revealed that the starting material trastuzumab showed a heavy chain peak at 50596 and a light chain peak at 23439. The reactant showed a heavy chain with one linker introduced (54942) and a light chain with the same peak at 23439 as the starting material.
[0417] (18-7-4) Confirmation of peptide / antibody binding ratio of trastuzumab-specifically modified forms using a DAR calculator. Table 11 shows the results of confirming the peptide / antibody binding ratio using a DAR calculator (Agilent software) for the MS data analyzed in (18-7-2). The average peptide / antibody binding ratio calculated from the DAR peak and %Area in Table 11 was 2.0. Therefore, the formation of an antibody intermediate represented by the following structural formula (average peptide / antibody binding ratio of 2.0) was confirmed.
[0418] [ka] [Here, Ig represents an immunoglobulin unit (IgG) containing two heavy chains and two light chains, and forms amide bonds with two adjacent carbonyl groups (C=O) via amino groups in the side chains of lysine residues located at positions 288 / 290 in the two heavy chains according to Eu numbering.] Y represents the affinity peptide represented by the amino acid sequence of SEQ ID NO: 7. The average bond ratio r between Ig and the two adjacent carbonyl groups (C=O) is 2.0.
[0419] [Table 11]
[0420] (18-7-5) Production of thiol group-introduced antibody derivatives by cleavage of thioester groups The thiol-introduced antibody derivative described in (18-1-8) was obtained by subjecting the antibody intermediate obtained in (18-7-4) to the thioester group cleavage reaction described in (18-1-8).
[0421] (18-7-6) Peptide mapping by trypsin treatment Peptide mapping was performed on the trastuzumab thiol derivative obtained in (18-7-5) using the following procedure.
[0422] (18-7-6-1) Trypsin treatment of trastuzumab thiol derivatives The trastuzumab thiol transderm obtained in (18-7-5) was treated with trypsin in the same manner as in (18-1-9-1).
[0423] (18-7-6-2) LC-MS / MS measurement of trastuzumab LC-MS / MS measurements were performed under the same conditions as in (18-1-9-2).
[0424] (18-7-6-3) Analysis of modification sites of trastuzumab The analysis was performed in the same manner as in (18-1-9-3).
[0425] (18-7-6-4) Analysis results of modification sites of trastuzumab by LC-MS / MS Analysis using LC-MS / MS revealed the MS spectrum (measured value: m / z 769.04506, theoretical value: 769.04482, trivalent) of the peptide fragment FNWYVDGVEVHNAKTKPR (SEQ ID NO: 3), which consists of 18 amino acid residues including a lysine residue modification site (thiol derivative (+145.019Da)) induced by trypsin digestion of trastuzumab (measured value: m / z 769.04506, theoretical value: 769.04482, trivalent) (Figure 13). The CID spectrum confirmed a product ion with m / z 1022.71 (theoretical value: 1022.51) corresponding to the divalent y16, indicating modification of the lysine residue at position 288 or 290 in the EU numbering of the heavy chain (Figure 14). Furthermore, analysis using BioPharma Finder showed that the modification of the lysine residue at position 288 or 290 occurred with high selectivity (Figure 15). These results indicate that in the trastuzumab thiol derivative obtained in (18-7-5) above, regioselective conjugation occurs on the antibody heavy chain, specifically at Lys288 and Lys290 in the EU numbering.
[0426] (18-8-1) Peptide-linker binding [ka] Both of the above amino acid sequences are the same as the amino acid sequence of Sequence ID No. 8.
[0427] Ac-MQCQRRFYEALHDPNLNEEQRNARIRSIKEEC-NH2 (SEQ ID NO: 8) (30.0 mg, 7.06 μmol, where the 5th and 34th cysteine molecules each form intramolecular disulfide bonds) synthesized by the method described in (18-1-1) was linked with a linker in the same manner as in (18-2-2) to obtain the peptide thioester linker linked product - thiophenol activated product (16.8 mg, 3.87 μmol).
[0428] MS(ESI)m / z: z=4 1087.3[M+4H]4+
[0429] (18-8-2) Specific modification of the anti-HER2 antibody trastuzumab and analysis by ESI-TOFMS The peptide linker compound synthesized in (18-8-1) was dissolved in dimethyl sulfoxide to a concentration of 10 mM. 500 μg of the anti-HER2 antibody trastuzumab (Chugai Pharmaceutical) was dissolved in 200 μL (20 μM) of 50 mM HEPES buffer (pH 8.2), and 3.38 μL (10 equivalents relative to the antibody) of 10 mM peptide reagent was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was replaced with 20 mM ammonium acetate buffer. Mass measurement by ESI-TOFMS revealed a peak at 148223 for the starting material trastuzumab. Peaks were also observed at 152457 (with one binding peptide), 156692 (with two binding peptides), and 160929 (with three binding peptides).
[0430] (18-8-3) Confirmation of heavy chain selectivity of trastuzumab-specifically modified compounds by ESI-TOFMS analysis under reduction conditions. To the antibody-peptide conjugate prepared in (18-8-2), 2 μL of 100 mM tris(2-carboxyethyl)phosphine hydrochloride solution (equal volume to the antibody) was added and the mixture was stirred at room temperature for 15 minutes. Mass measurement by ESI-TOFMS revealed that the starting material trastuzumab had a heavy chain peak at 50596 and a light chain peak at 23439. The reactant had a heavy chain with one linker introduced (54829) and a light chain with the same peak at 23439 as the starting material.
[0431] (18-8-4) Confirmation of peptide / antibody binding ratio of trastuzumab-specifically modified forms using a DAR calculator. Table 12 shows the results of confirming the peptide / antibody binding ratio using a DAR calculator (Agilent software) for the MS data analyzed in (18-8-2). The average peptide / antibody binding ratio calculated from the DAR peak and %Area in Table 12 was 2.0. Therefore, the formation of an antibody intermediate represented by the following structural formula (average peptide / antibody binding ratio of 2.0) was confirmed.
[0432] [ka] [Here, Ig represents an immunoglobulin unit (IgG) containing two heavy chains and two light chains, and forms amide bonds with two adjacent carbonyl groups (C=O) via amino groups in the side chains of lysine residues located at positions 288 / 290 in the two heavy chains according to Eu numbering.] Y represents the affinity peptide represented by the amino acid sequence of SEQ ID NO: 8. The average bond ratio r between Ig and the two adjacent carbonyl groups (C=O) is 2.0.
[0433] [Table 12]
[0434] (18-8-5) Production of thiol group-introduced antibody derivatives by cleavage of thioester groups The thiol-introduced antibody derivative described in (18-1-8) was obtained by subjecting the antibody intermediate obtained in (18-8-4) to the thioester group cleavage reaction described in (18-1-8).
[0435] (18-9-1) Peptide-linker binding [ka] Both of the above amino acid sequences are the same as the amino acid sequence of Sequence ID No. 9.
[0436] Ac-QCQRRFYEALHDPNLNEEQRNARIRSIKEEC-NH2 (SEQ ID NO: 9) (30.0 mg, 7.06 μmol) synthesized by the method described in (18-9-1) A linker was attached to l (wherein the 5th and 34th cysteines each form an intramolecular disulfide bond) in the same manner as in (18-2-2) to obtain the peptide thioester linker-thiophenol activated product (14.1 mg, 3.35 μmol).
[0437] MS(ESI)m / z: z=4 1054.4[M+4H] 4+
[0438] (18-9-2) Specific modification of the anti-HER2 antibody trastuzumab and analysis by ESI-TOFMS The peptide linker compound synthesized in (18-9-1) was dissolved in dimethyl sulfoxide to a concentration of 10 mM. 500 μg of the anti-HER2 antibody trastuzumab (Chugai Pharmaceutical) was dissolved in 200 μL (20 μM) of 50 mM HEPES buffer (pH 8.2), and 3.38 μL (10 equivalents relative to the antibody) of 10 mM peptide reagent was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was replaced with 20 mM ammonium acetate buffer. Mass measurement by ESI-TOFMS revealed a peak at 148223 for the starting material trastuzumab. Peaks were also observed at 152236 (with one binding peptide), 156430 (with two binding peptides), and 160541 (with three binding peptides).
[0439] (18-9-3) Confirmation of heavy chain selectivity of trastuzumab-specifically modified compounds by ESI-TOFMS analysis under reduction conditions. To the antibody-peptide conjugate prepared in (18-9-2), 2 μL of 100 mM tris(2-carboxyethyl)phosphine hydrochloride solution (equal volume to the antibody) was added and the mixture was stirred at room temperature for 15 minutes. Mass measurement by ESI-TOFMS revealed that the starting material trastuzumab showed a heavy chain peak at 50596 and a light chain peak at 23439. The reactant showed a heavy chain with one linker introduced (54698) and a light chain with the same peak at 23439 as the starting material.
[0440] (18-9-4) Confirmation of peptide / antibody binding ratio of trastuzumab-specifically modified forms using a DAR calculator. Table 13 shows the results of confirming the peptide / antibody binding ratio using a DAR calculator (Agilent software) for the MS data analyzed in (18-9-2). The average peptide / antibody binding ratio calculated from the DAR peak and %Area in Table 13 was 2.0. Therefore, the formation of an antibody intermediate represented by the following structural formula (average peptide / antibody binding ratio of 2.0) was confirmed.
[0441] [ka] [Here, Ig represents an immunoglobulin unit (IgG) containing two heavy chains and two light chains, and forms amide bonds with two adjacent carbonyl groups (C=O) via amino groups in the side chains of lysine residues located at positions 288 / 290 in the two heavy chains according to Eu numbering.] Y represents the affinity peptide represented by the amino acid sequence of SEQ ID NO: 9. The average bond ratio r between Ig and the two adjacent carbonyl groups (C=O) is 2.0.
[0442] [Table 13]
[0443] (18-9-5) Production of thiol group-introduced antibody derivatives by cleavage of thioester groups The thiol-introduced antibody derivative described in (18-1-8) was obtained by subjecting the antibody intermediate obtained in (18-9-4) to the thioester group cleavage reaction described in (18-1-8).
[0444] (18-10-1) Introduction of bioorthogonal functional groups to thiols introduced at the Ly288 / Lys290 position of antibodies The Ly288 / Lys290-thiol-introduced antibody synthesized in Example (18-1-8) was modified using the azide linker (1) from Example 1. Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was then measured by ESI-TOFMS according to previously reported information (WO2019 / 240287A1). The starting material thiol-introduced antibody showed heavy chain peaks at 50683 and 50845 and a light chain peak at 23439. The product showed azide groups introduced into the heavy chain at 50816 and 50978, and a light chain peak at 23439, the same as the starting material.
[0445] Using a similar method, the Ly288 / Lys290 thiol-introduced antibody synthesized in Example (18-1-8) was modified using the azide linker (2) from Example 2. Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was then measured by ESI-TOFMS according to previously reported information (WO2019 / 240287A1). The starting material thiol-introduced antibody showed heavy chain peaks at 50683 and 50845 and a light chain peak at 23439. The product showed light chain peaks at 50848 and 51011, where an azide group was introduced into the heavy chain, and at 23439, the same as the starting material.
[0446] Using a similar method, the Ly288 / Lys290-thiol-transformed antibody synthesized in Example (18-1-8) was modified with the azide linker (6) synthesized in Example 6. The reaction mixture was replaced with 20 mM ammonium acetate buffer, and the mass was measured by ESI-TOFMS according to the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732). A peak of 149023, in which two azide groups were introduced into the antibody, was confirmed.
[0447] Using a similar method, the Ly288 / Lys290 thiol-introduced antibody synthesized in Example (18-1-8) was modified using the alkyne linker (8) from Example 8. Tris(2-carboxyethyl)phosphine hydrochloride solution (0.5 mM) was added to the product, and the mixture was stirred at room temperature for 10 minutes. The mass was then measured by ESI-TOFMS according to a previously reported method (WO2019 / 240287A1). The starting material thiol-introduced antibody showed heavy chain peaks at 50683 and 50845 and a light chain peak at 23439. The product showed heavy chain peaks at 51137 and 51304, where alkyne groups were introduced, and a light chain peak at 23439, the same as the starting material.
[0448] Using a similar method, the Ly288 / Lys290 thiol-transformed antibody synthesized in Example (18-1-8) was modified with the alkyne linker (11) synthesized in Example 11. The reaction mixture was replaced with 20 mM ammonium acetate buffer, and the mass was measured by ESI-TOFMS according to the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732). A peak of 149185, in which two alkyne groups were introduced into the antibody, was confirmed. It was done.
[0449] Example 19: Synthesis of DAR=4 type ADC using branched reagents (19-1) Synthesis of branched azide reagents (19-1-1)Synthesis of tert-Butyl N-[5-(tert-butoxycarbonylamino)-1-(hydrazinecarbonyl)pentyl]carbamate
[0450] [ka]
[0451] 9H-Fluoren-9-ylmethyl N-[2,6-bis(tert-butoxycarbonylamino)hexanoylamino]carbamate (191 mg, 0.328 mmol) was mixed with 3 mL of acetonitrile solution containing 5% piperidine and stirred at room temperature for 3 hours. After confirming the disappearance of the starting material by TLC, the crude product obtained by concentration under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain tert-Butyl N-[5-(tert-butoxycarbonylamino)-1-(hydrazinecarbonyl)pentyl]carbamate (136 mg).
[0452] MS(ESI) m / z:361[M+H]
[0453] 1 H NMR (400 MHz, Chloroform-d) δ = 7.97 (s, 1H), 5.33 (s, 1H), 4.74 (s, 1H), 4.12-4.04 (m, 1H), 3.95 (s, 2H), 3.11 (q, J=6.6, 2H), 1.84-1.77 (m, 1H), 1.72-1.65 (m, 1H), 1.54-1.37 (m, 4H), 1.45 (s, 18H).
[0454] Synthesis of (19-1-2)tert-butyl N-[5-(tert-butoxycarbonylamino)-1-(5-sulfanyl-1,3,4-oxadiazol-2-yl)pentyl]carbamete
[0455] [ka]
[0456] To an ethanol solution (8 mL) of tert-Butyl N-[5-(tert-butoxycarbonylamino)-1-(hydrazinecarbonyl)pentyl]carbamate (136.2 mg, 0.328 mmol), carbon disulfide (0.034 mL, 0.567 mmol) and potassium hydroxide (66.4 mg, 1.18 mmol) were added, and the mixture was stirred at 70°C for 20 hours. 1N hydrochloric acid was added to the reaction mixture, and the mixture was concentrated under reduced pressure, followed by extraction with ethyl acetate. The organic layer was then concentrated under reduced pressure, and the resulting crude product was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain tert-butyl N-[5-(tert-butoxycarbonylamino)-1-(5-sulfanyl-1,3,4-oxadiazol-2-yl)pentyl]carbamate (94 mg, 0.234 mmol, 2-step yield 71%).
[0457] MS(ESI) m / z:401[MH]
[0458] 1 H NMR (400 MHz, Chloroform-d) δ = 5.14 (s, 1H), 4.74 (s, 1H), 4.55 (s, 1H), 3.06 (d, J=6.7, 2H), 1.84-1.76 (m, 2H), 1.46-1.41 (m, 2H), 1.38 (s, 18H), 1.22-1.20 (m, 2H), 0.81 (t, J=6.8, 1H).
[0459] Synthesis of (19-1-3)tert-butyl N-[5-(tert-butoxycarbonylamino)-1-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)pentyl]carbamate
[0460] [ka]
[0461] A THF solution (3 mL) of tert-butyl N-[5-(tert-butoxycarbonylamino)-1-(5-sulfanyl-1,3,4-oxadiazol-2-yl)pentyl]carbamete (94.1 mg, 0.234 mmol) was cooled to 0°C, and methyl iodide (0.044 mL, 0.702 mmol) and triethylamine (0.097 mL, 0.702 mmol) were added. The mixture was returned to room temperature, stirred, and the disappearance of the starting materials was confirmed by TLC. The reaction mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain tert-butyl N-[5-(tert-butoxycarbonylamino)-1-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)pentyl]carbamete (81 mg, 0.194 mmol, yield 83%).
[0462] MS(ESI) m / z:417[M+H]
[0463] 1 H NMR (400 MHz, Chloroform-d) δ = 5.08 (s, 1H), 4.89 (s, 1H), 4.53 (s, 1H), 3.05 (q, J=6.6, 2H), 2.64 (s, 3H), 1.89-1.74 (m, 2H), 1.48-1.41 (m, 4H), 1.37 (d, J=2.5, 18H).
[0464] Synthesis of (19-1-4)1-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)pentane-1,5-diamine
[0465] [ka]
[0466] 80.9 mg, 0.194 mmol of tert-butyl N-[5-(tert-butoxycarbonylamino)-1-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)pentyl]carbamate (5 mL) was added to a dichloromethane solution (5 mL) and stirred at room temperature for 2 hours. The reaction mixture was then concentrated under reduced pressure. 1N hydrochloric acid and ethyl acetate were added to the resulting residue to extract the target product into the aqueous layer. The mixture was freeze-dried to obtain 1-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)pentane-1,5-diamine (57 mg).
[0467] MS(ESI) m / z:217[M+H]
[0468] 1 H NMR (400 MHz, Methanol-d) δ = 4.81 (dd, J=8.3, 5.8, 1H), 2.97 (t, J=7.7, 2H), 2.79 (s, 3H), 2.22-2.09 (m, 2H), 1.82-1.73 (m, 2H), 1.61-1.50 (m, 2H).
[0469] Synthesis of (19-1-5)2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]-N-[5-[[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]acetyl]amino]-5-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)pentyl]acetamide
[0470] [ka]
[0471] To a 3 mL DMF solution of 1-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)pentane-1,5-diamine (57.3 mg, 0.200 mmol), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide,hydrochloride (134.2 mg, 0.700 mmol), triethylamine (0.139 mL, 1.00 mmol), N,N-dimethylaminopyridine (4.9 mg, 0.040 mmol), and 11-Azido-3,6,9-trioxaundecanoic acid (102.0 mg, 0.44 mmol) were added. After stirring at room temperature for 3 hours, some starting material remained, so 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide,hydrochloride (40.0 mg, 0.209 mmol), triethylamine (0.070 mL, 0.505 mmol), and 11-Azido-3,6,9-trioxaundecanoic acid (37.0 mg, 0.160 mmol) were added, and the mixture was stirred for another hour. The reaction mixture was diluted with acetonitrile water and purified by preparative HPLC, and the fraction containing the product was recovered. After removing acetonitrile by concentration under reduced pressure, the aqueous solution was freeze-dried to obtain (1-4)2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]-N-[5-[[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]acetyl]amino]-5-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)pentyl]acetamide (48 mg, 0.0734 mmol, 2-step yield 38%).
[0472] MS(ESI) m / z:647[M+H]
[0473] 11H NMR (400 MHz, Chloroform-d) δ = 7.46 (d, J=9.0, 1H), 7.01 (t, J=6.1, 1H), 5.35 (td, J=8.5, 6.2, 1H), 4.07 (d, J=3.2, 2H), 4.00 (s, 2H), 3.79-3.58 (m, 20H), 3.40 (dt, J=5.7, 4.3, 4H), 3.30 (q, J=6.9, 2H), 2.72 (s, 3H), 2.15-2.01 (m, 1H), 2.10-1.84 (m, 1H), 1.68-1.53 (m, 2H), 1.53-1.35 (m, 2H).
[0474] (19-1-6) Synthesis of 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]-N-[5-[[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]acetyl]amino]-5-(5-methylsulfonyl-1,3,4-oxadiazol-2-yl)pentyl]acetamide
[0475]
Chem.
[0476] 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]-N-[5-[[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]acetyl]amino]-5-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)pentyl]acetamide (47.5 mg, 0.0734 mmol) was dissolved in dichloromethane (2 mL) and 3-chloroperbenzoic acid (containing approximately 30% water) (112.4 mg, 0.456 mmol) was added. After stirring at room temperature for 5 hours, the reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by preparative HPLC. The fraction containing the product was collected, concentrated under reduced pressure to remove acetonitrile, and the aqueous solution was freeze-dried to obtain the target product (92 mg). Since residual impurities were still observed, further purification was performed by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]-N-[5-[[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]acetyl]amino]-5-(5-methylsulfonyl-1,3,4-oxadiazol-2-yl)pentyl]acetamide (31 mg, 0.0457 mmol, yield 62%).
[0477] MS(ESI) m / z:679[M+H]
[0478] 1 H NMR (400 MHz, Chloroform-d) δ = 7.67 (d, J=8.6, 1H), 7.04 (t, J=5.6, 1H), 5.46 (td, J=8.5, 6.2, 1H), 4.10 (d, J=5.4, 2H), 4.00 (s, 2H), 3.76-3.64 (m, 20H), 3.49 (s, 3H), 3.44-3.37 (m, 4H), 3.32 (q, J=6.8, 2H), 2.23-2.08 (m, 1H), 2.08-1.94 (m, 1H), 1.56-1.40 (m, 2H), 1.38-1.21 (m, 2H).
[0479] (19-2) Conjugation of branched azide reagents and thiol-transferred antibodies The thiol-transferred antibody was reacted with the azid linker synthesized in Example 19-1-6 using the same method as described in Example 2(2).
[0480] Following the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732), the mass was measured by ESI-TOFMS, and a peak of 149620 was identified, indicating that four azide groups had been introduced into the antibody.
[0481] (19-3) Synthesis of ADCs by click reaction In accordance with previously reported information (WO2019 / 240287A1 and WO2019 / 240288A1) and Example 15-1, the branched azide-transformed trastuzumab obtained in Example 19-2 was treated with a DMF solution of DBCO-VC-PAB-MMAE (manufactured by ABZENA). 20 equivalents of 5 mM were added, and the mixture was stirred at room temperature for 20 hours. After purification using NAP-5 Columns (GE Healthcare), ADC was obtained.
[0482] Following the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732), the mass was measured by ESI-TOFMS, and a peak of 155284 was identified, in which four DBCO-VC-PAB-MMAE molecules were introduced into the antibody.
[0483] (19-4) Synthesis of branched protected thiol reagents Synthesis of (19-4-1)tert-Butyl(1,3-dihydroxypropan-2-yl)carbamate
[0484] [ka]
[0485] To a methanol solution (1.8 mL) of 2-Amino-1,3-propanediol (186.2 mg, 2.00 mmol), t-butyl alcohol (1.8 mL) was added, and a t-butyl alcohol solution (1.4 mL) of di-tert-butyl dicarbonate (597.3 mg, 2.60 mmol) was added dropwise. After stirring at room temperature for 17 hours, the reaction mixture was concentrated under reduced pressure. When hexane (4 mL) was added to the resulting crude product, a white solid precipitated. The solid was filtered, washed with hexane (3 mL), and dried in a vacuum line to obtain tert-Butyl(1,3-dihydroxypropan-2-yl)carbamate (352.9 mg, 1.845 mmol, yield 92%).
[0486] MS(ESI) m / z:213[M+Na]
[0487] 1 H NMR (400 MHz, Chloroform-d) δ = 5.22 (s, 1H), 3.84 (qd, J=11.0, 4.3, 4H), 3.71 (s, 1H), 1.48 (s, 9H)
[0488] (19-4-2)Synthesis of tert-Butyl N-[2-allyoxy-1-(allyloxymethyl)ethyl]carbamate
[0489] [ka]
[0490] To a 4 mL DMF solution of tert-Butyl(1,3-dihydroxypropan-2-yl)carbamate (324.9 mg, 1.70 mmol), allyl bromide (0.547 mL, 6.34 mmol) was added, and potassium hydroxide (359.0 mg, 6.40 mmol) was gradually added. After stirring at room temperature for 4 hours, the reaction mixture was concentrated under reduced pressure, and the resulting residue was extracted with dichloromethane and water. The organic layer was washed with saturated brine, and the crude product obtained by concentration under reduced pressure was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain tert-Butyl N-[2-allyoxy-1-(allyloxymethyl)ethyl]carbamete (326.6 mg, 1.20 mmol, yield 71%).
[0491] MS(ESI) m / z:294[M+Na]
[0492] 1 H NMR (400 MHz, Chloroform-d) δ = 5.95-5.86 (m, 2H), 5.29(dq, J=17.2, 1.7, 2H), 5.20 (dq, J=10.4, 1.4, 2H), 4.94 (s, 1H) 4.01 (dt, J=5.5, 1.5, 4H), 3.91 (s, 1H), 3.58 (dd, J=9.4, 4.3, 2H), 3.51 (dd, J=9.4, 6.0, 2H), 1.47 (s, 9H).
[0493] Synthesis of (19-4-3)S-[3-[3-acetylsulfanylpropoxy]-2-(tert-butoxycarbonylamino)propoxy]propyl]ethaneethioate
[0494] [ka]
[0495] 2,2′-azobisisobutyronitrile (1.993 g, 25.66 mmol) was added to a toluene solution (7.4 mL) of tert-Butyl N-[2-allyoxy-1-(allyloxymethyl)ethyl]carbamete (323.8 mg, 1.19 mmol). Thioacetic acid (0.890 mL, 11.88 mmol) was added to the suspended reaction mixture in five portions, and the mixture was stirred at 65°C for 21 hours. The reaction mixture was returned to room temperature and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain S-[3-[3-acetylsulfanylpropoxy]-2-(tert-butoxycarbonylamino)propoxy]propyl]ethanethioate (362.0 mg, 0.854 mmol, yield 72%).
[0496] MS(ESI) m / z:446[M+Na]
[0497] 1 H NMR (400 MHz, Chloroform-d) δ = 4.95 (s, 1H), 3.87 (s, 1H), 3.55-3.44 (m, 8H), 3.03-2.89 (m, 4H), 2.35 (s, 6H), 1.93-1.76 (m, 4H), 1.47 (s, 9H).
[0498] Synthesis of (19-4-4)S-[3-[3-(3-acetylsulfanylpropoxy)-2-amino-propoxy]propyl]ethanethioate
[0499] [ka]
[0500] A 2 mL solution of S-[3-[3-acetylsulfanylpropoxy]-2-(tert-butoxycarbonylamino)propoxy]propyl]ethanethioate (360.1 mg, 0.850 mmol) in dichloromethane was mixed with trifluoroacetic acid (2 mL) and stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and 10 mL of 0.1 N hydrochloric acid was added to the resulting residue. The aqueous solution was concentrated again under reduced pressure, and the resulting solution was freeze-dried to obtain the hydrochloride salt of S-[3-[3-(3-acetylsulfanylpropoxy)-2-amino-propoxy]propyl]ethanethioate (384.4 mg).
[0501] MS(ESI) m / z:324[M+H]
[0502] 1 H NMR (400 MHz, Chloroform-d) δ = 4.51 (s, 2H), 3.82-3.64 (m, 5H), 3.64-3.45 (m, 4H), 3.10-2.92 (m, 4H), 2.37 (s, 6H), 1.95-1.81 (m, 4H).
[0503] Synthesis of (19-4-5)S-[3-[3-(3-acetylsulfanylpropoxy)-2-[3-(2,5-dioxoppyrrol-1-yl)propanoylamino]propoxy]propyl]ethaneethioate
[0504] [ka]
[0505] To a 1.5 mL THF solution of 3-maleimidopropionic acid (17.6 mg, 0.10 mmol), o-Benzotriazol-1-yl-tetramethyluronium hexafluorophosphate (56.9 mg, 0.15 mmol), triethylamine (0.021 mL, 0.15 mmol), and a 0.5 mL THF solution of S-[3-[3-(3-acetylsulfanylpropoxy)-2-amino-propoxy]propyl]ethanethioate (53.2 mg, 0.11 mmol) were added. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography. The fraction containing the product was recovered and concentrated under reduced pressure to obtain S-[3-[3-(3-acetylsulfanylpropoxy)-2-[3-(2,5-dioxoppyrrol-1-yl)propanoylamino]propoxy]propyl]ethanethioate (18.7 mg, 0.039 mmol, yield 41%).
[0506] MS(ESI) m / z:475[M+H]
[0507] 1 H NMR (400 MHz, Chloroform-d) δ = 6.72 (s, 2H), 6.43 (s, 1H), 4.18 (s, 1H), 3.88 (t, J=7.0, 2H), 3.59-3.38 (m, 8H), 3.07-2.88 (m, 4H), 2.61 (t, J=7.1, 2H) 2.36 (s, 6H), 1.88-1.84 (m, 4H).
[0508] (19-5) Conjugation of branched protective thiol reagents with thiol-introducing antibodies The thiol group-introduced antibody was reacted with the branched linker synthesized in Example 19-4-5 using the same method as described in Example 2(2).
[0509] Following the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732), the mass was measured by ESI-TOFMS, and a peak of 149392 was identified, in which four protected thiol groups were introduced into the antibody.
[0510] (19-6) Production of branched thiol group-introduced antibody derivatives by cleavage of thioester groups To the antibody intermediate obtained in (19-5), a hydroxylamine solution was added according to the previously reported (WO2019 / 240287A1), and the mixture was allowed to stand at room temperature for 1 hour. After 2 hours, the mixture was replaced with 20 mM PBS buffer and 10 mM EDTA (pH 7.4) to obtain the thiol-transformed antibody derivative. Mass measurement by ESI-TOFMS revealed a peak at 149231, indicating that the deprotection reaction had progressed.
[0511] (19-7) Synthesis of ADC mimic (19-7-1) Synthesis of Maleimide-VC-Pyrene Maleimide-VC-Pyrene was synthesized as follows: It was synthesized in one step from commercially available MC-VC-PAB-PNP (CAS No: 159857-81-5) and a known sarcosine-pyrene (WO2018 / 218004A1).
[0512] [ka]
[0513] Commercially available MC-VC-PAB-PNP (CAS No: 159857-81-5) (15.5 mg, 0.021 mmol) was dissolved in dichloromethane (1 mL), and a dimethylformamide solution (0.5 mL) of N,N-diisopropylethylamine (0.025 mL, 0.142 mmol) and a known sarcosine-pyrene (WO2018 / 218004A1) (7.6 mg, 0.025 mmol) was added. The mixture was stirred for 17 hours. After purification by reverse-phase preparative chromatography, the fraction containing the product was collected, concentrated under reduced pressure to remove acetonitrile, and then freeze-dried to obtain Maleimide-VC-Pyrene (7.3 mg, 0.008 mmol).
[0514] 1 H NMR(400 MHz,DMSO-d6)δ9.98(s,1H),8.34(d,J=9.2Hz,2H),8.32-8.23(m,4H),8.16(s,2H),8.10-8.00(m,4H),7.80(d ,J=8.8Hz,1H),7.59(d,J=8.4Hz,2H),7.31(d,J=8.0Hz,2H),6.99(s,2H),5.96(m,1H),5.40(s,2H),5.01(s,2H) ),4.95(d,J=6.0Hz,2H),4.38(m,1H),4.19(m,1H),3.03-2.92(m,3H),2.67(m,1H),2.33(m,1H),2.20-2.07(m, 2H),1.97(m,1H),1.67(m,1H),1.59(m,1H),1.51-1.45(m,6H),1.26-1.15(m,3H),0.83(dd,J=12.8,6.8Hz,6H)
[0515] MS(ESI)m / z:901.45[M+H] +
[0516] (19-7-2) Synthesis of ADC mimic To a 20 μM solution (pH 7.4 PBS buffer) of the thiol-introduced antibody obtained in Example 19-6, 10 equivalents of a 1.25 mM DMF solution (Maleimide-VC-Pyrene) synthesized in Example 19-7-1 were added. After standing at room temperature for 2 hours, the solution was purified using NAP-5 Columns (GE Healthcare) to obtain the ADC mimic.
[0517] Following the previously reported method (Anal. Chem., 2019, 91, 20, 12724-12732), the mass was measured by ESI-TOFMS, and a peak of 152843 was identified, in which four Maleimide-VC-Pyrene molecules were introduced into the antibody.
Claims
1. Formulas (3) to (7) below: 【Chemistry 1】 (In the formula, m is an integer between 1 and 5. m' is an integer between 1 and 5. R1 is an alkyl group, R and R6 are alkyne residues or azides. A reagent for derivatization of antibodies or salts thereof having a thiol group in a cysteine residue or a chemically introduced thiol group, comprising a compound or a salt thereof, selected from the group consisting of compounds represented by (where Q is arylene or alkylene).
2. The reagent according to claim 1, wherein the reagent is a reagent for derivatizing an antibody or a salt thereof having a thiol group that has been chemically introduced by reacting with a thiol group introduced via the side chain of an amino acid residue other than a cysteine residue in the antibody.
3. The reagent according to claim 1 or 2, wherein the thiol group in the antibody having a chemically introduced thiol group is regioselectively bound to a nitrogen atom in the side chain of a lysine residue in the constant region of the antibody heavy chain via a linker that does not contain a peptide.
4. An antibody having a thiol group in a cysteine residue or a chemically introduced thiol group The reagent according to any one of claims 1 to 3, wherein the reagent is an IgG antibody.
5. The reagent according to claim 3 or 4, wherein the lysine residue is located at one or more positions selected from the group consisting of positions 246 / 248, 288 / 290, and 317 of the human IgG heavy chain in EU numbering.
6. The following formulas (3') to (7'): 【Chemistry 2】 (In the formula, Ab is an antibody, S is a sulfur atom, m is an integer between 1 and 5. m' is an integer between 1 and 5. R and R6 are alkyne residues or azides. Q is either allerene or alkylene. n is an integer from 1 to 8. Selected from the group consisting of antibody intermediates represented by ), Intersex bodies or their salts.
7. The antibody intermediate or salt thereof according to claim 6, wherein the sulfur atom (S) adjacent to the antibody (Ab) in formulas (3') to (7') is directly bound to an atom in the side chain of an amino acid residue other than a cysteine residue in the constant region of the antibody (Ab) heavy chain, or is bound via a linker.
8. The antibody intermediate or salt thereof according to claim 7, wherein the sulfur atom (S) adjacent to the antibody (Ab) in formulas (3') to (7') is regioselectively bound to the nitrogen atom in the side chain of the lysine residue in the constant region of the antibody (Ab) heavy chain via a linker that does not contain a peptide.
9. The antibody intermediate or a salt thereof according to any one of claims 6 to 8, wherein the antibody intermediate is an IgG antibody.
10. The antibody intermediate or salt thereof according to claim 8 or 9, wherein the lysine residue is located at one or more positions selected from the group consisting of positions 246 / 248, 288 / 290, and 317 of the human IgG heavy chain in EU numbering.
11. Formulas (3) to (7) below: 【Transformation 3】 (In the formula, m is an integer between 1 and 5. m' is an integer between 1 and 5. R1 is an alkyl group, R and R6 are alkyne residues or azides. Q is an arylene or alkylene. A compound selected from the group consisting of compounds represented by ( ) or a salt thereof is reacted with an antibody or a salt thereof having a thiol group in a cysteine residue or a chemically introduced thiol group, The following equations (3') to (7'): 【Chemistry 4】 (In the formula, Ab is an antibody, S is a sulfur atom, n is an integer from 1 to 8. A method for producing an antibody intermediate or a salt thereof, comprising producing an antibody intermediate or a salt thereof, selected from the group consisting of antibody intermediates represented by formulas (3) to (7).
12. The following formulas (3'') to (7''): 【Transformation 5】 (In the formula, Ab is an antibody, S is a sulfur atom, m is an integer between 1 and 5. m' is an integer between 1 and 5. R' and R6' are groups generated by the reaction between alkyne residues and azides. Q is either allerene or alkylene. Z and Z' are functional substances, n is an integer from 1 to 8. A conjugate of an antibody and a functional substance or a salt thereof, selected from the group consisting of conjugates represented by ).
13. The following equations (3') to (7'): 【Transformation 6】 (In the formula, Ab is an antibody, S is a sulfur atom, m is an integer between 1 and 5. m' is an integer between 1 and 5. R and R6 are alkyne residues or azides. Q is either allerene or alkylene. n is an integer from 1 to 8.) An antibody intermediate or a salt thereof, selected from the group consisting of antibody intermediates represented by ), is reacted with a functional substance having a bioorthogonal functional group that can react with alkyne residues or azides contained in the antibody intermediate. The following equations (3'') to (7''): 【Transformation 7】 (In the formula, R' and R6' are groups generated by the reaction between alkyne residues and azides. Z and Z' are functional substances, A method for producing antibody and functional substance conjugates or salts thereof, comprising generating antibody and functional substance conjugates or salts thereof selected from the group consisting of conjugates represented by formulas (3') to (7').
14. Formulas (3) to (7) below: 【Transformation 8】 (In the formula, R1 is an alkyl group, m, m', R, R6, and Q are the same as those in formulas (3') to (7'). A compound selected from the group consisting of compounds represented by ) or a salt thereof is reacted with an antibody or a salt thereof having a thiol group in a cysteine residue or a chemically introduced thiol group. The method according to claim 13, further comprising generating an antibody intermediate or a salt thereof represented by formulas (3') to (7').
Citation Information
Patent Citations
N-(1,3,4-oxadiazole-2-yl) aryl formamide or salt thereof, and preparation method thereof, weeding composition and application of weeding composition
CN111253333A
Fluorescent protein and / or coupled protein monoclonal antibody labeling method and kit thereof
CN112098640A
antibody conjugate
JP2008539270A
Selective radiolabeling of biomolecules
JP2011508194A
Cytotoxic peptides and their conjugates
JP2017503777A
